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1. INTRODUCTION 
 
1.1 Overview 
 
The term eosinophilia refers to a condition in which abnormally high amounts of 
eosinophils are found either in the blood or in body tissues. The commonest causes 
of eosinophilia in industrialized countries are allergic diseases, whereas worldwide 
the main cause is the presence of parasitic infection. Increased numbers of 
eosinophils are beneficial to cope with parasitic helminth infections, but they are 
detrimental in the case of allergic diseases like asthma or hypereosinophilic 
syndrome, where eosinophils accumulate in tissues and cause damage. Damage of 
the lung airways is typical for eosinophilia in the course of asthma. The pathology of 
asthma is thought to represent an aberration in the immune response to fight parasitic 
helminth infection. The prevalence of asthma is increasing worldwide affecting at 
least 300 million people. Because of this dramatic increase in prevalence, 
particularly in children, the World Health Organization considers the fight on asthma 
as a priority target (www.who.int/topics/asthma/en).  
Eosinophils were described by Paul Ehrlich in 1879. Eosinophils arise from 
CD34+ haematopoietic progenitor cells within the bone marrow and represent 1–3% 
of circulating leukocytes. Eosinophils predominately reside in the gastro-intestinal 
tract under healthy conditions and are thought to have evolved as part of the innate 
immune response against parasitic helminths. These granulocytes possess secondary 
granules containing four primary cationic proteins namely major basic protein 
(MBP), eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), 
and eosinophil peroxidase (EPO), all of which are important for killing extracellular 
pathogens.  
The diversity of secretory products of the eosinophils, together with the wide 
range of receptors expressed on the eosinophil surface, reflect their broad range of 
functions beyond the role of a basic granulocyte. Eosinophils are able to modulate 
immune mechanisms that contribute to inflammation and are important in the 
pathology of asthma. Due to the central role of eosinophils in the development of 
asthma, blocking their function is considered to be a useful therapeutic approach in 
asthma therapy.  
Cytokines play an important role in eosinophil activation. This activation is a 
dynamic process triggered by specific interaction of the cytokine molecule with their 
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corresponding cytokine receptor. Therefore, structure/function studies of the 
cytokine-receptor complex responsible for eosinophil activation may facilitate the 
design of molecules conferring antagonistic effects on the receptor activation that 
will be useful for the development of novel therapeutic strategies in eosinophilic 
diseases. 
 
1.2 Diseases 
 
1.2.1 Parasitic Infection  
 
Eosinophils are considered a fundamental diagnostic tool for the presence of 
parasitic helminth infections. Diseases caused by these extracellular pathogens are 
characterized by a sharp rise in eosinophil numbers in peripheral blood and high 
levels of circulating interleukin-5 (IL-5). The importance of IL-5 for this disease 
condition has been confirmed in e.g. helminth-infected IL-5-deficient knock out-
mice, where eosinophilia fails to develop. Interestingly these mice show normal 
antibody and cytotoxic T cell responses, suggesting that IL-5 does not affect these 
immunological responses (Kopf et al., 1996). In parasitic infections, eosinophils and 
IL-5 are required for the induction of a protective immune response and eosinophils 
are crucial for larval killing and the production of protective antibodies. These 
observations led to the conclusion that IL-5 plays a key role in innate and adaptive 
immunity against parasites (Herbert et al., 2000).  
 
1.2.2 Asthma 
 
Asthma is a chronic disease with several traits such as elevated concentrations of 
serum immunoglobulin-E (IgE), airway mucus production, airway 
hyperresponsiveness (AHR), and airway inflammation. The specific cause of this 
allergic disease is not completely understood. The risk factors for developing asthma 
include any antigen (allergen) or conditions that cause inflammation in the airways. 
The structural changes that take place in the airways are known as airway 
remodeling (Figure 1-1). A possible cause of this remodeling is an imbalance in 
tissue repair and airway injury that results in deposition of extracellular matrix 
(ECM) proteins in the lungs. Remodeling is possibly caused by differentiation of the 
eosinophil, that may cause damage to the airway by exocytosis of their cytotoxic 
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granule proteins onto the bronchial mucosa (Kay, 2005; Wills-Karp and Karp, 2004). 
These granules contain cytotoxic proteins such as major basic protein (MBP), 
eosinophil cationic protein (ECP) and eosinophil peroxidase (EP) that are 
responsible for the tissue damage. A large body of evidence exists showing a strong 
correlation between the number of airway eosinophils (Eosinophilia) in allergic 
asthma and disease severity (Enokihara et al., 1990; Magnan and Vervloet, 1998). 
 
 
Adapted from wills, Karp 2004 
 
Figure 1-1. Eosinophil activation. The allergen is phagocytosed, processed and presented to 
Th2 cells by dendritic cells (DC). Th2 cells produce different cytokines (IL-5, IL-4, IL-13) 
leading to activation of several cell types. The IL-5 promotes differentiation of CD34+ 
progenitor eosinophil cells in the bone marrow. Differentiated eosinophils migrate to swelling 
areas using vascular cell adhesion molecules-1 (VCAM-1) and vascular ligand adhesion-4 
(VLA-4). 
 
In asthmatic individuals, allergen presentation by dendritic cells (DC) 
stimulates Th2-cell differentiation and Th2-cytokine production e.g., IL-4, IL-5 and 
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IL-13 (Figure 1-1). It is well known that these Th2-cytokines orchestrate the 
immunopathogenesis of asthma. For example, IL-4 and IL-13 maintain the Th2 
phenotype and promote isotype switching to IgE. IL-5 participates in airway 
remodeling, increase hypertrophy of muscle cells and proliferation of goblet cells 
(Wills-Karp and Karp, 2004).  
Constriction of the airways is a consequence of the hypertrophy of muscle 
cells and metaplasia of goblet cells in the lung. In addition, IL-5 influences the 
development of eosinophil from CD34+ progenitor cells at the bone marrow level, 
resulting in an increased number of mature eosinophils that migrate to area of 
inflammation (Kay, 2005; Wills-Karp and Karp, 2004). The action of IL-5 is specific 
for eosinophils in humans due to the restricted expression of the IL-5 receptor alpha 
(IL-5Rα) on the eosinophil surface (Yamada et al., 1998). 
Transgenic knock out-mice (Humbles et al., 2004; Lee et al., 2004) and/or the 
use of monoclonal antibodies (Garrett et al., 2004) constitute major advances in our 
understanding of the biological functions of eosinophils and IL-5 in asthma. 
Different strategies to ablate the eosinophil populations have shown that these cells 
constitute an integral part of experimental allergic asthma (Humbles et al., 2004; Lee 
et al., 2004). In their seminal report, Humbles and colleagues demonstrated in 
eosinophil-deficient mice a decrease in the fibrotic area, due to less collagen 
deposition and increase smooth muscle (Humbles et al., 2004). In an another 
experimental approach, mice specifically devoid of eosinophils did not display 
mucus accumulation on the airway (Lee et al., 2004). These observations suggest 
that the eosinophil and IL-5 system may represent an alternative target for specific 
drug design as part of a novel asthma therapy. 
 
1.2.3 Hypereosinophilic Syndrome 
 
Hypereosinophilic syndrome (HES) is defined as a group of disorders characterized 
by the accumulation of large numbers of eosinophils in peripheral blood and organ 
tissues. These disorders are rare and multisystemic. The peripheral blood of patients 
contains more than 800 - 1500 eosinophils/mm3. Eosinophils cause inflammation 
and organ tissue damage. In some patients the eosinophilia correlates with an 
overproduction of IL-5 due to the activation of Th2 lymphocytes (Owen et al., 1989; 
Straumann et al., 2001).  
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1.3 Haematopoietic Cytokine Family 
 
The IL-5, IL-3, and granulocytes macrophage colony stimulator factor (GM-CSF) 
cytokines belong to the haematopoietic cytokine family or class I cytokines and have 
multiple biological functions through their interaction with cell surface receptors. 
These three cytokines (IL5, IL-3, and GM-CSF) do not share significant amino acid 
homology. However, they appear closely related with respect to their genetic 
localization. Genetic linkage analysis has shown that the IL-5, IL-3, and GM-CSF 
genes are all found on the long arm of the chromosome 5 (van Leeuwen et al., 1989). 
 
A
B
C
DAÕ
BÕCÕ
DÕ
A
B
C
D
AB
C
D
IL-3 GM-CSF IL-5
 
Figure 1-2. Haematopoietic related cytokines. IL-5, IL-3 and GM-CSF are mainly comprised 
of α-helices designated A-D, and A’-D’ for the second IL-5 monomer. IL-5, IL-3 and GM-CSF 
are short-chain cytokines with an up-up-down-down topology.  
 
In addition, these cytokines share a similar protein-folding motif consisting 
of four helices bundle architecture with two β-strands (Figure 1-2). These structural 
elements in IL-3 (Feng et al., 1996) and GM-CSF (Walter et al., 1992) fold in a 
single polypeptide chain, whereas IL-5 folds in a homodimer conformation (Milburn 
et al., 1993) (Figure 1-2). 
The cellular receptors of IL-5, IL-3 and GM-CSF consist of two different 
chains called α and β chains (Tavernier et al., 1991). All three cytokines have a 
cytokine specific α-chain for ligand binding called IL-5Rα, IL-3Rα, and GM-
CSFRα, respectively (Figure 1-3). The three different α-chains IL-5Rα, IL-3Rα, and 
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GM-CSFRα, and βc chain belong to the haematopoietic receptor family and they 
share common features.  
The haematopoietic receptor family is characterized by the presence of a so-
called cytokine recognition motif (CRM) within the extracellular portion, which is 
usually involved in cytokine binding (Figure 1-3). This CRM is formed by two 
domains each one containing approximately 100 amino acids that are classified as 
fibronectin III like domains (Fn-III like) (Bazan, 1990). Each Fn-III like domain 
contains seven β strands folded into anti-parallel β sandwiches. Known X-ray 
structures of complexes from some haematopoietic receptor family members show 
that these two Fn-III like domains fold in an L shape, and the cytokine binds in an 
elbow region (de Vos et al., 1992; Wells and de Vos, 1996). In contrast to the 
structure of the growth hormone receptor (GHR), the IL-5, IL-3, and GM-CSF 
receptor alpha chain contains an additional Fn-III like domain (Figure 1-3), whereas 
βc can be distinguished from each one of these receptor alpha external domains by 
the presence of two CRMs (Martinez-Moczygemba and Huston, 2001; Wells and de 
Vos, 1996). For IL-5, IL-3, and GM-CSF receptors, the N-terminal of the CRM 
contains four strictly conserved cysteine residues (Figure 1-3). These cysteine 
residues are buried in the core of the molecule and form two disulphide bridges 
(Bazan, 1990; Martinez-Moczygemba and Huston, 2003; Wells and de Vos, 1996). 
A membrane proximal Trp-Ser-X-Trp-Ser (WSXWS) motif is found in the C-
terminal part of the CRM (Figure 1-3) (Bazan, 1990; Martinez-Moczygemba and 
Huston, 2003; Wells and de Vos, 1996). All these features have been found in the 
human as well as in the mouse system (Martinez-Moczygemba and Huston, 2003; 
Wells and de Vos, 1996).  
In terms of biological activity IL5, IL-3, and GM-CSF have synergistic 
actions concerning differentiation and function of myeloid cells. However, the role 
of these cytokines in the immune response (IR) is clearly determined by the 
expression of tissue-specific receptors. For example, the IL-5 receptor is mainly 
expressed in eosinophils, while the IL-3 receptor is present on early haematopoietic 
cells. The GM-CSF receptor is expressed on myeloid progenitors, mature 
monocytes, eosinophils and basophils (Guthridge et al., 1998). 
In line with the cell receptor expression pattern, GM-CSF and IL-3 activate 
immature myelomonocytic cells of the haematopoietic system and promote 
differentiation into granulocyte and macrophage cells. On the other hand, IL-5 
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mainly acts on eosinophil, triggering maturation and survival of these cells 
(Woodcock et al., 1997). 
 
Extracellular
Intracellular
IL-5Rα IL-3RαGM-CSFRα
βc
CRMCRMCRM
WSXWS
CRM
CRM
 
_____________________________________________________________ 
 
Figure 1-3. Cartoon representation of the haematopoietic cytokine receptors. The IL-5Rα, IL-
3Rα, and GM-CSFRα and βc subunit are presented with their modular architecture. Three 
Fn-III-like domains form the extracellular parts of the alpha-receptors; in contrast, the same 
part in β receptor consists of four Fn-III-like domains. The white lines represent the 
conserved cysteine residues. The WSXWS motif is shown in red. The putative cytokine 
binding region is called cytokine recognition motif (CRM). 
 
1.4 Identification of Components of the Interleukin-5 System 
 
1.4.1 Interleukin-5 (IL-5) 
 
Activated T-cells produce soluble lymphokines that act on B-cells as growth factors 
(BCGF) or as B-cell differentiation factors (BCDF). BCGF induces B-cell 
proliferation in contrast to BCDF, which triggers maturation of B-cells into 
immunoglobulin secreting cells. The T-cell replacing factor (TRF) is a BCDF that 
can be constitutively produced by a murine T-cell hybridoma B151K12. TRF 
induces differentiation of pre-activated B-cells and the B leukemia cell line (BCL1) 
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into antibody secreting cells (Takatsu et al., 1980). In addition, a factor derived from 
thymona and/or hybridoma cells, identified as BCGF-II, induces B-cells 
differentiation (Swain et al., 1983). Activated T-cells also produce another cytokine, 
called eosinophil differentiation factor (EDF) (Sanderson et al., 1985). EDF induces 
eosinophil differentiation from mouse bone marrow cells in vitro and prolongs the 
survival of eosinophils. In addition, EDF stimulates the B-cell tumor (BCL1) cell line 
proliferation.  
Attempts to discriminate between the TRF and BCGF-II activity using 
different purification procedures such as ammonium sulphate precipitation, DEAE-
cellulose chromatography or hydroxyl apatite chromatography were unsuccessful 
due to the tendency of both proteins to co-elute together. This suggests that these two 
cytokines may represent the same molecule. In addition, the activity of TRF and 
BCGF-II were found in the same fractions eluted from reverse phase-HPLC (RP-
HPLC). 
BCGF-II as well as TRF active material was incubated with BCL1 cells and 
the resulting supernatant was assayed for residual BCFG-II and TRF activity using 
new BCL1 cells. The absorption of TRF and TCFG-II with BCL1 cells abolished not 
only the TRF activity but also the activity of BCGF-II. In addition, the monoclonal 
antibody 9TI that preferentially blocks the TRF activity in plaque-forming cell assay 
also blocks BCGF-II activity (Harada et al., 1985). Taking together these results it 
can be assumed that a single cytokine could be responsible for all the observed 
effects (Kinashi et al., 1986; Sanderson et al., 1986). 
The activities of TRF, EDF or BCGF-II are different from the function of 
already known cytokines such as IL-1, IL-2, IL-3 and IFN-γ in cell assays. This led 
to the assumption that the activity of TRF or EDF or BCGF-II on B-cells and 
eosinophils possibly corresponds to a novel cytokine (Harada et al., 1985; Kinashi et 
al., 1986; Sanderson et al., 1986). In 1986 Kinashi, Harada et al. proposed the new 
term IL-5 replacing the term TRF. Subsequent studies on continuation confirmed 
later that TRF or EDF or BCGF-II were indeed the same molecule, now called IL-5 
(Takatsu et al., 1987). 
The mouse IL-5 gene was initially cloned by Kinashi and collaborators using 
a murine complementary DNA (cDNA) library from T-cell messenger RNA 
(mRNA). The murine cDNA encodes a protein of 133 residues). Twenty amino acids 
at the amino terminal end (N-terminus) constitute the signal peptide (Figure 1-4). 
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The protein has three putative glycosylation sites (Kinashi et al., 1986). Without 
glycosylation, the polypeptide exhibits a theoretical molecular weight (MW) of 
12300 Da. The glycosylated protein has a MW that ranges between 32000-46000 Da. 
Additionally; mouse IL-5 cDNA contains three cysteine residues that may play a role 
in oligomer formation (Figure 1-4). 
On continuation, the human homologue of the IL-5 gene was cloned by 
several groups using Southern blot hybridization techniques with a mouse IL-5 
cDNA as a probe. The cDNA libraries were generated from different cell sources 
like human T cell leukaemia lines (Azuma et al., 1986), human liver DNA 
(Campbell et al., 1987), human fetal liver DNA, human placental DNA or human 
myeloma cell line 266B1 (Tanabe et al., 1987).  
The human cDNA encodes for a protein that consists of 134 residues. 
Nineteen residues in the N-terminus constitute the signal peptide. Of three 
glycosylation sites and three cysteine residues in the mouse IL-5, only two 
glycosylation sites and two cysteine residues were conserved in the human IL-5 
homologue (Azuma et al., 1986). Comparison of the cDNA- and amino acid 
sequences of murine IL-5 with those of the human IL-5 homologue (Figure 1-4) 
reveals 77% sequence homology at the nucleotide level and 70% at the protein level 
(Azuma et al., 1986). Human and mouse mature proteins have 115 and 113 amino 
acids, respectively (Figure 1-4).  
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Figure 1-4. Sequence alignment of human and mouse IL-5. (A) Nucleotide sequence and (B) 
amino acid sequences of hIL-5 and mIL-5 show 77% and 70% identity between the two 
cytokines. Red lines show the signal peptide (nucleotides or amino acids) of the two 
cytokines. Black squares show the codon of the first amino acid of the mature proteins. Red 
arrowheads point to the first residue of the mature protein. Matched nucleotides or residues 
are shown with the same color. Mismatched nucleotides or residues are not shown in color. 
Gaps are shown by hyphens. The alignments were done with the Jalview program using 
Clustal W analysis (Clamp et al., 2004). 
 
The biological activity of both, human and mouse IL-5, requires 
configuration of a homodimer protein, linked together by disulphide bridges 
(Tavernier et al., 1989). IL-5 is an important mediator of several biological 
processes, such as 1. induction of expression of the IL-2 receptor on activated B-
cells (Loughnan et al., 1987; Nakanishi et al., 1988), 2. activation of B-cell 
proliferation and differentiation into antibody-secreting cells (Harada et al., 1985; 
Kinashi et al., 1986; Sanderson et al., 1986; Takatsu et al., 1980). and 3. induction of 
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expression of the activation-induced cytidine deaminase (Aid) and B lymphocyte-
induced maturation protein-1 (Blimp-1) (Horikawa and Takatsu, 2006). 
Both, mouse IL-5 and human IL-5, have been expressed in eukaryotic 
expression systems such as Xenopus laevis oocytes, NIH-3T3, sf9, and 
Saccharomyces cerevisae cells (Ingley et al., 1991; Tavernier et al., 1989). In the 
prokaryotic expression system as E. coli, only human IL-5 could be expressed and 
purified so far (Proudfoot et al., 1990). The human IL-5 recombinant protein 
generated in bacteria shows high specific activity in biological assays in vitro. These 
results demonstrated that the carbohydrate moiety of the human IL-5 is not required 
for biological activity or IL-5 dimer formation (Proudfoot et al., 1990).  
 
1.4.2 Interleukin-5 Receptor (IL-5R) 
 
The knowledge of the biological functions of IL-5 on B-cells, eosinophil precursors 
and mature eosinophil has prompted the scientific community to extend the studies 
to the cellular receptor responsible for transmitting the specific signal into these 
cells.  
Analysis of the specific binding of mouse IL-5 to its receptor in cell assays 
demonstrated that IL-5 binds to B-cells with two different affinities. The affinity 
constant (KD) for the high affinity binding site was determined to be 66 pM, and for 
the low affinity binding sites to be 12 nM (Mita et al., 1988). Additionally, 
crosslinking experiments identified two crosslinked complexes with mouse IL-5. 
The first complex was shown to have a MW of 92.500 Da and the second complex a 
MW of 210.000 Da (Mita et al., 1988). The MWs of the mouse IL-5 crosslinked 
proteins in the first and second complexes were close to 46.500 Da and 114.000 Da, 
respectively. These result also suggests that the 46.500 MW component represents 
the complex with mouse IL-5 with the low affinity receptor subunit, while the high 
affinity receptor consists of this complex and one additional protein (receptor) with a 
MW of 114.000 (Mita et al., 1989). 
The low affinity receptor and the additional protein (receptor) constitute a 
complex of highly glycosylated proteins. Due to the glycosylation moiety, their 
MWs likely range between 46.500-60.000 and 114.000-130.000 Da, respectively. In 
1991 Mita and colleagues proposed to designate the low affinity receptor (46.500-
60.000 Da) and the additional peptide receptor chain (114.000-130.000 Da) as the 
alpha and the beta chains of the IL-5 receptor, respectively (Mita et al., 1991). The 
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alpha subunit (mIL-5Rα) can bind to mouse IL-5 on its own, while the beta subunit 
(mIL-5Rβ) does not (Takaki et al., 1990). Similar results were obtained during 
characterization of the human IL-5 receptor (hIL-5R) in the pro-myelocytic cells 
HL60 (Plaetinck et al., 1990), suggesting that the IL-5R/IL-5 system is highly 
conserved in mice and human. 
The gene structure of the IL-5Rα chain was first described in the murine 
system using a cDNA library derived from IL-5 dependent B-cells (Takaki et al., 
1990). For the human IL-5Rα, the cDNA was isolated from cDNA libraries of 
human eosinophils using a murine IL-5Rα cDNA as a probe (Murata et al., 1992). 
Both, human IL-5Rα and mouse IL-5Rα, share a 70% homology on amino acid (aa) 
sequence level (Murata et al., 1992). The mRNA of IL-5Rα undergoes alternative 
splicing (Takaki et al., 1990; Tavernier et al., 1992). Transcripts found in HL-60 
cells encode both, secreted and anchored forms, of IL-5Rα. The secreted form 
exhibits antagonist properties in an eosinophil differentiation assay (Tavernier et al., 
1991). 
Amino acid sequence analysis of mouse IL-5Rα demonstrated that the 
receptor is a glycoprotein of 415 residues with a MW of 45284 Da, including a N-
terminal hydrophobic region (17 aa), which is the signal peptide, an extracellular 
domain (322 aa), a single transmembrane segment (22 aa), and a cytoplasmic tail (54 
aa). Similarly, the cDNA human IL-5Rα encodes a glycoprotein of 420 amino acids 
with a MW of 47670, that consists of an N-terminal (signal peptide) hydrophobic 
region (20 aa), an extracellular domain (324 aa), a single transmembrane domain (21 
aa), and a short cytoplasmic domain of 55 amino acids (Murata et al., 1992). 
The mouse beta chain (mIL-5Rβ or βc) gene structure was initially 
characterized by Gorman and colleagues, and it was called AIC2B (Gorman et al., 
1990). They used a monoclonal antibody (anti-Aic2) against mIL-3 to characterize a 
cDNA library from the mouse mast cell line M/C9 cloned into COS-7 cells. The 
isolated cDNA was called AIC2B, due to its homology to the previously 
characterized cDNA for IL-3R that had been named AIC2A. AIC2B encodes for a 
glycoprotein of 874 amino acids with a MW of 96681 Da, that consists of a 22 
amino acid signal peptide, an extracellular domain of 419 amino acids, a single 
transmembrane domain of 22 residues, and a cytoplasmic domain of 433 residues 
(Swiss-Prot: IL-3Rβ-Mouse P26955). Binding assays with IL-3, IL-4, or GM-CSF 
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have shown that AIC2B does not bind to cytokines on its own (Gorman et al., 1990) 
confirming the previous results showed by Mita and colleagues (Mita et al., 1991) 
The human IL-5Rβ homologue (hIL-5Rβ) was subsequently identified using 
an AIC2B cDNA as probe. The homologous gene was identified in a cDNA library 
of TF-1 cells. The new gene reveals 56% amino acid sequence identity with AIC2B. 
The protein encoded by this cDNA has a MW of 120 kDa and showed no cytokine 
binding capability (Hayashida et al., 1990). 
Further experiments have demonstrated that the murine- and human IL-5-, 
IL-3-, and granulocyte-macrophage colony-stimulator factor-receptor (GM-CSFR) 
share a beta chain (Kitamura et al., 1991; Takaki et al., 1991; Tavernier et al., 1991). 
In contrast to the human receptor, the mouse receptor has two different but related β 
chain genes, AIC2A and AIC2B. The former is specific for the mouse IL-3 (Hara 
and Miyajima, 1992) and the latter is shared between GM-CSF, IL-3 and IL-5, now 
known as the common beta chain (βc). 
 
1.5 Interaction of IL-5 and IL-5 receptor 
 
Several studies aimed at elucidating the molecular basis of the IL-5/IL-5Rα 
interaction led to important findings on epitope usage. Initial results showed that the 
chemical proteolysis of human IL-5 with cyanogen bromide (CNBr) led to the 
cleavage of eight residues on the C-terminus of human IL-5 resulting in the complete 
loss of biological activity (Kodama et al., 1991). Furthermore, several cell assays 
showed that mouse IL-5 activates human responsive cells as effectively as human 
IL-5. However, human IL-5 is a weaker inducer of mouse responsive cells to IL-5. In 
IL-5 human/mouse protein chimeras, it has been shown that replacement of the last 
36 residues at the carboxyl terminal end (C-terminus) in human IL-5 with the last 36 
residues of mouse IL-5 produces a hybrid molecule with biological activity 
comparable to mIL-5. In this C-terminal, eight amino acids are not conserved 
between humans and mice. Replacing these eight amino acids in the C-terminal 
region of human IL-5 by those of mouse IL-5 resulted in the hybrid human IL-
5/mouse IL-5 exhibiting comparable activity in mouse responsive cells (McKenzie et 
al., 1991a). In addition, the substitution of Lys 84 and Asn 108 in human IL-5 by 
their respective murine counterpart residue Glu 84 and Ser 108 yielded molecules 
with the same activity of murine IL-5 (Cornelis et al., 1995). These results imply that 
the amino acid replacement did not disturb the overall-structure of the protein and 
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confirm the crucial role of the C-terminal residues of IL-5 for its receptor binding 
activity (Kodama et al., 1991; McKenzie et al., 1991a).  
However, the biological activity of IL-5 does not only depend on C-terminal 
residues as demonstrated by Shanafelt and colleagues (Shanafelt et al., 1991). 
Experiments using site-directed mutagenesis revealed that several key residues in the 
N-terminal α-helix of IL-5 also govern the recognition binding with IL-5Rβ, 
although the responsible residues were not identified (Shanafelt et al., 1991).  
The dimeric form of IL-5 was shown to be essential for bioactivity. Native 
human IL-5 monomers produced by site directed mutagenesis of cysteine residues to 
threonine (C44T or C86T) did not exhibit any biological activity neither on the 
murine eosinophils nor on an IL-5-dependent B-cell line (McKenzie et al., 1991b). 
In contrast, human IL-5 monomers obtained by protein engineering showed the same 
biological activity as native IL-5. Although these IL-5 monomers bind to its receptor 
with 30-40-fold lower affinity than wild type IL-5 dimeric protein, the monomers 
interact with the IL-5Rα with the same stoichometry as wild type IL-5 dimeric 
protein (Dickason et al., 1996a; Dickason et al., 1996b; Edgerton et al., 1997; Li et 
al., 1997). The latter results suggest that the role of IL-5 disulphide bonds is related 
to the structural maintenance of the functional domains. 
The residues in human IL-5, which are important for the molecular 
interaction with human IL-5Rα were found to be mainly charged residues (Figure 1-
5). Different human IL5 mutants such as H38A, K39A, H41A, E89A, R91A, and 
E110A showed a strong reduction in the activation of cell proliferation or binding to 
IL-5Rα compared with the wild type IL-5 (Graber et al., 1995; Tavernier et al., 
1995b). The human E13Q mutation was completely inactive and failed to induce 
proliferation in TF-1 cells, although crosslinking experiments demonstrated the 
interaction with the receptor (Tavernier et al., 1995b). Further mutation analysis on 
the human IL-5 Glu13 position confirmed the important role that this residue plays 
in receptor activation due to βc recruitment. Mutation which removed the charge 
(E13A) or led to charge reversal (E13K) were also shown to decrease cell 
proliferation activities (Graber et al., 1995; McKinnon et al., 1997). 
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Figure 1-5. Residues in human IL-5 important for binding. The residues involved in binding 
to the alpha chain of the receptor (IL-5Rα) are colored in red (Arg91), yellow (His38 and 
His41), magenta (Lys39) and blue (Glu89 and Glu110). The residue involved in binding to 
the beta chain of the receptor (IL-5Rβ) is colored in green (Glu13). 
 
On the other hand, site-directed mutagenesis studies of IL-5Rα provided 
further clues that the IL-5 binding properties are highly dependent on the amino 
acids at the first domain (N-terminal). Subsequent analysis defined as crucial the 
Asp55, Asp56, and Glu58 residues (Cornelis et al., 1995). Additionally, an 
alignment between the second and third Fn-III-like domains of the IL-5Rα and 
growth hormone receptor (GHR) was done to identify crucial residues in the 
cytokine recognition motif (CRM) of the IL-5Rα. The alignment reveals five 
residues that align with five known residues to contact the growth hormone ligand 
(GH). Afterwards, Arg188 in IL-5Rα corresponding to residue Trp104 in GH 
receptor (GHR) proved to be important for ligand interaction. Mutations at this 
position in IL-5Rα (R188A) showed strongly reduced human IL-5 binding affinity 
(Cornelis et al., 1995). These results demonstrated the importance of residues of the 
second Fn-III like for the ligand interaction. 
H38
H38
H41
H41
K39
K39
E89
E89
R91
R91
E110
E110
E13
E13
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More recent data suggest that the IL-5/IL-5Rα system adopts a complex and 
unique binding topology in which the cytokine is recognized by a combination of 
residues in the first (Asp55, Asp56 and Glu58), second (Lys186 and Arg188) and 
third (Arg297) Fn-III-like domains, forming a new type of cytokine recognition 
interface (Ishino et al., 2004).  
On the other hand, the Asp 56, Glu 58 and Arg 188 residues of the human IL-
5Rα seem to govern the species-specific interaction between human and mouse IL-5 
(Glu 56, D58 and Phe 188), since they are not conserved in the mouse IL-5Rα 
(Cornelis et al., 1995). With other words, the βc (IL-5Rβ) interacts with both 
cytokines of either human and mouse origin. The species-specific role of IL-5Rα in 
ligand interaction was demonstrated by Takaki and colleagues in 1994 (Takaki and 
Takatsu, 1994). By cell transfection, they succeeded in expressing human- and 
mouse IL-5Rα cDNA in the IL-3-dependent mouse cell line FDC-P1 producing the 
mouse βc constitutively. The transfected cells become responsive to stimulation with 
human and mouse IL-5 (Takaki and Takatsu, 1994). 
Furthermore, site directed mutagenesis, ligand binding and cell proliferation 
assays have demonstrated the critical role of Tyr 15, Phe 79 and Tyr 421 of the βc 
(IL-5Rβ) in high affinity binding, complex formation and receptor activation (Figure 
1-8) (Murphy et al., 2003; Woodcock et al., 1996). The way in which the βc interacts 
with IL-5Rα/IL-5 complex in the respective active complex is yet poorly 
understood. 
Although several key binding determinants between IL-5 and IL-5R are now 
known, a closer insight into the three dimensional structure of the complex is 
required to confirm the mechanism of the molecular interaction between IL-5 and 
IL-5R. So far, different experiments such as cross-linking, gelfiltration, 
ultracentrifugation, and titration microcalorimetry have shown a 1:1 stoichiometry 
for the interaction between IL-5 with IL-5Rα at the cellular level as well as in vitro 
(Devos et al., 1993; Johanson et al., 1995). In addition, the exact stoichiometry of the 
trimeric complex (IL-5/IL-5Rα/ IL-5Rβ) was assumed to consist of one copy of each 
IL-5/IL-5Rα/ IL-5Rβ in a 1:1:1 stoichiometry (Li et al., 1996). With the three-
dimensional structure of IL-5Rα/IL-5 complex the binding stoichiometry would be 
confirmed if they interact in a 1:1 relationship, since the dimeric conformation of the 
IL-5 suggest a potential accommodation of two IL-5Rα molecules, that denotes a 
binding stoichiometry of 1:2. 
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1.6 Intracellular Signaling Cascades of IL-5 Receptor 
 
Binding of IL-5 to its receptor occurs by a sequential mechanism. The IL-5 triggers 
its cellular responses by first binding the IL-5Rα (Johanson et al., 1995; Mita et al., 
1988; Mita et al., 1989; Takaki et al., 1990; Tavernier et al., 1991). The IL-5/IL-5Rα 
complex recruits the βc chain (Johanson et al., 1995; Mita et al., 1988; Mita et al., 
1989; Takaki et al., 1990; Tavernier et al., 1991), which leads to heteromeric 
receptor assembly and triggers intracellular signaling (Figure 1-6).  
The cytoplasmic domain of IL-5R lacks an intrinsic kinase activity. However, 
these cytoplasmic regions of the IL-5Rα and IL-5Rβ (βc) are critical in mediating 
signal transduction by the activation of intracellular protein kinases and transcription 
factors. The cytoplasmic domains of IL-5Rα and βc are associated with the Janus 
kinases (JAK) JAK2 and JAK1, respectively (Figure 1-6) (Kouro et al., 1996; Ogata 
et al., 1998). The trans-phosphorylation between JAK2 and JAK1 occurs after IL-5 
binding to IL-5Rα and recruiting of the βc chain into the complex 
The activated JAKs subsequently phosphorylate the βc in different tyrosine 
residues; six of them are conserved between mouse and human receptors (Tyr 577, 
Tyr 612, Tyr 695, Tyr 750, Tyr 806 and Tyr 866). The phosphorylation of the βc on 
Tyr 577 induces the activation of the ERK pathway (Guthridge et al., 1998; 
Martinez-Moczygemba and Huston, 2003), whereas tyrosine phosphorylation of Tyr 
577 and Tyr 612 is important for activation of the growth factor receptor-bound 
adaptor protein (Grb2). The ERK pathway is involved in the prevention of apoptosis, 
by increasing the levels of two anti-apoptotic proteins bcl-2 and bcl-x (Figure 1-6). 
Activated Grb2 activates downstream partners of the mitogen-activated protein 
kinase (MAPK) pathway (de Groot et al., 1998; Guthridge et al., 1998; Martinez-
Moczygemba and Huston, 2003).  
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Adapted from Martinez-Moczygemba, 2003 
 
Figure 1-6. Up-regulation and down-regulation pathways of the IL-5 receptor. IL-5 binds to 
the IL-5Rα and this dimeric complex recruits a second member of the receptor system βc. 
Simultaneously, pathways as MAPK, PI3K and syntenin-SOX4 are activated (green arrows). 
Ubiquitination, proteosome degradation, PIAS and SOCS appear as a down regulation 
mechanism (red arrows). 
 
JAK activation also results in tyrosine phosphorylation of the signal 
transducer and activator of transcription (STAT) STAT5. Activated STAT5 
translocates into the nucleus and regulates the transcription of genes encoding for 
proteins such as cytokine-inducible SH2-containing proteins (CIS), and the related 
suppressor of cytokine signaling proteins (SOCS). These are involved in the negative 
feedback, thus leading to down-regulation of JAK activity (Figure 1-6). NF-κB is 
also activated after phosphorylation of STAT5 as it was shown in murine Ba/F3 cells 
upon IL-5 activation (Nakamura et al., 2002). 
There are different sequence motifs (box) in the cytoplasmic domain of the βc 
related with cell proliferation, differentiation, and survival. For instance, the box 1 is 
a region formed by approximately 35 residues found proximal to the inner leaflet 
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membrane. Deletion of the box 1 was shown to interfere with cell proliferation. A 
second motif found downstream of box 1, called box 2, enhances the proliferation 
signals of box 1. The cell survival depends on a region that encompasses the residues 
544-763. This entire domain is required for cell survival in absence of serum 
(Guthridge et al., 1998; Martinez-Moczygemba and Huston, 2003). 
As well as the βc, the IL-5Rα cytoplasmic C-terminal domain also 
participates in mediating growth signal transduction and activation of JAK kinases 
and STAT5. The membrane proximal sequence (Pro 352-Pro353-X-Pro355) of the 
cytoplasmic domain of the IL-5Rα is required for cell proliferation and JAK/STAT 
activation (Kouro et al., 1996). In addition, the cytoplasmic tail of IL-5Rα is 
associated with the protein syntenin. Syntenin was found to directly interact with the 
transcription factor Sox4 which is important in B-cell development (Geijsen et al., 
2001). The down-regulation of the IL-5 signaling pathway is mediated by 
ubiquitination of the cytoplasmic domain of the βc (Figure 1-6). Ubiquitinated 
intracellular domain of the βc suffers proteasome degradation resulting in the 
generation of βc intracytoplasmic proteolysis (βIP). After that, the βIP/IL-5/IL-5Rα 
complex is endocytosed and degraded in the lysosomes (Figure 1-6) (Martinez-
Moczygemba and Huston, 2001).  
In addition, the suppressor of cytokine signaling (SOCS) and protein 
inhibitors of activated STAT (PIAs) proteins participate in the down-regulation of 
signaling, and thereby inhibit JAK and STAT pathways (Martinez-Moczygemba and 
Huston, 2003). Recently it was shown that the regulation of the IL-5 signaling 
pathway is a result of Dynamin-2 GTPase protein activation that is associated with 
alpha subunit of the IL-5 receptor. The specific role of Dynamin is the termination of 
the ERK1/2 signaling pathways. Dynamin also is required for the receptor 
endocystosis (Gorska et al., 2006).  
 
1.7 Structural Studies of IL-5 System 
 
Structure/function studies of the IL-5 complex are focused on understanding the 
molecular assembly of the protein molecules and how they interact to form an active 
complex. The first studies to determine the human IL-5/IL-5Rα complex X-ray 
crystal structure were performed by Johanson and colleagues in 1995 (Johanson et 
al., 1995). They deglycosylated human IL-5 using PNGaseF enzyme. After 
deglycosylation of the ligand, they co-crystallized the human IL-5/IL-5Rα complex 
INTRODUCTION 
____________________________________________________________________ 
20 
by hanging drop diffusion method. Only needle crystals were obtained from the 
complex crystals and the crystal structure of human IL-5/IL-5Rα complex could not 
be determined successfully (Johanson et al., 1995). The structure determination of 
IL-5/IL-5Rα/βc has also not been successful yet; instead of a complex X-ray 
crystallography structure picture, only the structure of individuals components of the 
IL-5 system such as human IL-5 (Milburn et al., 1993) or human βc (Carr et al., 
2001) has been determined so far. 
The first structure of the IL-5 system published was hIL-5. This structure of 
human IL-5 purified from E. coli was determined using X-ray crystallographic 
analysis (1-7). In 1992, Hassel and collaborators published the crystallization and 
preliminary X-ray diffraction studies of the recombinant hIL-5. They obtained 
crystals that belong to the space group C2 with cell unit constant of a = 122.1 Å, b = 
36.1 Å, c = 56.4 and β = 98.6° (Hassell et al., 1993). On continuation, the human IL-
5 protein structure was determined by Milburn and colleagues in 1993 (Milburn et 
al., 1993).  
The human IL-5 structure consists of two left-handed bundles of four helices 
(A-D) all positioned end to end, and two short β-sheets on opposite sides of the 
molecule (Figure 1-7). The two β-sheets are located between the helices A and B, 
and C and D. The helix bundle is formed by three helices A, B, and C from one 
monomer. Each one has a different length (Table 1-1); a fourth helix D (17 residues) 
is derived from the other monomer (Figure 1-7).  
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Figure 1-7. Structure of the human IL-5. The figure (ribbon) shows the complete molecule 
(upper) and each monomer (lower). Alpha helices of each monomer named A-D or A’-D’. β-
strands (green) and disulphide bonds (yellow) are designed 1 and 2. The structure was 
generated using PyMOL. 
 
Table 1.1 Amino acid sequences forming the secondary structure elements 
of hIL-5. 
 
Motif Start End Secondary 
structure 
Sequence 
A Thr 7 Ile 26 α TSALVKETLALLSTRTLLI 
B Hist 41 Glu 56 α HQLCTEEIFQGIGTLE 
C Val 65 Lys 84 α VERLFKNLSLIKKYIDGQKK 
D Val 93 Thr 109 α VNQFLDYLQEFLGVMNT  
Strand1 Arg 32 Val 35 β RIPV 
Strand2 Glu 89 Arg 92 β ERRR 
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The structure also reveals that the human IL-5 dimer is stabilized by two 
inter-chain disulfide bridges between Cys 44 and Cys 86 (Milburn et al., 1993). 
The secondary structure of the IL-5 system published was the human IL-5Rβ 
(βc). The crystal structure of the extracellular domain of βc was determined by X-ray 
crystallography (Carr et al., 2001; Gustin et al., 2001). This extracellular part of the 
human βc forms a stable intertwined dimer. The βc dimer is stabilized due to five 
disulfide bridges. The βc dimer has also been confirmed in chemical cross-linking 
experiments (Muto et al., 1996). 
 
A1
A2
A3
A4
B4
B3
B2
B1
 
__________________________________________________________ 
Figure 1-8. Structure of the human βc. Monomer A is colored blue and monomer B is colored 
magenta. Each monomer has four Fn-III-like domain designed A1-A4 or B1-B4. The 
residues involved in binding to the IL-5Rα/IL-5 complex are colored in yellow (Tyr15) and 
green (Phe79). 
 
Each human βc monomer consists of four domains with a Fn-III like topology 
(Figure 1-8). The WSXWS motif is found in domain four which is similar to those in 
other class I cytokine receptors (Carr et al., 2001).  
The elucidation of the crystallography structure of the IL-5R/hIL-5 complex 
represents an important breakthrough towards the design of antagonist molecules 
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that may affect the interaction of IL-5Rα with human IL-5. This complex may 
become the most promising target for rational drug design.  
 
1.8 Therapeutic Approaches in Asthma and Hypereosinophilic Syndrome 
Treatment 
 
Some therapeutic strategies have been developed to counteract eosinophil activation 
by IL-5 inhibition in asthma or hypereosinophilic symdrome. In this way, an anti-IL-
5 antibody (Mepolizumab) was used in eosinophils dermatitis patients. Mepolizumad 
effectively controlled the symptoms in these patients. Eosinophils counts and serum 
levels of eosinophil cationic proteins were normal 24 and 48 hours after initial 
treatment, respectively. Other symptoms (pruriginous, eczematous and urticarial skin 
lesions) diminished after the first infusion (Plotz et al., 2003).  
In another clinical setting, mepolizumab was administered to four men (10 
mg/kg, maximun 750 mg) with hypereosinophilic symdrome (HES) defined by 
peripheral blood and/or tissue eosinophilia. The patients showed a ten-fold reduction 
in tissue-eosinophil levels. Furthermore, the treatment improved the clinical 
symptoms and quality of life. The number of peripheral blood eosinophils had 
significantly decreased three months after the last dose (Garrett et al., 2004). 
Contradictory results were recently reported by Oldhoff and colleagues (Oldhoff et 
al., 2006); they showed that mepolizumad did not exhibit any effect on the atopic 
path test in atopic dermatitis. The atopic path test is an in vivo model used to study 
the induction of eczema by inhaled allergens in atopic dermatitis patients. 
Mepolizumab could not prevent the eczematous reactions or lower the number of 
eosinophils in the tissue. However, peripheral blood eosinophils were decreased by 
antibody therapy (Oldhoff et al., 2006). These discrepancies suggest that there is a 
possible redundancy in the cytokines, which participate in this biological 
phenomenon. 
Accordingly, anti-IL-5 humanized antibodies like mepolizumab have been 
used in several clinical tests. Different trials carried out in 2003 in asthmatic 
individuals showed that the anti-IL-5 (mepolizumab) therapy arrested the eosinophil 
maturation and decreased the number of eosinophil progenitors (Menzies-Gow et al., 
2003). The mepolizumab treatment also reduced the levels of extracellular matrix 
proteins such as tenascin, lumican and procollagen III (Flood-Page et al., 2003a). 
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However, the anti-IL-5 therapy did only partially reduce, but did not completely 
deplete the eosinophils in the airway (Flood-Page et al., 2003b).  
On the other hand, peptides with antagonist action to IL-5 have been 
developed as new therapies (England et al., 2000; Ishino et al., 2005; Ruchala et al., 
2004). The peptides evaluated so far seem to employ the same contact residues of 
IL-5 and in this way, they might block the interaction of the IL-5 with the receptor 
alpha chain. These in vitro results showed competition between IL-5 and the 
antagonist peptide for binding to IL-5Rα, and these antagonist peptide displayed the 
same affinity as IL-5 (England et al., 2000). More recently, by using cyclic peptides 
as therapeutic agents it could be demonstrated that they effectively mimic the CD 
turn recognition epitope for alpha-receptor. Additionally, the peptide could exhibit a 
similar interaction mechanism to that of IL-5. Also, biological experiments showed 
peptide inhibition of IL-5 activity (Ishino et al., 2005; Ruchala et al., 2004). Further 
experiments were performed using site-directed mutagenesis on the peptides, which 
were then examined for the type of IL-5Rα interaction. In order to interact with the 
receptor, the peptide must undergo a conformational rearrangement during binding. 
The studies also demonstrated that this peptides use two amino acids (Arg 6 at the N-
terminal and His 11 at the C-terminal) to stabilize the final complex (Ishino et al., 
2006). Most importantly, this peptide was able to deactivate the IL-5 receptor 
function. Taken together these results it can be hypothesized that such peptides may 
have good potential to act as antagonist molecules for modern asthma therapy. 
In order to improve the current strategies of asthma therapy, it would be 
highly beneficial to increase our understanding of the molecular IL-5 receptor and 
IL-5 agonist interaction. The knowledge of the three dimensional structure of this 
complex will provide new insights in this crucial step of asthma pathogenesis. 
Ultimately, this may create new options to design specific antagonist molecules, 
which may result in a breakthrough of our current arsenal of targeted 
pharmacological options to relieve this disease condition of increasing importance.  
 
AIMS 
____________________________________________________________________ 
25 
 
2 AIMS  
 
Interleukin-5 (IL-5) belongs to the family of haematopoietic cytokines and plays a 
key role during development of Th2 immune responses. IL-5 contributes to the 
differentiation and function of eosinophils, which are implicated in the 
pathophysiology of asthma disease as well as the hypereosinophilic syndrome. Both 
diseases are characterized by tissue damage due to eosinophil activation as a result of 
the interaction of IL-5 and the extracellular membrane IL-5 receptor. The IL-5 and 
its IL-5R represent a promising target for the development of new therapeutic 
strategies that can block the pathophysiological eosinophil activation. Structural 
aspects of the IL-5R/IL-5 complex should be clues towards the understanding of the 
mechanism of their interaction. Additionally, the structural features of the mouse IL-
5 system can be used to study the species-specific interaction. Thus, the receptor 
ectodomain of human IL-5Rα (IL-5RαECD) in complex with human IL-5 (hIL-5) and 
mouse IL-5 (mIL-5) X-ray structure should be examined in this work.  
The principal objective of this thesis was to resolve the three-dimensional 
structure of the extracellular domain of the receptor-specific binding chain of the IL-
5 (hIL-5RαECD) in complex with hIL-5, which is essential to recruit the second 
receptor chain, in order to trigger intracellular signaling. In addition, the elucidation 
of the three-dimensional structure of the mIL-5 was also a primary goal of this work. 
The first step towards deciphering the complex and the mIL-5 structure was to 
achieve the expression of the proteins in an E.coli expression system that would 
allow the production of large amounts of protein. Another important task to be 
accomplished was to find the specific crystallization conditions of the hIL-
5RαECD/hIL-5 complex and of the mIL-5. A further objective was to resolve the 
three-dimensional structures of mIL-5 and to compare it with the hIL-5, in order to 
determine the molecular basis for the species-specific receptor binding properties. 
Last but not least, the specific binding topology of the hIL-5RαECD/hIL-5 complex 
should be analyzed and compared to other receptors of the same family. 
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3 MATERIALS AND METHODS 
 
3.1 Reagents 
 
The basic chemicals were obtained from Applichem, Merck, Roth and Sigma-
Aldrich. The enzymes were purchased from New England Biolab and Fermentas. 
Crystallization buffers were from Hampton research and Jena Bioscience. 
The proteins were dialyzed in Spectra/por 3 (132720) regenerated cellulose 
membranes from Roth. The Spectra/por 3 has a Molecular Weight Cutoff (MWCO) 
of 3500, a diameter of 11.5 mm, and a capacity of volume/length of 1 ml/cm. 
Proteins were concentrated by ultra-filtration membranes regenerated cellulose YM3 
membranes with 3000 MWCO. Amicon ultra-4 with 5000 MWCO (UFC 800524) 
were from Millipore. Viva flow 200 system with 5000 MWCO membranes was used 
to concentrate proteins in large volume. 
For bacteria and mammalian culture medium, destilled and standard 
deionized water were used, respectively. For the preparations of stock solutions for 
crystallization, Milli Q quality water [18.2 MΩ cm] was used. 
 
3.2 Kits 
 
The sequencing kit “DTCS Quick Start” was purchased Beckman Coulter. Kits for 
PCR product purification (QIAquick PCR), plasmid purification (QIAfilter plasmid), 
and DNA agarose cleaning (QIAquick Gel Extraction) were obtained from 
QIAGEN. The sensor chips CM5, and the amine coupling kit with the N-ethyl-N’-
(3-diethylaminopropyl) carbodiimide, N-hydroxysuccinimide and ethanolamine 
hydrocloride were from Pharmacia (Pharmacia, BIAcore). 
 
3.3 Sterilization 
 
Buffers and media were autoclaved for 20 min at 121°C, 1.1 bar. Crystallization 
stocks solutions were sterile filtered through Millipore 0.22 μm filters. 
 
3.4 Bacterial Strains 
 
E. coli Rosetta-gami (DE3)pLysS (Novagen) 
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Genotype: Δ(ara-leu) 7697 ΔlacX74 ΔρhoA Pvull ρhoR araD139 ahpC gale galK 
rpsL (DE3) F’[lac+ laclq pro] gor522::Tn 10 trxB pLysSRARE (CamR, KanR, StrR, 
TetR). 
E. coli AD494 (DE3) (Novagen) 
Genotype: Δ(ara-leu) 7967 ΔlacX74 ΔρhoA Pvull ρhoR ΔmaIF3 F’[lac+ laclq pro] 
trx::kan 
 
3.5 Expression Vectors 
 
pET expression vectors: pET-3d, pET-31b, pET-32a, pET-44a (Novagen) 
 
3.6 Oligonucleotides 
 
Mutation (hIL-5Rα)  
C66A: 5’-ACTGAAAGCAAAGCTGTAACCATCCTC-3’ 
D55E: 5’-GCTCCAAAAGAAGAAGACTATGAAACC-3’ 
Y57F: 5’-AAAGAAGATGACTTTGAAACCAGAATC-3’ 
F182A: 5’-TTTCCCAGGACTGCTATCCTCAGCAAAG-3’ 
I183A: 5’-CCAGGACTTTTGCCCTCAGCAAAGGGC-3’ 
R188K: 5’-CTCAGCAAAGGGAAAGACTGGCTTGCG-3’ 
L72M Forward 5’-ACCATCCTCCACATGGGCTTTTCAGCA-3’ 
L138M Forward 5’-CACTGCACCTGGATGGTTGGCACAGAT-3’ 
L167M Forward 5’-CAAGAATACAGCATGGACACACTGGGG-3’ 
L234M Forward 5’-GAAGGAACTCGTATGTCTATCCAATGG-3’ 
 
Mutation (hIL-5)  
E13Q Forward: 5’-GCATTGGTGAAACAGACCTTGGCACTG-3’ 
 
Mutation (mIL-5)  
M5T Forward: 5’-GGAGATTCCCACCAGCACAGTGGTG-3’ 
M29L Forward: 5’-GCAATGAGACGCTTAGGCTTCCTGTC-3’ 
M65R Forward: 5’-GGTACCGTGGAAAGACTATTCCAAAAC-3’ 
M105L Forward: 5’-TTCCTTGGTGTGCTTAGTACAGAGTGG-3’ 
M111I Forward: 5’-ACAGAGTGGGCAATTGAAGGCTAAGGA-3’ 
E13Q Forward: 5’-ACAGTGGTGAAACAGACCTTGACACAG-3’ 
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Truncation (hIL-5Rα) 
10aaRaForward: 5’-TTACCATGGCAATTTCACTTCTCCCACCTG-3’ 
20aaRaForward: 5’-TTACCATGGCAAAAGTTACTGGTTTGGCTCAAG-3’ 
Reverse BamH I: 5’-TTTTTTGGATCCTATCTTGAGAACCC-3’ 
Del2 Forward: 5’-TTTTTTTCCATGGCAGACTTACTTCTTG-3’ 
Del2Reverse: 5’-TTTTGGATCCTCAATTTATTTGATCAATGGCGTGA-3’ 
Del3 Forward: 5’-TTTTTTTCCATGGCAGACTTACTTCTTG-3’ 
Del3Reverse: 5’-TTTTGGATCCTCAGGCATGAAGTTCAGCAGAAG-3’ 
 
Cloning (mIL-5) 
Forw NcoI: 5-‘TTTTTTTTTCCCATGGAGATTCCCATGAGCAC-3’  
Reve BamH I: 5’-TTTTTTGGATCCTTAGCCTTCCATTGCCCA-3’ 
Forw AlwN I: 5’-CAGATGCTGGAGATTCCCACCAGCACAGTG-3’ 
Reve Xho I: 5’-CTCGAGTTAGCCTTCAATTGCCCACTC-3’ 
 
Sequencing 
T7 Promoter: 5’-TAATACGACTCACTATAGGG-3’ 
T7 Terminator: 5’-GCTAGTTATTGCTCAGCGG-3’ 
 
3.7 Site Directed Mutagenesis 
 
3.7.1 Single mutation by Cyclic PCR  
 
Master mix 2.5 μl 10X pfu buffer (200 mM Tris-HCl, pH 8.8, 100 mM 
(NH4)2SO4, 100 mM KCl, 1 % (v/v) Triton X-100, 1 mg ml-1 
BSA) 
5.0 μl plasmid DNA [5 ng/μl]  
   2.0 μl dNTP (2.5 mM) 
   1.0 μl Forward primer (10 pmol/μl) 
   1.0 μl Reverse primer (10 pmol/μl) 
   1.0 μl pfu Polymerase (prepared by Dr. Joachim Nickel) 
   12.5 μl water 
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Mutations were introduced into the DNA template with two complementary 
mutagenesis oligonucleotide primers (3.6). The PCR was performed in a reaction 
volume of 25 μl (Maxter mix). For PCR mutagenesis a total of 25 cycles were run 
with 2 min denaturation at 94°C, 2 min annealing at 60°C; and 6 min extension at 
72°C; with a last extension time of 10 min at 72°C. The parental Dam-methylated 
plasmid was digested with 10 U Dpn I restriction enzyme at 37°C for 1 hour, and the 
E. coli cells were transformed with the newly synthesized, nonmethylated and thus 
Dpn I resistant plasmid. 
 
3.7.2 Two Step PCR  
 
First PCR  Reaction I 
Master mix  2.5 μl 10X pfu buffer 
1.0 μl plasmid DNA [2 ng/μl] 
   2.0 μl dNTP (2.5 mM) 
   1.0 μl T7 Promoter primer (10 pmol/μl) 
   1.0 μl Reverse primer of the specific mutation (10 pmol/μl) 
   1.0 μl pfu Polymerase (prepared by Dr. Joachim Nickel) 
   16.5 μl water 
 
   Reaction II 
Master mixes  2.5 μl 10X pfu buffer 
1.0 μl plasmid DNA [2 ng/μl] 
   2.0 μl dNTP (2.5 mM) 
   1.0 μl Forward primer of the specific mutation (10 pmol/μl) 
   1.0 μl T7 Terminator primer (10 pmol/μl) 
   1.0 μl pfu Polymerase (prepared by Dr. Joachim Nickel) 
   16.5 μl water 
 
Technical device Thermocycler (Master cycler personal, Eppendorf) 
 
Second PCR 
Master mixes  2.5 μl 10X pfu buffer 
2.0 μl DNA from Reaction I 
2.0 μl DNA from Reaction II 
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   2.0 μl dNTP (2.5 mM) 
   1.0 μl T7 Promoter primer (10 pmol/μl) 
   1.0 μl T7 terminator primer (10 pmol/μl) 
   1.0 μl pfu Polymerase (prepared by Dr. Joachim Nickel) 
   13.5 μl water 
 
Mutations were introduced into template DNA with two complementary mutagenesis 
and two sequencing oligonucleotide primers (3.6). The two PCR reactions were 
carried out in a reaction volume of 25 μl. The PCR reactions (I and II) were 
performed for 25 cycles of 45 sec at 94°C (denaturation), 45 sec at 60°C (annealing), 
and 45 sec extension at 72°C, followed by the final extension step of 10 min at 72°C. 
The PCR reaction I employs a 5’ sense primer annealing to the T7 promoter region 
and a 3’ antisense primer harboring the mutation. The reaction II employs a 5’ sense 
primer encoding the mutation and a 3’ antisense primer, which is complementary to 
the T7 terminator region in the expression vector. After the first PCR, the two PCR 
products matched in 24 nucleotides and the mismatched (mutation) is found in the 
middle of the matched region. 
Afterwards, a second PCR reaction was done with 2 μl of Reaction I and 2 μl 
of Reaction II following the same cycling parameters (First PCR). The PCR products 
were analyzed by agarose gel stained with EtBr to verify the molecular size. 
 
3.7.3 Truncation by PCR  
 
Master mixes  2.5 μl 10X pfu buffer 
1.0 μl plasmid DNA [2 ng/μl] 
   2.0 μl dNTP (2.5 mM) 
   1.0 μl Forward primer (10 pmol/μl) 
   1.0 μl Reverse primer (10 pmol/μl) 
   1.0 μl pfu Polymerase (prepared by Dr. Joachim Nickel) 
   16.5 μl water 
 
Mutations were introduced by simultaneous annealing of two oligonucleotide 
primers to one strand of the denatured double strand plasmid DNA (3.6). One primer 
introduces the desired mutation. The PCR was performed for 25 cycles which were 
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run for 45 sec denaturation at 94°C, 45 sec annealing at 60°C; and 45 sec extension 
at 72°C; with a last extension time of 10 min at 72°C. 
All mutations were verified by DNA sequencing (DTCS Quick start kit, 
Beckman Coulter # 608120) 
 
3.8 Cloning 
 
3.8.1 DNA digestion 
 
Digestion reaction 1.0 μl restriction enzymes (s) (10 or 20 U) 
2.5 μl 10 X specific buffer (see catalog) 
2.0 μl plasmid DNA or PCR products (0.5-1.0 μg/μl)  
   19.5 μl dH2O 
Technical Device Thermo Block (TDB-120, Biosan) 
 
The digestion reaction was incubated for 3 hours at 37°C. Restriction enzyme 
activity was stopped by incubating 20 minutes at 65°C. The digestion products were 
visualized on 1.2% agarose gels stained with EtBr. The different digestion products 
were purified by QIAquick Gel purification kit (QUIAGEN) before ligation reaction. 
 
3.8.2 DNA ligation 
 
Set up   1.0 μl T4 DNA ligase (40 U) 
1.0 μl 10 X T4 DNA ligase buffer 
50-100 ng digested PCR product (2.0 μl) 
25-50 ng digested Vector (1.0 μl) 
   5.0 μl dH2O 
Technical device Thermocycler (Master cycler personal, Eppendorf) 
 
Digested plasmid and PCR products were purified by QIAquick Gel purification kit 
(3.8.1). The ligation reaction was set up with a ratio of 1:2 (vector:insert) and it was 
incubated at RT for 2 hours, or at 16°C ON. The ligated DNA was transformed in 
competent E. coli cells (Nova Blue) to amplify the DNA. 
 
3.9 Preparation of Competent Cells (RbCl2 Method) 
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Buffer I, pH 5.8  30 mM Potassium acetate 
100 mM RbCl2 
10 mM CaCl2 
50 mM MnCl2  
15 % Glycerin (v/v) 
Adjust pH with Acetic acid 
Buffer II, pH 6.5  10 mM MOPS 
10 mM RbCl2 
75 mM CaCl2 
15 % Glycerin (v/v) 
Adjust pH with NaOH 
 
One colony from transformed E.coli cells was picked and transferred into 2 ml LB 
with a specific antibiotic. The culture was incubated at 37°C with shaking at 130 rpm 
overnight. This 2 ml culture was used to inoculate a flask containing 100 ml LB 
medium with respective antibiotics and the culture was incubated at the same 
conditions. The cells were incubated until the OD600 0.4-0.6 was reached. The cells 
were transferred to 50 ml centrifuge tubes and pelleted by centrifuge at 3000 rpm at 
4oC for 5 min. After that, the cells were dissolved into 40 ml of cold buffer I and 
incubated in ice for 15 min. New centrifugation was performed at 3000 rpm at 4oC 
for 5 min. The last pellet was re-dissolved in 10 ml cold buffer II and the cells 
suspension was stored in ice for 15 min. After that, the cell suspension was split in 
100 μl aliquot and immediately frozen in liquid nitrogen. The aliquots were stored at 
-74°C. 
 
3.10 Transformation of E. coli 
 
LB-agar plates Add 10 g agar powder (Applichem) to 250 ml dH2O 
Add 500 μl 2 M NaOH 
Sterilized by autoclaving 
Add antibiotic (s) at 45°C 
 
LB-broth  Add the following to 800 ml of dH2O 
10 g Bacto-tryptone, 10 g NaCl and 5 g Bacto-yeast 
Adjust to pH 7.4 with NaOH 
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Adjust volume to 1 liter with dH2O 
Sterilize by autoclaving 
 
One aliquot of competent E. coli cells was thawed on ice and 10-20 ng of plasmid 
DNA or 2.0-4.0 μl of a ligation reaction was added and mixed with the cells by 
stirring gently with a pipette tip. The vial was incubate on ice for 30 min. 
Afterwards, incubate the cells for 60 sec at 42°C (heat shock) block heater. Remove 
the cells from the block and place them on ice for 2 min. The volume of solution was 
increased by adding 250 ml of LB medium without antibiotics and the cells were 
incubated at 37°C for 1 hour with shaking. Transformed cells were spread on agar 
plate containing the specific antibiotic. Cells without plasmid DNA was seeded on a 
new agar plate as negative control. The plates were incubated at 37°C for 24 hours. 
 
3.11 E. coli Protein Expression 
 
3.11.1 Native proteins 
 
TB-broth  Add the following to 800 ml of dH2O 
13.4 g Bacto-tryptone, 26.6 g Bacto-yeast and 4.4 ml glycerin 
Adjust volume to 1 liter with dH2O 
Sterilize by autoclaving 
 
Pi Buffer (10X) Add the following to 800 ml of dH2O 
23.1 g KH2PO4 (0.17 M) and 25.4 g K2HPO4 (0.72 M) 
Adjust volume to 1 liter with dH2O 
Sterilize by autoclaving 
 
Working medium: Use 9 volumes of TB with 1 volume Pi 
 
LB-broth  Add the following to 800 ml of dH2O 
10 g Bacto-tryptone, 10 g NaCl and 5 g Bacto-yeast 
Adjust to pH 7.4 with NaOH 
Adjust volume to 1 liter with dH2O 
Sterilize by autoclaving 
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Technical devices: Incubator shaker (Multitronic INFORS), centrifuge HERAUS 
Suprafuge 22 (12.500 rotor), Ultrospect 3000 (Pharmacia Biotech). 
 
One colony from transformed E.coli cells was picked from an agar plate (3.10) and 
transferred into 500 ml E.coli culture medium with the respective antibiotic (s) and 
incubated at 37°C with shaking at 130 rpm ON. Next day, a 40 ml aliquot were used 
to inoculate twelve 2-L Erlenmeyer flasks containing 800 ml (1:20) fresh medium. 
The flasks were incubated at 37°C with shaking until an optical density of 0.6 
O.D600nm was reached. At this point, IPTG was added to a final concentration of 1 
mM to induce protein expression. Then, the culture was incubated for additional 3 
hours. Cells were harvested by centrifugation at 6500 rpm (Heraeus, 12.500 rotor) 
for 20 min at 4°C. The cell pellet was resuspended in 10-15 volumes of lysis buffer 
(TBSE, STE or TE). 
 
3.11.2 Selenomethionyl-proteins  
 
M9-media (10X)  Add the following to 800 ml of dH2O 
60g Na2HPO4, 30g KH2PO4, 5g NaCl, 10g NH4Cl,  
Adjust pH to 7.2-7.4 with NaOH 
Sterilize by autoclaving  
 
Trace Metals (100X)  Add the following to 800 ml of dH2O  
5 g EDTA, 0.8 g FeCl3, 0.05 g ZnCl2, 0.01 g CuSO4, 
0.01 g CoCl2, 0.01 g H3BO3, 1.6 g MnCl2, 0.01 g 
Na2WoO4 
    Sterilize by Filtration  
    Adjust to 1 L with water 
 
Complete M9 medium Add the following to 800 ml of dH2O 
   100 ml of M9 (10X) 
Add 1 ml MgSO4 (1.0 M) 
100 μl CaCl2 (1.0 M) 
10 ml Trace metals  
40 ml 20 % (w/v) glucose  
100 mg Thiamine 
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Adjust to 1 L with water 
 
Amino acids:  Add 100 mg L-Lysine, 100 mg L-Phenylalanine, 100 mg L-
Threonine, 50 mg L-Leucine, 50 mg L-Isoleucine, 50 mg L-
Valine and 50 mg L-SelenoMet. 
 
Cells from a fresh transformation were transferred from an 16-24 hours old plate into 
2.0 ml LB with specific antibiotic (s) and incubated at 37°C with shaking at 130 rpm 
over day. Then, the 2.0 ml cultured cells were centrifuged at 4°C for 5 min at 4000 
rpm and the pellet was resuspended to inoculate 400 ml of complete M9-media 
without L-amino acids, and incubated at 37°C with shaking ON. Next day, a 40 ml 
aliquot of the culture was added into an Erlenmeyer flask containing 800 ml M9 
medium freshly without L-amino acids. The culture cells was incubated at 37°C with 
shaking until an optical density of 0.6 O.D was reached. At this point, L-amino acids 
were added and after 30 min further incubation, IPTG was added to a final 
concentration of 1 mM to induce protein expression. The culture was incubated for 
additional 18 hours at 37°C with shaking. Cells were processed as it was described 
above. 
 
3.12 Receptor  
 
3.12.1 Inclusion bodies isolation  
 
Buffers 
 
6M or 8M GuHCl 50 mM NaAc, pH 5.0 
6M or 8M GuHCl 
 
TBSE   10 mM Tris-HCl, pH 8.0 
   150 mM NaCl 
1mM EDTA 
0.001 % (v/v) β-ME 
 
TE   10 mM Tris-HCl, pH 8.0 
   1 mM EDTA 
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Size exclusion chromatography with GuHCl (SEC-GuHCL) 
SEC-GuHCL Buffer   50 mM NaAc pH 5.0 
6M GuHCl 
1 mM EDTA 
 
Column  Superdex 200 (preparative grade 16/60, 
Pharmacia) 
Column volume   120 ml 
 
Technical devices 
Sonifier (KLM system 585), centrifuge Sorwall RC5C (GSA rotor), centrifuge 
HERAUS Suprafuge 22 (22.50 rotor), Ultrospect 3000 (Pharmacia Biotech), 
Chromatography system (Äkta prime plus, Pharmacia) and magnetic stirrer. 
 
The cells in TBSE (native 3.11.1 or Se-protein 3.11.2) were supplemented with 20 μl 
of a protease inhibitor cocktail (Calbiochem). To isolate the inclusion bodies (IB), 
the cell suspension was disrupted by sonication. Sonication was carried out for 5 min 
at 300 watts on ice and the suspension was centrifuged at 11500 rpm (Sorvall, GSA 
rotor) for 30 min at 4°C. The pellet was resuspended with 200 ml of TBSE buffer 
and the cell lysis was repeated as it was described above. The pellet (IB) was washed 
twice with 200 ml TBSE buffer; each wash was followed by centrifugation at 11500 
rpm for 20 min. The pellet was resuspended in 30 volumes TBSE (w/v) and 10 
volumes 8 M GuHCl (w/v), and shaken for 30 min at RT. Then, IB were precipitated 
by centrifugation at 11500 rpm for 30 min at 4°C. The protein was then extracted by 
resuspension of the pellet into 4 volumes TE (w/v), 5 volumes 8 M GuHCl (w/v) and 
100 μl β-ME (v/v). The solution was incubated at room temperature with mild 
shaking ON. Next day, the suspension was centrifuged for 90 min to 16000 rpm at 
4°C (HERAUS, 22.50 rotor) to clarify the supernatant. Afterwards, the supernatant 
was filtered with paper filters by flow gravidity. The protein concentration was 
determined by optical density (OD) spectrum at 280 nm using the Ultrospect 3000 
(Pharmacia Biotech). Protein concentration was adjusted to 40 mg ml-1 using an 
Amicon system. To eliminate bacterial DNA in the protein preparation, 200 mg of 
protein were loaded into the equilibrated column. The column was pre-equilibrated 
with 2 volumes of buffer 6M GuHCl at a flow rate of 1.5 ml min-1 before the protein 
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was loaded. 7 ml protein fractions were collected. Protein concentration was adjusted 
to 20 mg ml-1. 
 
3.12.2 Renaturation  
 
Protein renaturation was carried out as follows: approximately 100 mg of denatured 
protein (13.12.1) were diluted into one liter of refolding buffer (50 mM Tris-HCl pH 
9.5, 7.5 M Urea, and 0.1 mM reduced cysteine. The solution was then incubated for 
2 hours at RT with mild shaking. Afterwards, the solution was dialyzed in 10-fold 
volume of dialysis buffer (50 mM Tris-HCl pH 9.5, 3 M Urea, and 100 μg/L CuSO4) 
for one day at 4°C. After that, the urea concentration was reduced by 50 % in 
dialysis buffer by replacing 50% with fresh 50 mM Tris-HCl pH 9.5 buffer, until 
0.75 M urea concentration was reached. After, the protein was changed to 50 mM 
Tris-HCl pH 9.5 buffer, for 24 hours and finally, the protein was dialyzed in 50 mM 
Tris-HCl pH 8.1 buffer, for 24 hours. The protein was concentrated to a final volume 
of 100 ml with a protein concentration of approximately 1 mg ml-1. 
 
3.12.3 Purification  
 
3.12.3.1 Anion Exchange chromatography I 
 
Pre-equilibration buffer  50 mM Tris-HCl, pH 8.1 
 
Wash buffer    50 mM Tris-HCl, pH 8.1 
150 mM NaCl 
 
Elution buffer   50 mM Tris-HCl, pH 8.1 
0.5 M NaCl 
 
Column    HighLoad 16/10 Q-sepharose 
Column volume   20 ml 
Chromatography system  Akta prime plus (Pharmacia) 
 
100 ml of refolded protein (3.12.2) were applied to Q-sepharose column equilibrated 
with 10 volumes of pre-equilibration buffer at a flow rate of 1.5 ml min-1 and then 
washed with 10 volumes. A linear gradient leading to a final concentration of 0.5 M 
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NaCl was used to elute bound material. 5 ml protein fractions were collected and 
analyzed by SDS-PAGE. 
 
3.12.3.2 Anion Exchange chromatography II 
 
Buffer A1    40 mM TAPS 
Buffer A2    40 mM Sodium TAPS 
Buffer B1    Water 
Buffer B2    2 M Sodium Chloride 
Column    UNO Q1 column (Bio-Rad) 
Chromatography system  Biologic Duo Flow (Bio-Rad) 
Software    Biologic Duo Flow software (Bio-Rad) 
     Scouting program (Bio-Rad) 
 
Refolded protein from Anion exchange chromatography I was purified by an UNO 
Q1 column. The column was pre-equilibrated with 10 volumes of 40 mM TAPS 
buffer at a flow rate of 1.5 ml min-1. After that, the protein was loaded on the column 
at a flow rate of 1.5 ml min-1. Then, the column was washed with 5 volumes of 
buffer A at a flow rate of 2.0 ml min-1. The bound protein was eluted with a gradient 
between 0 % - 100 % buffer B2, at constant pH (7.8), and at a flow rate of 3.0 ml 
min-1. The gradient profile utilized for solvent B2 was 0% for 6.5 min and 0 to 100% 
for 12 min. 1 ml protein fractions were collected and analyzed by SDS-PAGE.  
 
3.12.3.3 Size exclusion chromatography  
 
Buffer    50 mM Tris-HCl, pH 8.1  
Column   HiLoad 16/60 Superdex 200 (Pharmacia) 
Column volume  120 ml 
Chromatography system Akta prime plus (Pharmacia) 
 
The column was previously pre-equilibrated with 2 volumes of buffer at a flow rate 
of 1.5 ml min-1 before loading protein (3.12.3.1). 5 ml protein fractions were 
collected and analyzed by SDS-PAGE. 
 
3.12.3.4 Affinity chromatography 
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Matrix    CNBr-activated sepharose 4 fast flow  
Conjugate protein   hIL-5 (6.0 mg ml-1) 
Dialysis buffer   0.1M NaHC03 pH 8.3 
     0.5mM NaCl 
Acid solution    1mM HCL 
Coupling buffer   0.1M NaHCO3 pH 8,3 
0.5M NaCl 
Store buffer    0,1M Tris-HCl pH 8.0 
Centrifuge    Eppendorf 5702 
 
The protein was previously dialyzed overnight at 4°C into dialysis buffer. Add 3 g of 
matrix into 40 ml of 1mM HCl; mix gently but thoroughly by inverting 5 min. After 
that, the suspension was centrifuged at 4000 rpm at 4°C for 5 min. Then, the matrix 
was washed with 200 ml coupling buffer. The protein was immediately immobilized 
onto activated matrix by adding aliquots of 5 mg one by one until 30 mg. The 
solution was incubated for 60 min at 4°C with rotation. To remove the unbound 
protein the centrifugation was carried out at 1000 rpm for 5 min at 4°C. The matrix 
was resuspended in 25 ml of 0,1M Tris-HCl, pH 8.0 and packed into a Biorad yellow 
column.  
 
Chromatography 
 
Pre-equilibration buffer  50 mM Tris-HCl, pH 8.1 
Elution buffer   4M MgCl2 
Column Immobilized hIL-5 in CNBr-activated 
sepharose 4B (Amersham pharmacia biotech) 
Pump     Peristaltic-pump LKB 
Detector    2238 UVICORD SII (LKB) 
 
The affinity column was pre-equilibrated for 60 min at 4°C with pre-equilibration 
buffer. The refolded protein (3.12.2) was loaded at a flow rate of 1.0 ml min-1. Then, 
the column was washed for 60 min with pre-equilibration buffer to eliminate the 
unbound protein. The bound protein was eluted with 4 M MgCl2 at a flow rate of 1.0 
ml min-1. 5 ml protein fractions were collected and they were immediately dialyzed 
in cold (4°C) pre-equilibration buffer.  
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3.13 Ligand  
 
3.13.1 Inclusion bodies isolation (Human) 
 
Buffers 
 
6 M and 8 M GuHCl  50 mM NaAc, pH 5.0 
6 M or 8 M GuHCl 
 
STE (lysis buffer)  50 mM Tris-HCl, pH 8.0 
    0.375 M Sucrose 
1mM EDTA 
 
NaAc  50 mM Sodium acetate, pH 50 
EDTA  250 mM, pH 8.0 
 
Size exclusion chromatography with GuHCl (SEC-GuHCL) 
SEC-GuHCL Buffer  50 mM NaAc pH 5.0 
6M GuHCl 
1mM EDTA 
1mM DTT  
 
Cells were lysed by sonication (300 watts for 5 min at 4°C) and the centrifugation 
was carried out at the same condition mentioned before (3.12.1). Pellet was 
dissolved in 8 volumes NaAc (w/v), 1 volume 6 M GuHCl (w/v), and 1 mM EDTA; 
shaking the solution for 30 min at RT. The inclusion bodies (IB) were precipitated 
by centrifugation at 11500 rpm for 30 min at 4°C. The last pellet was weighted and 
resuspended in 1.5 volumes NaAc (w/v), 7.5 volumes 8 M GuHCl (w/v) and 100 μl 
β-ME (v/v). The solution was incubated overnight at room temperature with mild 
shaking. Next day, the suspension was centrifuged for 90 min at 16000 rpm at 4°C 
(HERAUS, 22.50 rotor) to remove cellular debris. Afterwards, the supernatant was 
filtered with paper filters by flow gravidity. The protein concentration was 
determined by optical density (OD) spectrum at 280 nm using the Ultrospect 3000 
(Pharmacia Biotech). Protein was purified by size exclusion chromatography as it 
was described before (3.13.1). 
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3.13.2 Inclusion bodies isolation (Mouse) 
 
Buffers 
 
6 M or 8 M GuHCl  50 mM NaAc, pH 5.0 
6 M GuHCl 
 
TE   20 mM Tris-HCl, pH 7.8 
0.5 mM EDTA 
 
Washing buffer 20 mM Tris, pH 7.8 
   0.5 mM EDTA 
   2 % (v/v) Triton X-100 
 
Dissolving buffer 50 mM Tris, pH 7.8 
   2 % (v/v) β-ME 
   2 % (w/v) SDS 
 
Acetone  Pure Acetone 
Acid    Formic Acid 
 
The cell pellet was resuspended in TE buffer (3.11.1). Sonication and centrifugation 
were carried out at the same conditions as mentioned before. Then, the pellet (IB) 
was washed one time in washing buffer; followed by centrifugation at 11500 rpm for 
20 min (Sorvall). The pellet was resuspended in 100 ml of dissolved buffer and 
incubated at 37°C with shaking for 60 min. To clarify the supernatant, the 
suspension was centrifuged at 16500 rpm, for 30 min at 4°C (Heraeus, rotor 22.50) 
and the pellet was discarded. Two volumes of cold acetone were added to 
supernatant and incubated on ice for 20 min. After that, the solution was centrifuged 
at 11500 rpm for 60 min at 4°C (Sorvall, GSA rotor). The pellet was dissolved in 40 
ml 80% formic acid and centrifuged at 16000 rpm for 60 min at 4°C. The 
supernatant was used to CNBr digestion. Fusion protein was digested by 100 μl of β-
ME and 125 mM final concentration of cyanogen bromide (CNBr). The reaction was 
incubated overnight at room temperature with shaking. Next day, the formic acid 
concentration was reduced to 40 % with one volume of water, and the protein was 
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dialyzed (2-3 liters) in 6 M GuHCl pH 6.5 for two days by changing the buffer each 
24 hours. To avoid a possible reaction of sulfhydryl group with other thiols or 
irreversible oxidation of sulfhydryl groups the protein was subjected to sulphonation 
treatment. The protein was incubated for 5 hours at 37°C with 2 g of Na2SO3 and 0.5 
g of Na2S4O6 (Hoppe et al., 1989; Hoppe et al., 1990). To eliminate insoluble 
material, the solution was centrifuged to 16000 rpm for 60 min at 4°C and the 
supernatant filtered. Protein was purified by size exclusion chromatography as it was 
described above (3.13.1). 
 
3.13.3 Ligand renaturation 
 
Refolding buffer  100 mM Tris-HCl pH 8.5 
     2.0 M Urea 
1 mM Oxidized glutathione (GSSH) 
0.1 mM Reduced glutathione (GSH)) 
 
Dialysis buffer I  100 mM Tris-HCl pH 8.5 
     2.0 M Urea 
0.1 mM Oxidized glutathione (GSSH) 
0.01 mM Reduced glutathione (GSH) 
 
Dialysis buffer II  100 mM Tris-HCl pH 8.5 
0.1 mM Oxidized glutathione (GSSH) 
0.01 mM Reduced glutathione (GSH)) 
 
50 mg of the denatured protein (3.13.1 and 3.13.2) were dissolved in refolding buffer 
at 4°C overnight with mild shaking. Afterwards, the protein solution was dialyzed at 
4°C for two days in different buffers. The first day the dialysis was performed in 
buffer I, and the second day the buffer II was used. After the dialysis, the IL-5 was 
concentrated at a final volume of 5 ml. 
 
3.13.4 Ligand purification  
 
3.13.4.1 Size exclusion chromatography I 
 
Buffer    100 mM Tris-HCl, pH 8.5  
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Column   HiLoad 16/60 Superdex 200 (Pharmacia) 
Column volume  120 ml 
Chromatography system Akta prime plus (Pharmacia) 
Pressure   0.35 bar 
 
The column was previously pre-equilibrated with 2 volumes of buffer at a flow rate 
of 1.5 ml min-1 before loading protein. 5 ml protein fractions were collected and 
analyzed by SDS-PAGE. 
 
3.13.4.2 Size exclusion chromatography II  
 
Buffer    100 mM Tris-HCl, pH 8.5  
Column   Analytical Superdex 75 (Pharmacia) 
Column volume  30 ml 
Chromatography system DuoFlow (Biorad) 
Pressure   300 psi  
 
The column was previously pre-equilibrated with 2 volumes of buffer at a flow rate 
of 0.5 ml min-1 before loading protein. Protein was purified with a flow rate of 0.25 
ml/min. 1 ml protein fractions were collected and analyzed by SDS-PAGE. 
 
3.14 Protein Analysis Methods  
 
3.14.1 RP-HPLC 
 
Buffer A    0.1% TFA 
Buffer B    Acetonitril with 0.1% TFA 
Column    VYDAC 214TP1010 C4  
Chromatography system  Biologic Duo Flow (Bio-Rad) 
Software    Biologic Duo Flow software (Bio-Rad) 
 
Protein purity was analyzed by reversed-phase high-performance liquid 
chromatography (RP-HPLC). The column was pre-equilibrated during 30 min with 
buffer A. After that, the protein was loaded at a flow rate of 1.5 ml min-1; the 
separation was conducted via gradient elution of two solvents: TFA 0.1% buffer A 
and ACN/0.1% TFA buffer B at a flow rate of 1.5 ml min-1. The gradient profile 
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utilized for solvent B was as it follows: 0% for 9 min, 0 to 100% 37 min, 100% for 2 
min, 100 to 0% in 2 min, and 0% for 4 min, with a total run time of 54 min at RT. 
The fractions were collected into 2 ml tubes and each fraction was analyzed with 
SDS-PAGE. 
 
3.14.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Stacking gel buffer (4X)  504 mM Tris 
10 % SDS (w/v) 
pH 6.7 
 
Running gel buffer (4X)   1.5 M Tris 
10 % SDS (w/v) 
pH 8.8 
 
Sample Buffer   125 mM Tris pH 6.8 
     20 % glycerol (v/v) 
     4 % SDS (w/v) 
     10 μM bromophenol blue 
 
Electrophoresis buffer (10X) 50 mM Tris-HCL 
     196 mM glycine 
     0.1 % SDS 
 
Polyacrylamide solution  40 %, 29:1 solution (Roth #A515.1) 
 
Stacking Gel preparation  0.625 ml stacking buffer 4X 
     0.25 ml polyacrylamide 
     1.6 ml ddH2O 
     9 μl 40% Ammonium persulfate (APS) 
     9 μl TEMED 
 
Running gel preparation  1.25 ml running buffer 4X 
1.5 ml polyacrylamide  
1 ml glycerin 87% 
1.25 ml ddH2O 
10 μl 40% Ammonium persulfate (APS) 
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10 μl TEMED 
Protein marker   Low molecular weight (Pharmacia) 
 
Equal amounts of all purified proteins were suspended in 100 μl of 1X sample buffer 
and the solution was boiled for 5 min. Afterwards, samples (5-15 μl) were loaded 
onto a 12 % SDS-PAGE gel and separated at 320 V for 30 min. The proteins were 
revealed by coomassie blue or silver stained procedures. 
 
Coomassie blue staining buffer  2.5 g coomassie blue 
     40 % Methanol (v/v) 
     10 % acetic acid (v/v) 
     50 % dH2O to 1L 
 
Destaining buffer   10 % methanol (v/v) 
     10 % acetic acid (v/v) 
     80 % water 
 
After the SDS-PAGE, the electrophoresis system was disassembled and the gel was 
recovered. The gel was put in a glass box and incubated with staining solution for 30 
min at room temperature with agitation. Then, the staining solution was removed and 
the gel was washed with water. Afterwards, the gel was put for 60 min with 
destaining buffer. Alternatively, the glass box was sealed with alum paper and left 
overnight with shaking at RT. 
 
Silver stain 
 
Stock solution 1   50 % (v/v) Acetone in water 
Stock solution 2   50 % (w/v) TCA in water (stored in glass 
container) 
Stock solution 3   20 % (w/v) Silver Nitrate in water 
Stock solution 4   10 % (w/v) Sodium thiosulfate pentahydrate  
Stock solution 5   1 % (v/v) Glacial Acetic Acid  
Stock solution 6   37 % Formaldehyde solution 
 
The gel was put in a clean glass box and incubated with 60 ml acetone stock with 1.5 
ml TCA stock and 25 μl formaldehyde solution for 5 min with shaking. After three 
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washes with water, the gel was left with water for additional 5 min. After that, the 
gel was rinsed in water 15 sec. Then, the gel was immersed in acetone stock solution 
for 5 min. Afterwards 100 μl sodium thiosulfate stock solution in 60 ml water was 
added for 1 min. The gel was washed with water and immersed in 0.8 ml silver 
nitrate stock solution and 0.6 ml formaldehyde solution in 60 ml water for 8 min. 
Proteins bands were developed with 1.2 g Na2CO3, 25 μl formaldehyde solution and 
25 μl sodium thiosulfate stock solution dissolved in 60 ml water for 30 sec. The 
reaction was stopped with 1% acetic acid. 
 
Drying gel solution  30% methanol (v/v) 
5% glycerol (v/v) 
ddH2O to 1L 
 
Envelop   Cellophane membrane 
 
Frames   Two  
 
Developed gel by coomassie blue or silver stained was incubated with drying 
solution for 15 min at room temperature with shaking. Two cellophane sheets were 
soaked in water. One soaked cellophane membrane was spread out to cover one 
frame. The gel was placed on the cellophane membrane in the center. The second 
wet cellophane sheet was then carefully placed so that it covers the first cellophane 
sheet and the gel. The second frame is placed upon the first. Four clamps were used 
to press together the frames. The gel was maintained at room temperature at least 
one day. 
 
3.14.3 Mass spectrometric analysis  
 
All purified proteins were dialyzed in Milli Q water to remove salt content. The 
molecular weights of the proteins or peptides were determined using a mass 
spectrometer device (APEX-II FT ICR). The desalted oligopeptides were dissolved 
in a 1:1 solution of methanol and 2% acetic acid, at a final concentration of 5 μM. 
The protein was then applied to the ion source with a flow rate of 2.0 μl/min. The 
data were analyzed with the X-mass software (Bruther Daltonics, Bremen), which 
was supplied with the instrument. 
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3.14.4 Circular dichroism (CD)  
 
The secondary structure of the protein was analyzed by circular dichroism method. 
For CD analysis, each protein was dialyzed against Milli Q water. A JASCO J-720 
spectropolarimeter was used for all measurement and the spectra were recorded from 
190 to 240 nm. Proteins (0.2-0.5 mg ml-1) were measured in a 0.1 cm path length 
cells. Qualitative data analysis was carried out with JASCO Spectra Manager 
Analysis software. 
 
3.14.5 Biomolecular interaction analysis (BIAcore) 
 
Reagent required Sulfo-NHS-LC Biotin (Pierce) 4 mM stock solution in DMSO 
0.5 M NaHCO3, pH 8.5 
CM5 chip 
 
BIAcore analysis was performed to measure the binding of the interaction between 
hIL-5Rα or hIL-5Rα variants with hIL-5. The CM5 sensor chip surface was coated 
with streptavidin according to the protocol of the amide coupling method. Briefly, 
streptavidin was diluted in 10 mM sodium acetate buffer (pH 4,5) and perfused over 
a biosensor chip surface that had been pre-activated with N-hydroxysuccinimide and 
N-ethyl-N’(dimethyllaminopropyl) carbodiimide, as described by the manufacturer. 
Typically, 2800-3000 resonance units (1RU = 1pg/mm2) were immobilized. The 
hIL-5 was biotinylated with EZ-Link sulfo-NHS-LC biotin (PIERSE) in a 1:1 molar 
reaction following the BIAcore handbook protocol. The biotinylated hIL-5 was 
immobilized onto the CM5 chip via interaction between biotin and streptavidin. The 
streptavidin coated flow cell 1 was used as a control for nonspecific binding and bulk 
face effects. However, hIL-5 was immobilized in flow cell 2-3-4 on the sensor chip 
with an average of 500 resonance units (RU). To further reduce bulk face effects, 
proteins were extensively dialyzed against running buffer (10 mM HEPES, pH 7,4, 
150 mM NaCl, 3,4 mM EDTA and 0,005% (v/v) surfactant P20). All experiments 
were carried out at RT. The association rate was determined using six different 
protein concentrations from 20 nM to 180 nM at a flow rate of 10 μl/min. For the 
dissociation rate analysis, the chip surface was perfused only with running buffer. 
Between each analyte binding experiment, injecting 4 M MgCl2 regenerated the chip 
surface. The sensorgrams were evaluated using the software BIAevaluation version 
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2.0 assuming a 1:1 Langmuir association model. The association rate constant (kon) 
and the dissociation rate constant (Koff) were obtained after analysis. In order to 
reduce mass transfer and rebinding effects only the last 10% of the association phase 
before reaching steady state were used to analyze the kon, and the first 10% of the 
dissociation phase were used to analyze the koff. Apparent dissociation constants, KD, 
were calculated as KD = koff/ kon. 
 
3.14.6 TF-1 cells proliferation assay 
 
Media   RPMI 1640 (Gibco BRL) 
 
Supplement  10 % (v/v) Fetal calf serum 
   2 mM L-glutamine  
   100 U/ml penicillin 
   100 µg/ml streptomycin 
 
The biological activity of purified recombinant proteins were evaluated by 
measuring [3H] thymidine incorporation into the human promyeloid cell line TF-1 
(Kitamura et al., 1989). TF-1 culture cells were counted using a Neubauer counting 
chamber and a vital-dye (Trypan Blue) that was incorporated by death cells. Cells 
were cultured in RPMI medium supplemented with 10% FCS and 2ng ml-1 
recombinant GM-CSF. After that, the cells were washed twice with RPMI without 
GM-CSF. Cells were seeded at a density of 20000 cells/well in a 96 well plate in 
RPMI medium without GM-CSF to growth cells starve factor. Cells were grown in 
the presence of serial dilutions of purified recombinant proteins (log3 dilutions 
starting at 1μg as the highest concentration) for 72 hours. Tritiated thymidine 
(Amersham, 0.25 μCi/well) was added to each well 24 h before the plates were 
harvested using a Skatron cell harvester (Skatron Inc., USA). Filters were counted in 
a β plate counter. Each experiment was performed in triplicate, and the concentration 
of half maximal response (EC50) in TF-1 cells was plotted using the statistic program 
“Origin”. 
 
3.15 Limited proteolysis of protein 
 
The protein (3.16) was dialyzed in 100 mM Tris, pH 8.5 for 24 hours at 4°C. Trypsin 
protease was prepared following the manufacturers recommendation. The digestion 
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reaction was carried out with 50 μg of protein and 0.25 μg of trypsin in a ratio of 
200:1 (protein : trypsin) at 37°C. Eight reactions were set up in a 1.5 ml eppendorf 
tube and each 5 min one reaction was stopped. Control digestion was carried out 
without trypsin. Each reaction was stopped with 10 μl 10 % (v/v) thrifluoroacetic 
acid (TFA). Afterwards, samples taken from each reaction were mixed and boiled 
with sample buffer, and loaded on a 12% SDS-PAGE. After electrophoresis, the gel 
was stained with coomassie blue buffer. 
 
3.16 Crystallization 
 
3.16.1 Complex crystallization 
 
Buffer    10 mM Tris-HCl, pH 8.1 
    150 mM NaCL 
Column   HiLoad 16/60 Superdex 200 (Pharmacia) 
Column volume  120 ml 
Chromatography system Akta prime plus (Pharmacia) 
Pressure   0.35 bar 
 
Sparse matrix screens:  Crystal screen I (Hampton Research) 
    Crystal screen II (Hampton Research) 
    PEG/Ion screen (Hampton Research) 
    Index Screen (Hampton Research) 
    Malonat Screen (Hamton Research) 
    JBS screen 4 (Jena Bioscience) 
    JBS screen 5 (Jena Bioscience) 
 
Plates for sitting drop Crystal Quick (96 wells) 
Cover    Plastic film 
Plates for hanging drop Linbro plates (24 wells) 
For hanging drop  Siliconized glass circle cover slides (∅ 22)  
Silicon fat 
 
Purified proteins (3.12.4 and 3.13.3) were used for complex formation. The complex 
was formed using the molar ratio of 1:1.1 of the receptor to ligand. To remove 
unbound components the complex was purified by gelfiltration chromatography with 
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a S200 column equilibrated with 10 mM Tris-HCl pH 8.1 and 150 mM NaCl buffer, 
with a flow rate of 1.5 ml/min as it was described above. Protein fractions were 
analyzed by SDS-PAGE. The protein fractions, which were present bands with 
similar amount of receptor and hIL-5 were pooled. Amicon system with 5000 
MWCO membrane was used to concentrate the complex up to 10 mg/ml. Initial 
crystallization experiments were carried out by the sitting drop or hanging drop 
vapor diffusion method (Cudney et al., 1994) at room temperature. Each sitting-drop 
was prepared by mixing 1 μl each of the complex (10 mg ml-1) and 1 μl reservoir 
solution. It was placed with 100 μl of the of the reservoir solution in each well of the 
96 well plate. After that, the plate was capped with plastic film. 
The initial conditions yielding crystals were submitted to a fine-tuning screen 
procedure using the hanging drop method. Briefly, the optimization of the these 
conditions were carried out as follows: (i) complex was concentrated at presence of 
0.3% (w/v) CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-
propanesulfonate), to avoid protein aggregation and increase protein stability (Chen 
et al., 2000; Gall et al., 2003; Garman et al., 2000; Itou et al., 2002); (ii) 
crystallization was performed in 0.1 M MOPS buffer, pH 6.5; (iii) the buffer was 
supplemented with 20% glucose (w/v) as a cryoprotectant for X-ray analysis; (iv) the 
buffer was also supplemented with 2.5 % (v/v) of MPD (2-methyl-2,4-pentandiol). 
Finally, hanging drop was prepared by mixing complex with reservoir buffer at ratio 
of 1:2 (1 μl of the complex 7.8 mg ml-1 and 2 μl of reservoir solution) and it was 
placed over 500 μl reservoir solution. To evaluate the components of the crystal, the 
crystal was removed from the X-ray machine goniometer. Crystal was washed three 
times with 10 μl reservoir solution and dissolved in SDS sample buffer. The protein 
was loaded on SDS-PAGE gel and revealed by silver staining (3.14.2).  
 
3.16.2 Ligand crystallization (Mouse) 
 
Initial screening for crystallization of mIL-5 (3.13.4) was carried out by sitting and 
hanging drop using 8 mg ml-1 of mIL-5. The screening and the optimization 
experiments were performed at room temperature. Suitable crystals for analysis were 
obtained using hanging-drop vapor diffusion technique with a final reservoir solution 
contained 26 % PEG 4000, 0.1 M Tris, pH 8.5, 0.21 M Sodium acetate. Each drop 
was formed by mixing 1 μl of the mIL-5nullMet (6 mg ml-1) and 1 μl of reservoir 
solution at 291° K. The drop was placed over 500 μl of the of the reservoir solution. 
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3.17 X-ray data analysis 
 
Datasets were collected from single crystals at the beam line of the home source 
(Biocentrum-Wuerzburg University (Rigaku, MSC, USA)). Crystals were mounted 
in a nylon loop and flash-frozen in liquid nitrogen without further soaking. Crystal-
to-detector distance can be set to 130 mm. The X-ray wavelength is 1.54 Å and data 
collection was performed at 100 K. For high-resolution data, datasets were collected 
from single crystals at the Cyclotron beam line (SLS, Switzerland); the crystal was 
rotated through a total of 170°, with a 0.5° oscillation per frame and a different 
exposure time per frame. Data processing was performed using the software 
“Crystalclear 1.3.6” (Rigaku, MSC, USA), and for high resolution data were used 
the software HKL and SHELX. 
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4 RESULTS  
 
4.1 Structural studies of the human IL-5Rα/IL-5 complex 
 
4.1.1 Expression, refolding and purification of wild type human IL-5Rα and 
human IL-5Rα variants 
 
The interleukin-5 receptor alpha (IL-5Rα) is expressed as a transmembrane protein 
as well as a soluble protein. The soluble isoform is produced as a result of alternative 
splicing and it consists of the extracellular part of the receptor lacking the 
transmembrane and cytoplasmic regions (Shanafelt, Miyajima et al. 1991). Both 
isoforms are involved in the binding of IL-5 (Monahan et al., 1997; Shanafelt et al., 
1991).  
The cDNA that encodes the different extracellular domains of the wild type 
human IL-5Rα (wt-hIL-5Rα) (Swiss-Prot Q01344-2) was cloned into a pET-3d 
expression vector (Figure 4-1). A bacterial expression system was used for protein 
expression, as it is an efficient, widely used host for recombinant protein production 
due to its high transformation efficiency, cultivation simplicity, fast protein 
expression and low cost method. In addition, E.coli is the organism of choice for the 
expression of a wide variety of recombinant proteins used in structural studies, such 
as X-ray analysis, due to the fact that E.coli does not glycosylate proteins. Hence, the 
resulting proteins tend to be more homogeneous. 
E.coli Rosetta cells were transformed with the pET-3d/wt-hIL-5Rα vector 
(3.10) and grown in Terrific broth medium (TB) (3.11). The protein expression was 
induced with 1 mM IPTG during three hours (4-2). Afterwards, cells were harvested 
to produce 2,0 g of bacteria per liter culture medium. 
The wt-hIL-5Rα protein accumulated as insoluble protein in form of 
inclusion bodies. Samples of bacteria culture were analyzed by SDS-PAGE to verify 
protein expression (Fig 4-2, lane 3). Cells were disrupted by sonication to release the 
inclusion bodies. The inclusion bodies represented approximately 20-30% of the 
total bacterial weight. The inclusion bodies were washed (3.12) to remove remaining 
bacteria cell membranes (Fig 4-2, lane 5). After washing, 95% of inclusion bodies 
were recovered and solubilized overnight with guanidinium hydrocloride (GuHCl) at 
room temperature to extract the protein under denatured conditions (Fig 4-2, lane 6).  
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Figure 4-1. Schematic representation of the expression vector. The pET-3d vector contains 
the wt-hIL-5Rα gene (magenta). The cDNA was cloned between Nco I and BamH I 
restriction sites. T7 promoter is used for hIL-5 transcription. pET-3d carries an Ampicillin 
resistance gene (Amp R). 
 
Nucleic acids and host proteins can also contaminate the inclusion bodies 
during its solubilization and all of these components can induce aggregation during 
the refolding process. To avoid these difficulties the denatured protein was purified 
by size exclusion chromatography (3.12.1). The yield of denatured protein obtained 
after gelfiltration was 70 mg of wt-hIL-5Rα per liter of bacterial culture. 
wt-hIL-5Rα refolding was carried out by diluting 100 mg of protein in 1 liter 
of renaturation buffer containing high denaturant concentrations (3.12.2). Dialysis 
provides means to change the buffer solution from denaturing to non-denaturing 
conditions. The protein was dialyzed stepwise against buffers with decreasing urea 
concentration until the desired final buffer condition without urea. After protein 
refolding and concentration, the wt-hIL-5Rα was bound to a Q-sepharose column 
(3.12.3.1). To remove protein aggregates the column was washed with Tris-HCl 
buffer and the bound wt-hIL-5Rα was eluted by application of 0.0-0.5 M gradient of 
NaCl. 
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Figure 4-2. Expression of wild type hIL-5Rα in E.coli Rosetta cells (red oval). Protein 
expression was induced with 1 mM IPTG for three hours. Protein was analyzed onto a 12% 
SDS-PAGE. The gel shows: lane M; the protein marker, lane 1; non-induced cells, lanes 2 
and 3; IPTG induction after 1 and 3 hours, lane 4; supernatant after washing of inclusion 
bodies (IB), lane 5; the protein pre-extraction of IB, lane 6; protein main-extraction of IB, lane 
7; hIL-5Rα after Q-sepharose chromatography and lane 8; hIL-5Rα after hIL-5 affinity 
column. Proteins were separated by reducing (lanes 1-6) and non-reducing (lanes 7 and 8) 
SDS-PAGE and stained with Coomassie Blue (lanes 1-7) or silver staining (lane 8). 
 
Due to presence of some protein aggregates after anion exchange 
chromatography, the wt-hIL-5Rα was further purified (Fig 4-2, lane 7). The active 
receptor was purified by affinity chromatography (3.12.3.4) making use of the 
specific binding interaction between IL-5 and IL-5Rα (Fig 4-2, lane 8). The active 
wt-hIL-5Rα was eluted with 4 M MgCl2, yielding 2-3 mg of pure and active protein 
(Table 4-1). 
The wt-hIL-5Rα formed aggregates and precipitated after affinity column 
purification when it was concentrated above 5.0 mg ml-1. Wild type hIL-5Rα also 
aggregates and precipitates at room temperature at the extent of at least 50% in 12 
hours. 
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Table 4-1. Production of non-labeled wild type hIL-5Rα 
 
Protein  wt-hIL-5Rα 
Bacteria culture (g) 20 
Inclusion Bodies (g) 4-6 
Recover IB after wash (g) 3.8-5.7 (represents 95 %) 
Refolded Protein (mg) 100 
Yield active protein (mg) 2-3 
 
Aggregation is a broad definition that includes several types of interaction. 
For instance, covalent aggregation takes place through the formation of a chemical 
bond between monomers. Unpaired free thiols on cysteines residues are the reason 
for covalent aggregation due to disulfide bond formation. With respect to wt-hIL-
5Rα, the extracellular part of this receptor contains 7 cysteine residues (Cys 66, Cys 
114, Cys 135, Cys 162, Cys 176, Cys 249 and Cys 296). One cysteine residue is 
located in the first domain (Cys 66). Four of them are involved in the function of 
conserved disulfide bridges in the second domain (Cys 114, Cys 135, Cys 162 and 
Cys 176). The two remaining cysteine residues (Cys 249 and Cys 296) are found in 
the third domain linked through a disulfide bridge (Devos et al., 1994). Mutagenesis 
analysis in hIL-5Rα of these two cysteine residues showed that Cys 249 or Cys 296 
are necessary for the maintenance of the active biological conformation. However, 
the free Cys 66 mutation did not affect IL-5 binding (Devos et al., 1994). 
Different groups have shown that mutation of the free cysteine residue 
increases protein stability (Amaki et al., 1994; Miyazaki et al., 1993). Therefore, Cys 
66 in the wild type receptor might be responsible for receptor precipitation during 
protein concentration. To avoid receptor aggregation Cys 66 of wt-hIL-5Rα was 
mutated to Ala. The resulting hIL-5Rα C66A variant (3.7.1) was purified in the 
same way as it was described for wt-hIL-5Rα. This receptor could be finally 
concentrated up to an amount of 6.0 mg per ml. Precipitation at room temperature 
was reduced by 60% after 24 hours.  
On continuation, four point mutations (3.7.2) within the hIL-5Rα C66A 
variant were generated (K72M, L138M, K167M and L234M) and the effects of these 
amino acid substitutions on selenium incorporation were determined by E.coli 
transformation and protein expression. Expression of Se-hIL-5Rα C66A was 
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performed in complete M9 medium (3.11.2). No changes were observed in cell 
growth and protein expression. Inclusion body preparation of the Se-human IL-5Rα 
resulted in proteins of the same quantity and quality as the wild type receptor. 
Renaturation of Se-hIL-5Rα C66A required an increase in β-mercaptoethanol to a 
concentration of 0.1%. After renaturation the Se-hIL-5Rα was purified by affinity 
column chromatography. Additional variants of human wt-IL-5Rα such as D55E, 
Y57F, C66A, F182A, I183A, R188K (Figure 4-3), and truncated variants of IL-5Rα 
C66A such as Δ10Rα, Δ20Rα, Del 1, Del 2, and Del 3 were generated by site-
directed mutagenesis (3.7.1 and 3.7.3, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Purification of hIL-5Rα mutants. hIL-5Rα variants were purified employing S200 
gelfiltration chromatography. High molecular weight protein aggregates eluted before the 
monomeric protein (red arrows). Chromatograms show (left to right) D55E, I183A, R188K, 
Y57F and F182A. 
 
Protein expression, inclusion body purification and solubilization, as well as 
protein refolding, were performed under the same conditions as described for the wt-
hIL-5Rα. Similar to wt-hIL-5Rα, these hIL-5Rα variants were not totally pure after 
purification by anion exchange chromatography. The IL-5Rα variants except hIL-
5Rα Del 1 were therefore further purified by S200 size exclusion chromatography 
     50           100            150          200             250 
OD280nm
0.5 
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(3.12.3.2). As shown in figure 4-3, the different mutants showed the same elution 
profile. The yield for the mutant proteins was slightly different (Table 4-2), but in all 
cases, their purity was close to 95% as confirmed by non-reducing SDS-PAGE (Fig 
4-4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4. Analysis of hIL-5Rα mutants. hIL-5Rα variants were analyzed by SDS-PAGE 
under non-reducing conditions (Coomassie stained). The gel shows in lane 1, D55E; lane 2, 
I183A; lane 3, R188K; lane 4, Y57F and lane 5, F182A.  
 
The hIL-5Rα Del 1 variant could not be purified using these techniques. A 
second anion exchange chromatography (3.12.3.3) provided a suitable procedure to 
remove aggregates (Fig 4-5). The result indicated that at pH 7.8 with a gradient of 0-
100% Na-TAPS buffer, the hIL-5Rα Del 1 was eluted at 30-62 % of NaCl buffer 
(3.12.3.3) and its purity was confirmed by non-reducing SDS-PAGE (Fig 4-5 B).  
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Figure 4-5. Purification of hIL-5Rα Del 1 variant. (A) hIL-5Rα Del 1 was purified employing 
(2.0 mg) anion exchange chromatography, aggregates eluted ahead of the gradient (head 
red arrow). (B) Several fractions (1-7) of hIL-5Rα Del 1 were analyzed by SDS-PAGE (silver 
stained) under non-reducing conditions. All fractions 1-7 show a single band migrating at 25 
kDa approximately.  
 
All hIL-5Rα proteins were stored at -20°C in 50 mM Tris buffer at pH 8.1. 
The table 4-2 summarizes the yields of all different mutants and describes the 
position of the mutation. 
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Table 4-2. Description of wild type hIL-5Rα and hIL-5Rα variants 
 
Protein Da Domain containing 
mutation 
Yield 
(mg/L culture) 
WT 36011  2,5 
D55E 36025 M1 1.4 
Y57F 35995 M1 1.5 
C66A 35903 M1 2,5 
Δ10Rα 35358 M1 3.4 
Δ20Rα 34195 M1 3.0 
F182A 35935 M2 1.7 
I183A 35970 M2 0.6 
R188K 35984 M2 1.9 
* Del 1 24487 ΔM1 2,5 
* Del 2 11320 ΔM2 and ΔM3 8.0 
* Del 3 25017 ΔM3 6.0 
 
* Deletion with either domain designated M1, M2 or M3. 
 
4.1.2 Analytical Methods 
 
Analytical methods such as reverse-phase high performance liquid chromatography 
(RP-HPLC), circular dichroism (CD), electro-spray mass spectrometry (ESI) and 
SDS-PAGE were used to analyze the purified proteins with respect to purity, 
secondary structure and the molecular weight.  
The wt-hIL-5Rα purity and homogeneity were determined by RP-HPLC. By 
employing this technique, the protein impurities and protein aggregates can be 
detected, due to different polarity with the target protein. For the mobile phase, RP-
HPLC was used with a linear gradient 0-100% of acetonitril. As shown in Fig 4-6, a 
single peak of the purified hIL-5Rα was obtained. The wt-hIL-5Rα eluted after 20 
min at 40-44% of acetonitril. SDS-PAGE analysis of the fractions showed the wt-
hIL-5Rα as a single visible band (Fig 4-6). 
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Figure 4-6. Analysis of interleukin-5 receptor alpha. 500 μg of wild type hIL-5Rα were 
analyzed using C4 column. The RP-HPLC shows the chromatogram of wild type hIL-5Rα 
(above). Gel analysis of fractions 34 and 35 from tail peak (red arrow) indicates that the 
peak appendage is performed by the HPLC column (red arrow). 
 
Circular dichroism (CD) spectroscopy comprises a technique, which allows 
the analysis of protein secondary structures. The CD is the difference between the 
absorption of left and right-handed circularly polarized light. The conformation of 
the hIL-5Rα variants was compared with the conformation of wt-hIL-5Rα by 
circular dichroism (3.14.4). The results of the CD spectra analysis suggest that the 
secondary structures of variants D55A, D55N, and L184A are similar or almost 
identical to wt-hIL-5Rα, confirming that these substitutions do not affect the hIL-
5Rα general protein folding pattern (Figure 4-7). However, the variant Y57A shows 
a marked difference in its CD spectrum compared to wt-hIL-5Rα. These data provide 
RESULTS 
____________________________________________________________________ 
61 
evidence that that Tyr57 plays a very important role in maintaining the folding 
pattern of hIL-5Rα (Figure 4-7).  
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Figure 4-7. Circular dichroism spectrum of wild type hIL-5Rα and variants. The qualitative 
analysis shows that D55A, D55N and L184A proteins possess similar secondary structure 
elements as wt- hIL-5Rα. The Y57A variant shows a different spectra indicating variation in 
the secondary structure. 
 
Mass spectrometry was used to analyze the molecular weight of the purified 
proteins (3.14.3). The purified wt-hIL-5Rα and hIL-5Rα variants, which contain 
Cys66, were found to exceed the predicted molecular weight by approximately 76.0 
Da (Table 4-3).  
Different observations suggested the possibility that the Cys66 could be the 
residue responsible for the increased molecular weight of these proteins. The first 
observation leading to this hypothesis was that the Del 1 hIL-5Rα variant, which 
lacks Cys66, exhibits the expected molecular weight (Table 4-3).  
The second observation in the SDS-PAGE analysis was that Del 2 and Del 3 
hIL-5Rα variants, which harbor Cys66, appeared highly pure after final gelfiltration, 
but they formed aggregates after concentration by ultrafiltration. The aggregates 
disappeared only after mutating Cys66 to Ala. On the other hand, the molecular 
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weight of two variants with the C66A mutation showed the expected molecular 
weight.  
Finally, in wt-hIL-5Rα the cysteine at position 66 appears to undergo 
covalent modification with isothiazolone compounds (Devos et al., 1994) which 
modify the molecular weight of the receptor protein, thus indicating that the 
sulfhydryl group is highly reactive. Furthermore, recombinant proteins with highly 
reactive thiol groups can form disulfide adducts with reducing agents normally used 
in protein purification (Gillian E. Begg., 1999).  
 
Table 4-3. Mass spectrometry of hIL-5Rα proteins 
 
Receptor α Expected 
mass 
Measured 
mass 
Difference in Da 
WT 35936.065 36011.893 75.8 
D55E 35950.081 36025.814 75.7 
Y57F 35920.070 35995.806 75.7 
C66A 35903.091 35903.151 0.06 
F182A 35859.030 35935.614 76.5 
I183A 35894.018 35970.342 76.3 
R188K 35908.059 35984.013 75.9 
Del 3 C66A 25018.636 25017.968 0.00 
 
Based on the results employing isothiazolone compounds and disulfide 
adduct interaction with highly reactive free cysteines, it seems highly probable that 
Cys66 residue of wt-hIL-5Rα reacts with β-mercaptoethanol (β-ME), which is used 
in the buffer for the wt-hIL-5Rα preparation (3.12.1). The molecular weight 
difference of 76.0 Da found in purified hIL-5Rα proteins with Cys66, corresponded 
exactly to the molecular weight of β-ME (78.1 g/mol), thus suggesting that the 
chemical modification occurs by disulfide bond formation (Cys66 + β-ME ⇒ 
Cys66-S-S-β-ME + 2H + 2e-).  
With Cys66 mutated to Ala (C66A), we found that the measured weight 
matched the expected weight within the error limit of the method (Table 4-3). For 
Se-labeled proteins 100% incorporation of Se-Met instead of S-Met could be 
confirmed by mass spectrometry.  
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4.1.3 Expression, refolding and purification of the human IL-5 
 
The human IL-5 cDNA was cloned into the pET-3d expression vector using Nco I 
and BamH I restriction sites. E. coli Rosetta cells were transformed with the 
expression vector pET-3d/hIL-5. The transformed bacteria were grown in LB 
medium under the same conditions as described for the hIL-5Rα expression. A 
whole cells lysate (0.01 ml) was loaded onto a SDS-PAGE for the analysis of protein 
induction (Figure 4-8 B, lane 2). A main protein band of 13 kDa corresponding to 
the hIL-5 monomer appeared after IPTG-induction and this protein was accumulated 
in inclusion bodies.  
The inclusion bodies were 20-30 % of the wet weight of the total bacteria. 
Protein was purified under denaturing conditions by gelfiltration chromatography 
(Sephacryl 200) and 6 M guanidinium hydrochloride. Yield was approximately 60-
70 mg per L culture medium (3.13.1). 
Human IL-5 was refolded in a single step refolding procedure overnight in 
the presence of urea and oxidized and reduced glutathione (3.13.3). This redox 
system facilitates the formation of the disulphide bridges. The refolding buffer was 
removed by dialysis. After dialysis, recombinant hIL-5 was concentrated up to 10 
mg/ml and loaded onto a Superdex 200 column (16/60). A clear separation of the 
high molecular weight aggregates (20-40 ml or 13-26 min), hIL-5 dimer (40-60 ml 
or 26-40 min) and hIL-5 monomer (after 90 ml or after 60 min) was obtained (Figure 
4-8 A). The purified hIL-5 dimer was analyzed by SDS-PAGE. It migrates as a 
protein band of approximately 26 kDa (Figure 4-8 B). Yield of the pure dimeric hIL-
5 was approximately 6 mg per L of cell culture. 
The molecular weight of hIL-5 (26473 Da), as determined by mass 
spectrometry, corresponded to the predicted molecular weight based on protein 
sequence.  
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Figure 4-8. Expression and purification of hIL-5. (A) Gelfiltration chromatography indicates 
high molecular weight aggregates (number 1), hIL-5 dimeric protein (number 2) and the hIL-
5 monomer (number 3). (B) SDS-PAGE was used to verify the protein expression and 
purification (red ovals). Lanes represent: M, MW; 1, non-induced cells; 2, IPTG induction for 
3 hours; 3 and 4 supernatant after washing of inclusion bodies; 5 and 6, protein in IB; and 7 
and 8 purified protein. Proteins were separated by reducing (lanes 1-6) and non-reducing 
(lane 7) SDS-PAGE and stained with Coomassie Blue (lanes 1-7) or silver staining (lane 8). 
 
4.1.4 Biomolecular interaction analysis (BIAcore) 
 
Protein-protein interaction between hIL-5Rα and hIL-5 was analyzed using surface 
plasmon resonance (3.14.5). For measurements, chemically biotinylated hIL-5 was 
immobilized on a streptavidin-coated BIAcore sensor CM5 chip and the different 
RESULTS 
____________________________________________________________________ 
65 
hIL-5Rα proteins were perfused to distinct concentrations (3.14.5). For the BIAcore 
experiments the immobilized hIL-5 on the sensor chip was found to be a more 
efficient system than the immobilized receptor, due to the fact that when the receptor 
was immobilized on the sensor chip, the receptor lost significant binding capabilities 
after regeneration (3.14.5). This phenomenon was also reported by Brown and 
colleagues in 1995 using the hIL-5Rα (Brown et al., 1995). 
 
Table 4-4. Biomolecular interaction analysis of hIL-5Rα and hIL-5 
 
Receptor kon x 10-5 [s-1 M-1] koff x103 [s-1] KD (nM) 
Wild type 3.0 ± 1.0 2.4 ± 0.6 8.5 ± 4.0 
hIL-5Rα D55E 3.9 ± 0.11 13.0 ± 1.5 34.8 ± 10.0 
hIL-5Rα Y57F 4.4 ± 2.0 5.2 ± 0.05 14.9 ± 9.7 
hIL-5Rα C66A 5.2 ± 1.8 1.4 ± 0.4 3.0 ± 0.04 
hIL-5Rα F182A 5.0 ± 1.3 4.2 ± 0.1 8.8 ± 2.5 
hIL-5Rα I183A 8.4 ± 2.3 12.0 ± 1.1 16.0 ± 7.6 
hIL-5Rα R188K 4.6 ± 1.6 18.0 ± 2.2 35.6 ± 17.0 
Δ10Rα 8.8 ± 1.0 2.1 ± 1.2 2.4 ± 1.0 
Del 1 nb - - 
Del 2 nb - - 
Del 3 na na na 
 
nb: no binding 
na: no analyzed (protein precipitated at room temperature) 
The KD is defined as KD= koff/kon 
 
Analysis of the data from the last 10% of the association phase before 
reaching steady state and the first 10% of the dissociation phase yielded kon and koff 
values. The equilibrium binding constant KD was calculated from the equation KD = 
koff/kon. The hIL-5Rα variants F182A and I183A had binding properties almost 
identical to wt-hIL-5Rα, indicating that Phe or Ile substitutions for Ala residues did 
not alter the over all structure and that these residues are not involved in critical 
interactions (Table 4-4). The hIL-5Rα variants D55E (Figure 4-9) and R188K, 
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however, exhibit a lower binding affinity, indicating that Asp55 or Arg188 are 
involved in receptor binding (Table 4-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9. BIAcore analysis of human IL-5Rα variants. Solutions of the indicated IL-5Rα 
variants (concentration 140 nM) were perfused over a sensor chip with immobilized hIL-5.  
 
BIAcore analysis also showed that the two hIL-5Rα variants, hIL-5Rα C66A 
(Figure 4-9) and Δ10Rα had a similar affinity for the ligand compared with wt-hIL-
5Rα. Remarkably, the mutations hIL-5Rα C66A and Δ10Rα caused a decrease in the 
koff value and a slight increase in kon value (hIL-5Rα C66A, see figure 4-9) or only 
increasing the kon value (Δ10Rα). These receptor variants bind stronger, due to low 
off-rate and higher on-rates (Table 4-4). The BIAcore results reflect the interaction 
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of β-ME with the Cys66 leading to a decrease in the affinity binding of the wt-hIL-
5Rα. 
Our data also show that the deletion of the first N-terminal Fn-III-like domain 
totally disrupts the receptor affinity (Del 1). Deletion of the third Fn-III-like (C-
terminal) showed also significant reduction in affinity, but the data could not be 
analyzed, possibly due to protein precipitation at room temperature. 
 
4.1.5 Limited proteolysis approaches 
 
Flexible protein loops can disturb crystal growth as well as crystal diffraction. 
Removing such unstructured regions may considerably improve the crystal quality. 
Limited proteolysis was used to detect possible flexible loop(s) or termini in the 
components of the binary complex (hIL-5Rα/hIL-5) which can disturb crystal 
growth. 
In order to identify parts of the IL-5 complex sensitive to protease digestion, 
receptor plus ligand was mixed in a 1:1.1 ratio. The complex was purified by 
gelfiltration and afterwards digested with trypsin (3.15).  
The protease trypsin cuts at the C-terminal end of the Lys and Arg residues. 
Mass spectrometry analysis was used to analyze the peptides resulting from the 
trypsin proteolysis of the wt-hIL-5Rα/hIL-5 complex (Table 4-5). The largest 
peptides were identified as a flexible stretch spanning the first 40 N-terminal 
residues of the wt-hIL-5Rα. Other peptides were also identified as the first 8, 20, 31 
or 40 N-terminal residues of the wt-hIL-5Rα (Table 4-5). No other peptides from 
hIL-5 were found after trypsin digestion. In addition, the SDS-PAGE confirmed the 
absence of corresponding peptides in the digested complex (Figure 4-10).  
In line with these results, several deletion variants of hIL-5Rα with a 
truncated N-terminus were generated. The new hIL-5Rα variants were designated 
Δ10R and Δ20R, but generated with the hIL-5Rα C66A cDNA. 
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Table 4-5. Analysis of peptides by mass spectrometry 
 
m/z 
(mass/charge) 
Peak 
Intensity 
Residues Peptide Sequence 
2320.2 19.0 21-40 aa VTGLAQVLLQWKPNPDQEQ 
 
4524.6 
 
14.5 
 
1-40 aa 
 
ADLLPDEKISLLPPVNFTIKVTGLAQVLLQWKPNPDQEQ 
 
1341.8 9.3 9-20 aa ISLLPPVNFTIK 
3643.0 1.1 9-40 aa ISLLPPVNFTIKVTGLAQVLLQWKPNPDQEQ 
 
96
66
45
30
20
14
M    1       2      3     4     5     6    7      8
hIL-5
hIL-5R
 
 
Figure 4-10. Complex proteolysis. Purified complex was digested with trypsin protease at 
37°C for 40 min at ratio 200:1 (complex:trypsin). Untreated complex (5.0 μl) was used as a 
control and only two bands were observed (lanes 1 and 2). Different volumes of digested 
complex were loaded onto the gel: lanes 3 and 4 (2.5 μl); lanes 5 and 6 (5.0 μl), and lanes 7 
and 8 (7.5 μl). Reducing conditions lanes 1, 3, 5, and 7; non reducing conditions lanes 2, 4, 
6, and 8. 
 
4.1.6 Crystallization 
 
To crystallize the hIL-5Rα/hIL-5 complex it was necessary to 1. produce sufficient 
amounts of highly pure proteins (above), 2. to evaluate the stoichiometric interaction 
and 3. to find the specific crystallization conditions. Although previous reports 
suggested that hIL-5 and wt-hIL-5Rα interact in a 1:1 ratio (Devos et al., 1993; 
Johanson et al., 1995), we experimentally tested the stoichiometry via different 
molar ratios of receptor and ligand (Figure 4-11). 
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Gelfiltration chromatography of the complexes formed in the presence of a 
molar excess of receptor showed a different elution profile compared to that of 
complexes formed at a near equimolar ratio (Fig 4-11). SDS-PAGE analysis of 
single fractions indicated that a high excess of the wt-hIL-5Rα formed aggregates 
that eluted ahead of the complex (Fig 4-11 A, first and second peak, respectively).  
The unbound wt-hIL-5Rα and hIL-5 eluted as a little shoulder of the highest 
peak (Fig 4-11 A). However, fractions belonging to the complex formed with a small 
excess of ligand (1:1.1 ratio) suggest that all fractions present a complex of 1:1 ratio 
(Fig 4-11 B). An unbound ligand was not detected by SDS-PAGE. In conclusion, 
both ratios 2:1 or 1:1.1 (receptor:ligand) showed the same elution times (40-60 min, 
Superdex 200 16/60) for the fractions that contain 1:1 stoichiometry. The 1:1 
complex is maintained during the chromatography procedure. 
These results confirm, indeed, the previously reported stoichoimetry for the 
IL-5 and IL-5Rα ecto-domain interaction as 1:1, despite the dimeric structure of the 
ligand suggesting two receptor binding sites. Mixing 1 equivalent of hIL-5Rα with 
1.1 equivalent of the hIL-5 the binary complex of hIL-5Rα with hIL-5 was 
subsequently formed. 
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Figure 4-11. Gelfiltration chromatography and SDS-PAGE analysis of the wt-hIL-5Rα/hIL-5 
complex. (A) Complex was formed with a two fold molar excess of wt-hIL-5Rα. The 
chromatogram shows small additional peaks (arrows). (B) Complex was formed with a small 
excess of ligand (10%). Only one peak was formed and the analyzed fractions showed equal 
amounts of receptor and ligand. The highest peak in both chromatograms display similar 
amounts of receptor and ligand. 
 
The complex containing fractions were pooled and concentrated to 10 mg ml-
1. An aliquot from this concentrated complex was analyzed again by gelfiltration 
using a FPLC system with a Superdex 200 chromatography column (analytical 
column) to verify the quality of the complex (Fig 4-12). The chromatogram of the 
complex shows a high sharp peak followed by small peak (Fig 4-12).  
The highest peak contained the wt-hIL-5Rα/hIL-5 complex, which has a 
predicted molecular weight of 62 kDa. The elution time of the highest peak of 28-30 
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min corresponds to a molecule with a molecular weight of 61-63 kDa. The small 
peak that contains hIL-5 has an elution time of 31 min. This corresponds to a protein 
with a molecular weight of approximately 26 kDa. The small peak could be detected 
in this chromatography only after complex concentration. Both proteins also display 
high purity and there were not aggregates formed after complex concentration (Fig 
4-12). 
 
 
Figure 4-12. Concentrated complex analyzed by Fast Protein Liquid Chromatography 
(FPLC). Elution profile shows one peak at 28 min and one peak at 31 min. The major peak 
(28 min) corresponds to the 1:1 complex. In addition, the human IL-5 dimer can be seen (the 
small peak at 31min). SDS-PAGE analysis under non-reducing conditions of the peak eluted 
at 28 min shows two bands corresponding to hIL-5Rα and hIL-5 that migrated to 36 kDa and 
26 kDa, respectively. 
 
Initial crystallization trials (3.16.1) were performed with a complex 
concentration of 10 mg per ml. Using commercial crystallization kits following the 
sparse matrix screening, crystals with different morphologies were obtained 
(needles, dendrites, spherulites, and plates), but after the initial screening none of 
these crystals proved suitable as three-dimensional single crystal for further analysis 
(Table 4-6). Varying individual parameter such as the buffer composition, pH value, 
complex concentration, the precipitant/protein, temperature and the additives, the 
initial conditions were subsequently optimized. 
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Table 4-6. Crystallization buffers  
 
Screen Number Buffer Result 
Crystal 
Screen1 
36 8% PEG 8.000, 0.1M Tris-HCl pH 8.5 Needles 
Crystal 
Screen2 
22 12% PEG 20.000, 0.1M MES pH 6.5 Needles and 
Plates  
Crystal 
Screen2 
37 10% PEG 8.000, 0.1M HEPES pH 7.5, 
8% Ethylene Glycol 
Needles 
Crystal 
Screen2 
38 20% PEG 10.000, 0.1M HEPES pH 7.5 Needles 
Crystal 
Screen2 
42 12% Glycerol, 0.1M Tris pH 8.5, 1.5M 
Ammonium Sulphate 
Needles 
PEG/Ion 2 0.2M Potassium Fluoride, 20% PEG 
3.350 
Small needles 
PEG/Ion 40 0.2M di-Sodium hydrogen Phosphate, 
20% PEG 3.350 
Small needles 
and spherulites 
PEG/Ion 42 0.2M di-Potassium hydrogen Phosphate, 
20% PEG 3.350 
Long needles 
PEG/Ion 44 0.2M di-Ammonium hydrogen 
Phosphate, 20% PEG 3.350 
Needles 
JBS5 A2 12% PEG 8.000, 10% Glycerol, 0.5M K 
Chloride 
Needles 
JBS5 B3 18% PEG 8.000, 0.1M Tris-HCl pH 8.5, 
0.2M Li Sulphate 
Spherulites 
JBS5 D4 10% PEG 20.000, 0.1M Na MES pH 6.5 Needles 
 
Optimization with buffer 36 from crystal screen 1 (8% PEG 8.000, 0.1M 
Tris-HCl pH 8.5), buffer 2 (0.2M Potassium Fluoride, 20% PEG 3.350), 40 (0.2M 
di-Sodium hydrogen Phosphate, 20% PEG 3.350, 42 (0.2M di-Potassium hydrogen 
Phosphate, 20% PEG 3.350) and 44 (0.2M di-Ammonium hydrogen Phosphate, 20% 
PEG 3.350) from PEG/Ion, and buffer A2 (12% PEG 8.000, 10% Glycerol, 0.5M K 
Chloride) from JBS5 showed the same spherulites and needle crystals. These crystal 
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forms, however, did not improve, although various parameters were modified in the 
fine screening procedure. 
Improvement was observed using buffer B3 (18% PEG 8.000, 0.1M Tris-HCl 
pH 8.5, 0.2M Li Sulphate) from JBS5 leading to the growth of long needles. 
However, all attempts to increase the crystal size were finally unsuccessful. 
Optimization of the initial crystallization results with buffer 37 (10% PEG 8.000, 
0.1M HEPES pH 7.5, 8% Ethylene Glycol), 38 (20% PEG 10.000, 0.1M HEPES pH 
7.5) and 42 (12% Glycerol, 0.1M Tris pH 8.5, 1.5M Ammonium Sulphate) from 
crystal screen2 and buffer D4 (10% PEG 20.000, 0.1M Na MES pH 6.5) from JBS5 
only led to protein precipitation.  
The best results were obtained with buffer 22 (12% PEG 20.000, 0.1M MES 
pH 6.5) from crystal screen 2 in which the crystal improved the size and morphology 
(Table 4-6). Under these conditions, the complex could be reproducibly crystallized 
in two different forms such as long needles and thin but three-dimensional plates 
(Fig 4-13 A). Nevertheless, first X-ray diffraction experiments revealed that these 
crystals did not diffract. A breakthrough was the use of the hIL-5Rα C66A variant 
that yielded single morphology crystals of the complex (Fig 4-13 B). Although the 
X-ray diffraction also failed with this receptor, the crystal morphology was 
significantly improved (Figure 4-13 B). The hIL-5Rα C66A variant was 
subsequently used for all further crystallization experiments. 
In order to further improve the crystallization properties of the complex, the 
detergent 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) 
was used to minimize protein aggregation and to increase protein complex stability. 
CHAPS was added after complex purification by gelfiltration. The pool fraction of 
the complex was divided in three aliquots and each aliquot was supplemented with 
distinct concentrations of CHAPS (0.1%, 0.2% and 0.3%). Crystals were grown 
from 0.1 M MES pH 6.5, 12 % PEG 20000 buffer (crystal screen 2, buffer 22). Only 
one condition showed improved crystal growth, after addition of CHAPS. With 0.3% 
CHAPS concentration, the resulting crystals grew in about five days. The CHAPS 
screen indicated that three-dimensional growth of the crystals could be induced in a 
reproducible way by the addition of 0.3% CHAPS and not by 0.1% or 0.2% CHAPS. 
At 0.1% and 0.2% of CHAPS concentration crystals displayed a more cluster-like 
morphology.  
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Figure 4-13. Optimization of crystallization conditions for the complex hIL-5Rα/hIL-5. 
Crystals of the hIL-5Rα/hIL-5 complex were grown under different crystallization conditions. 
(A) Complex comprising wild type hIL-5Rα/hIL-5 grown from 0.1 M Imidazol pH 6.5, 10% 
PEG 20.000. (B) Complex comprising hIL-5Rα C66A/hIL-5 grown from 0.1 M Imidazol pH 
6.5, 10% PEG 20.000. (C) Complex consisting of hIL-5Rα C66A/hIL-5, the complex 
prepared with buffer containing 0.3% CHAPS, the crystals grown from 0.1M KH2PO4 pH 6.5, 
10% PEG 20.000, 20% glucose and 2.5% MPD. (D) Complex comprising hIL-5Rα C66A/hIL-
5 prepared with buffer containing 0.3% CHAPS and crystals grown from 0.1M MOPS, pH 
6.5, 10% PEG 20.000, 20% glucose and 2.5% MPD. 
 
In addition, the complex was also prepared by adding 0.3% CHAPS to the 
individual complex components (hIL-5Rα C66A and hIL-5). Subsequently, the 
complex was formed. The complex was purified by gelfiltration and crystallized 
under the same conditions mentioned above. Despite of maintaining these 
conditions, the crystal morphology was different resulting in only small needles.  
In order to test whether the chemical composition of the buffer could 
influence crystallization and diffraction properties of the crystals, different buffers 
were used in the optimization screening (Fig 4-13). Buffer screen could be shown 
that crystals diffracted only from very few buffers such as Bis-Tris (8.0Å), KH2PO4 
(4.0-5.0Å) and MOPS (3.5-4.0Å). Crystals grown from Imidazol, Tris-HCl, CHES 
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and MES buffer did not diffract at all. Since crystals grown from MOPS buffer 
showed the best diffraction properties, MOPS buffer was used for further 
crystallization optimization (Fig 4-13 D). 
Small concentrations of additives such as ethanol, NiCl2, MPEG 400, MEG 
550, and 2-methyl-2,4-pentanediol (MPD) were included in order to determine 
whether they could improve crystal size and quality (Wilmanns, 1999). Long thin 
cluster crystals grew from crystallization buffer supplemented with ethanol or PEG 
400 (compare Fig 4-14 B and C). Using 2.5% MPD (v/v) resulted in more single 
crystals in comparison to those from buffer without MPD (compared Fig 4-14 A and 
D).  
Finally, glucose was evaluated as a cryoprotectant reagent, and various 
glucose concentrations were examined. With 20% glucose, the resulting crystals had 
clearly the same morphology and size as those crystals grown without glucose. 
These conditions were also examined with various complex concentrations 
(3, 5, 7.8, 10 and 11.0 mg ml-1) and different ratios of protein solution buffer (1:1, 
1:1.5, 1:2 and 1:3). A complex concentration greater than 3 mg per ml in the drop 
leads to precipitation of the complex. However, at a complex concentration below 
2.4 mg per ml only crystals with morphologies like thin plates and needles could be 
obtained. The best complex concentration was found to be 2.6 mg per ml, but 
concentrations in the range of 2.4-2.8 mg ml yielded single crystals in a reproducible 
way. 
Additionally, different crystallization temperatures as 4°C, 12°C and 37°C 
along with paraffin- and silicon oil to vary the rate of vapor diffusion were tested. At 
low temperatures e.g, 4°C no crystallization was observed. At 12°C the complex 
crystallized in small needles after 15 days. Only small needles were also obtained at 
37°C but they appeared already within 24 hours. Using oils to control the rate of 
vapor diffusion did not improve crystallization and was, therefore, abandoned. In 
summary, the addition of 0.3% (v/v) CHAPS after complex preparation, and 
crystallization in 0.1M MOPS pH 6.5, 10% PEG 20.000, 20% glucose and 2.5% 
MPD buffer with 1:2 ratio protein:buffer (7.2-7.8 mg ml-1) promotes in a 
reproducible way the growth of single crystals with an approximate size of 400 μm x 
200 μm x 50 μm, at room temperature in approximately 3-5 days (Figure 4-14 D). 
Under these conditions, the growth of cluster was significantly reduced. Crystals of 
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selenomethionyl complex (Se- hIL-5Rα C66A and Se-hIL-5) were obtained with the 
same crystallization conditions. 
 
 
 
Figure 4-14. Optimization of the crystallization of the hIL-5Rα C66A/hIL-5 by detergent use. 
Complex was prepared with 0.3% (v/v) CHAPS and crystals grown in 0.1M MOPS, pH 6.5, 
10% PEG 20.000, 20% glucose. Crystals of hIL-5Rα C66A/hIL-5 complex were grown in the 
presence or absence of additives (A) without additives; (B) 2.5% (v/v) ethanol (C) 2.5% (v/v) 
PEG 400, and (D) 2.5% (v/v) MPD. 
 
Additionally, the Δ10Rα variant was used to crystallize in complex with hIL-
5. Complex preparation was performed as described above for the hIL-5Rα 
C66A/hIL-5 complex. The complex was concentrated to 10 mg per ml or 7.8 mg per 
ml in the presence of CHAPS. The highest complex concentration was used to set up 
initial screens at a 1:1 ratio (crystallization screen 1 and 2). In these screens, the 
Δ10Rα/hIL-5 complex precipitated under the following conditions: crystallization 
screen 1; buffer #3 (0.4 M Ammonium Phosphate) and buffer #12 (30% Isopropanol, 
0.1 M Na Hepes pH 7.5, 0.2 M Magnesium Chloride). However, the majority of the 
crystallization conditions only led to clear drops. Long needle clusters grew from 
two conditions: buffer #22 (12% PEG 20000, 0.1M MES pH 6.5) and buffer # 42 
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(12% Glycerol, 0.1M Tris pH 8.5, 1.5M Ammonium sulphate). The optimization of 
these two conditions did not improve the crystallization. 
Alternatively, the Δ10Rα/hIL-5 complex was crystallized applying the same 
conditions found for hIL-5Rα C66A/hIL-5 (0.1M MOPS pH 6.5, 10% PEG 20.000, 
20% glucose and 2.5% MPD) using 7.8 mg ml-1 complex concentration. But, 
although crystallization followed the same procedure, crystals obtained exhibited a 
different morphology (small needles). Fine-tuning using different concentrations of 
PEG 20000 or MPD was performed, but only very small needles or medium size 
needles could be obtained depending on the PEG concentration. These results 
suggest that, although the Δ10Rα has a similar affinity as hIL-5Rα C66A, as well as 
the purification characteristics of the Δ10Rα/hIL-5 complex are similar to those of 
hIL-5RαC66A/hIL-5 complex, this Δ10Rα/hIL-5 complex requires other 
crystallization conditions. 
 
4.1.7 X-ray analysis and complex structure 
 
A preliminary dataset was collected from a single crystal (hIL-5Rα 
C66A/hIL-5 complex) using a Rigaku X-ray machine (Rigaku, MSC, USA). Crystals 
were mounted in a nylon loop and immediately flash-frozen in liquid nitrogen. 
Crystal-to-detector distance was set to 130 mm, wavelength was 1.54 Å, and data 
collection was performed at 100 K. The crystal diffracted at a resolution of 3.2 Å. 
Data analysis indicated a monoclinic space group P21 with unit cell parameters a = 
85.13 Å, b = 60.03 Å c = 139.64 Å; and α = γ = 90°, and β = 97.98°. 
After data acquisition, the crystal was removed, washed three times in fresh 
reservoir buffer and dissolved in non-reducing SDS sample buffer. SDS-PAGE 
analysis showed that the crystal was composed of hIL-5Rα and hIL-5 in a 1:1 ratio 
(Figure 4-15), indicating that the dataset obtained was derived from a 1:1 complex of 
hIL-5 : hIL-5Rα C66A extracellular domain. 
 
RESULTS 
____________________________________________________________________ 
78 
67
45
30
22
14
Wash to remove
 protein solution
hIL-5Rα
hIL-5 Dimer
400x100x50 μm
 
 
Figure 4-15. hIL-5Rα/hIL-5 crystal content analysis. A SDS-PAGE silver stained gel revealed 
that the crystal consisted of hIL-5Rα C66A/hIL-5. The crystal was washed three times in 
0.1M MOPS pH 6.5, 10% PEG 20.000, 20% glucose and 2.5% MPD buffer, solubilized in 
SDS-sample buffer and analyzed onto a 12 % polyacrylamide gel. 
 
The final data were collected from a single crystal (Se-hIL-5Rα C66A/Se-hIL-5 
complex) using a Cyclotron beam line (SLS, Switzerland). The data analysis of the 
selenomethionyl complex (Se-complex) showed the same space group and the same 
unit cell parameters as determined before. The preliminary data processing and 
refinement statistics for Se-complex are summarized in table 4-7.  
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Table 4-7. Data collection of hIL-5RαC66A/hIL-5 complex 
 
Crystal hIL-5RαECD (C66A):hIL-5 
Space group P21 
Cell constants a = 85.13 Å, b = 61.03 Å, c = 139.64Å 
α = 90.0°, β = 97.98°, γ = 90.0° 
 
Solvent content (%, v/v) 57.23 
 Se-Met (λ1)    Se-Met (λ2)    Se-Met (λ3) 
Wavelength 0.97972           0.97955          0.90794 
Resolution (Å)a 46.10-2.58     38.71-2.64 Å Å    38.80-2.60 Å 
  (2.67-2.58 Å)    (2.73-2.64 Å)      (2.69-2.6 Å) 
 
 λ1 (inflection)        λ2 (peak)        λ3 (remote) 
Number of measurement  
reflectionsb  
159539              165069               131037 
Number of unique 
reflectionsb 
86507                 79327                  79783 
Completeness 98.8 (98.6)           96.7 (96.6)           90.2 (91.7) 
Rsym for all reflectionsc 0.062 (0.464)        0.062 (0.440)       0.055 (0.399) 
<intensity/σ> 6.8 (1.5)              7.2 (1.8)               7.7 (1.6) 
a) Numbers in parentheses indicate highest resolution shell 
b) Cut-off for reflections F > 0σ 
c) Rsym = ∑hkl|Ihkl - <Ihkl>|/∑hkl<Ihkl> where <Ihkl> is the mean intensity of symmetry 
related observations of a unique reflection 
 
The density map shows coherent density areas resulting from proteins, and 
empty areas occupied by water (Fig 4-16). Thus, at first glance, the electron density 
map revealed a crystal suitable for structure analysis. The structure of the hIL-5 
could be easily placed into the electron density map confirming the presence of two 
molecules in the electron density (PDB file: 1HUL). The main feature of the hIL-5 is 
the four α-helices bundle patterns, which form a symmetric homodimer. The ribbon 
representation (green) of IL-5 in the electron density map shows its position in the 
unit cell (Fig 4-16). The structure of hIL-5Rα C66A was partially traced by 
automated building/tracing routine using RESOLVE program. 
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Figure 4-16. Electron density map of the hIL-5Rα/hIL-5 complex. The electron density map 
displays density areas occupied by proteins (magenta) in which the IL-5 molecules (green 
ribbon) are placed, and empty areas corresponding to crystal solvent molecules that are not 
ordered. 
 
The extracellular domain of the hIL-5Rα C66A consists of three 
modules/domains, each comprising approximately 100 residues which are linked by 
loops. Each domain was described to contain a Fn-III like domain/motif (Bazan, 
1990). The preliminary structure obtained from initial data analysis of the hIL-5Rα 
C66A and hIL-5 complex demonstrated that hIL-5 binding requires the participation 
of all Fn-III like domains (Fig 4-17).  
IL-5
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Figure 4-17. Schematic representation of the hIL-5Rα C66A/hIL-5 complex. The initial trace 
of the complex in the electron density map shows the three Fn-III domains (labeled with 
numbers 1, 2 and 3) of the receptor appearing in contact with IL-5. The C-terminus of the 
receptor is in proximity to the cellular membrane. The N-terminus is at the top of the figure. 
 
This finding is in agreement with previously reported results which provided 
evidence by use of site directed mutagenesis and interaction analysis that two 
clusters  contain the crucial residues required for the interaction with hIL-5 (Ishino et 
al., 2005). In particular, the mutagenesis studies showed that the first cluster consists 
of residues Asp55 and Tyr57 of the first Fn-III like domain, whereas the second 
cluster is formed by residues Ile183 and Arg188 of the second Fn-III like domain 
and Arg297 of the third Fn-III like domain, respectively (Ishino et al., 2005). 
Our preliminary results of the hIL-5Rα C66A/hIL-5 complex structure 
demonstrate a unique binding topology in which the participation of all three Fn-III 
like domains of the IL-5Rα is required for binding of IL-5. Hence, the three Fn-III 
like domains of the receptor appear to form a cytokine binding cleft to accommodate 
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the IL-5. Further refinement of the structure is currently ongoing, in order to reveal 
more details of the molecular hIL-5-hIL-5Rα interaction. 
On the ligand side, three regions are supposed to be in contact with the 
receptor (Fig 4-17), thus confirming the results of the mutagenesis studies of IL-5 
(Graber et al., 1995; Tavernier et al., 1995b). These three interaction regions of IL-5 
are located in the β-sheet 2 (Glu89 to Arg91), in the loop between β-sheet 1 and α-
helix B (His38, Lys39 and His41), and at the C-terminal end of α-helix D (Thr109, 
Glu110, and Trp112). The mutant variants in which Ala replaced these residues 
confirmed their crucial function in binding. These mutants reduced the binding 
behaviour and activity as determined by interaction analysis and cell-based assays 
(Graber et al., 1995; Tavernier et al., 1995b) 
Taken together, this result suggests that the binding interface between hIL-
5Rα/hIL-5 in the dimeric complex is composed of: (i) the interaction between the 
first Fn-III domain residues Asp55, Asp56 and Glu58 of the hIL-5Rα with the 
residues Glu89 and Arg91 of IL-5; (ii), the second Fn-III domain residue Arg188 of 
the receptor with His38, Lys39 and His41 of IL-5, and (iii), the third Fn-III domain 
residue Arg 297 of the receptor with Thr109, Glu110 and Trp112 of IL-5 (Figure 4-
17). The data of the crystal structure are absolutely in line with all the previously 
published mutations on the hIL-5Rα or hIL-5. 
The knowledge of the hIL-5Rα C66A/hIL-5 complex structure also gives an 
explanation for the unexpected 1:1 stoichoimetry of the hIL-5Rα/hIL-5 complex. 
The hIL-5Rα interaction site is spread over the dimer interface and, as a 
consequence, only one hIL-5Rα can bind to each hIL-5 dimer (Devos et al., 1993; 
Johanson et al., 1995). A possible second binding site on IL-5 appears to be blocked 
by the first receptor. Additionally, the residues of IL-5 in contact with the residues 
N-terminal to C-terminal of the hIL-5Rα are on the opposite side of each IL-5 
monomer (see Fig 4-18 yellow arrow for the second receptor). This suggests that, if a 
second hIL-5Rα molecule binds, this molecule is derived from a second cell, leading 
to a sandwich structure, in which IL-5 being is shared (sandwiched) between the two 
cells (Figure 4-18, see red arrow for the second receptor). So far, this possible cell 
organization has only been observed during the interaction of antigen presenting 
cells and T-cells.  
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Figure 4-18. Stoichiometry of the hIL-5Rα/hIL-5 complex. The location of the hIL-5 residues 
in contact with hIL-5Rα C66A (yellow arrows). The hIL-5Rα C66A binds the ligand in the 
center of its homodimeric structure (left) and in this way leads to a blockade of the second 
binding site by the first bound receptor molecule (right). The red arrow indicates the 
hypothetical direction of the second receptor. 
 
In conclusion, this is the first experimental approach so far which presents the crystal 
structure of the binary complex of the hIL-5RαECD with hIL-5 at a resolution of 2.5 
Å. This structural data may lay the ground to study the molecular architecture of 
both proteins and depict the molecular assembly of the complex required for signal 
transduction. 
 
4.2 Structural studies of the mouse interleukin-5 
 
4.2.1 Expression, refolding and purification of mouse IL-5 (mIL-5) 
 
So far, there are no reports available on the structure of the mIL-5 protein expressed 
in E. coli. The first approach was to amplify the cDNA by PCR using the wt-mIL-
5.wt-BiP (pMT/V5-HisA) as template and specific oligonucleotide primers (3.7). 
The PCR products were digested (3.8.1) with restriction enzymes (Nco I and BamH 
I) and cloned into different expression vectors such as pET-3d, pET-28b (Novagen) 
RESULTS 
____________________________________________________________________ 
84 
and QKA (Qiagen). Transformed Rosetta cells with each vector failed to express 
wild type mIL-5. The first 10 or 20 residues on mIL-5 were subsequently replaced 
by their respective human counterpart residues. However, these chimeric mIL-5 
molecules also failed to be expressed in the bacterial expression system. 
The cDNA that encodes the wt-mIL-5 was cloned into pET-32a and pET-44a 
vectors to express mIL-5 as a fusion protein with thioredoxin or NUS A, 
respectively. AD 494 or Rosetta cells were transformed with pET-32a/wt-mIL-5 and 
pET-44a/wt-mIL5, respectively, and the cells were grown in TB medium. Wild type 
mIL-5 was expressed in fusion with thioredoxin- or NUS A protein after IPTG 
induction and the fusion protein accumulated in inclusion bodies (IB). The inclusion 
bodies were solubilized with high concentrations of guanidinium hydrocloride and 
the fusion protein was recovered under denaturing conditions with 6 M guanidinium 
hydrochloride (GuHCl). The digestion of the fusion protein with thrombin or 
enterokinase proteases was unsuccessful, because GuHCl denatures the protease. As 
consequence, chemical cleavage was chosen, in order to digest the fusion protein, 
and this cleavage could be performed under denaturing conditions. One of the most 
frequently used reagents for chemical cleavage is cyanogen bromide (CNBr). CNBr 
cleaves specifically C-teminal of Met residues using acidic conditions such as 70-
80% formic acid.  
The mIL-5 contains 6 methionine residues (Met 1, Met 5, Met 29, Met 65, 
Met 105, and Met 111, according to mIL-5 numbering). Multiple sequence 
alignments of IL-5 were performed with 6 different species (Fig 4-19). Several 
interesting substitutions were observed on the IL-5 sequence level between the 
different species. The sequence aligments showed that these methionine residues are 
not conserved in the different species (Fig 4-19). Thus, these observations were 
taken as a useful starting point to decide which residues could be used for the 
replacement of the methionine residues on mIL-5. Any Met residue of IL-5 was 
shown to participate in receptor binding. 
Sequence alignment also showed the amino acid counterpart of the six mIL-5 
methionines in hIL-5. To generate a methionine deficient mIL-5 protein, We 
replaced five mIL-5 methionines by the respective amino acid of hIL-5. The 
mutations generated were M5T, M29L, M65R and M111I. The only conserved 
methionine (M105L) was mutated to leucine. Mutations were performed in pET-
32a/mIL-5, which was used as template DNA for PCR (3.7.2). The clones obtained 
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were verified by DNA-sequencing using DTCS Quick Start kit. The resulting variant 
is referred to as mIL-5nullMet. 
 
 
 
Figure 4-19. Sequence alignment of IL-5 from six different species. Methionine positions are 
shown in red. The sequence alignment was performed using the program JalView (Clamp et 
al., 2004).  
 
Expression and purification of the protein was carried out as described for 
hIL-5 using the pET-32a/mIL-5nullMet and AD 494 (DE3) E. coli strain. The 
expression of Trx-mIL-5nullMet fusion protein was confirmed by SDS-PAGE showing 
a major band of approximately 26 kDa corresponding to the molecular weight 
expected for Trx/mIL-5nullMet. Subsequently, CNBr cleavage of denatured Trx-mIL-
5nullMet was performed under acidic conditions (80 % formic acid). Cleaved protein 
was dialyzed in GuHCL buffer for 48 hours. Later on, the protein was loaded onto 
Sephacryl 200 column to purify the mIL-5 monomer from any remaining bacteria 
components and peptides derived from bacterial proteins and thioredoxin (3.13). 
Protein refolding was performed using the same parameters and conditions as for 
hIL-5. After protein renaturation, the mIL-5 was loaded onto S200 column using 
Tris-HCl buffer (3.13.4), but surprisingly the elution profile of refolded mIL-5nullMet 
was totally different to that of hIL-5. The SDS-PAGE analysis showed that the mIL-
5 dimer did not elute as a pure fraction. Different peptides possibly derived from 
thioredoxin were found after CNBr cleavage. Further chromatography purification 
steps implemented to remove these peptides were unsuccessful.  
We took advantage of the pET-31b vector as it harbours a unique AlwN I 
cloning site allowing the unidirectional insertion of several tandem-coding regions. 
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The fusion protein (ketosteroid isomerase) does not have internal methionine and, 
thus, does not produce additional peptides after CNBr cleavage (Fig 4-20). The mIL-
5nullMet was cloned into the pET-31b vector and expressed as a fusion protein with 
bacterial ketosteroid isomerase (KSI) under the same conditions used before (3.11). 
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Figure 4-20. Schematic representation of the pET-31b/mIL-5nullMet vector. The cDNA of mIL-
5nullMet (brown) was cloned between AlwN I and Xho I restriction sites. T7 promoter is used 
for KSI/mIL-5 transcription. pET-31b carries Ampicillin resistance gene. The KSI is shown in 
green. 
 
After IPTG-induced protein expression, a band of approximately 26 kDa 
molecular weight appeared corresponding to the KSI/mIL-5nullMet fusion protein (Fig 
4-21, lane 2). The fusion protein was exclusively targeted into inclusion bodies (Fig 
4-21, lane 4). Cells were sonicated and inclusion bodies were prepared following the 
protocol of Hoppe and collaborators (3.12.2) (Hoppe et al., 1989; Hoppe et al., 
1990). The fusion protein isolated from inclusion bodies was precipitated with 
acetone and subsequently dissolved in 80% formic acid. The fusion protein was 
chemically cleaved with CNBr at the single Met residue between KSI and mIL-5 
(Fig 4-21). After protection of the thiol groups by S-sulfonation with Na2SO3 and 
Na2S4O6 (Hoppe et al., 1989; Hoppe et al., 1990), mIL-5nullMet monomers were 
purified by S200 column under denaturing conditions (Fig 4-21, lanes 5-7). 
Refolding (3.13.3) and purification (3.13.4) of the mIL-5nullMet dimer was performed 
under identical conditions as for hIL-5. No additional peptides could be observed 
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after CNBr cleavages. The mIL-5nullMet represented a final yield of about 2-3% of 
refolded protein (2-4 mg/L).  
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Figure 4-21. Expression of mouse IL-5nullMet in E.coli Rosetta cells (red oval). Protein 
expression was induced with 1 mM IPTG for three hours. Protein was analyzed on 12% 
SDS-PAGE. The gel shows: lane M; the protein marker, lane 1; non-induced cells, lane 2; 
IPTG induction of fusion protein (3 hours), lane 3; supernatant after washing of inclusion 
bodies (IB), lane 4; protein main-extraction of IB, lanes 5-7; fractions from gelfiltration after 
CNBr cleavage, and lane 8; mIL-5nullMet dimer. Proteins were separated by reducing (lanes 1-
7) and non-reducing (lane 8) SDS-PAGE and stained with Coomassie Blue (lanes 1-7) or 
silver staining (lane 8). 
 
The hIL-5 E13Q is an antagonistic mutant that causes a reduced activation of 
the hIL-5 receptor. The Glu13 of IL-5 is highly conserved in different species 
(Figure 4-19). Based on the hIL-5 data, we engineered an antagonist molecule 
targeted against mIL-5 by replacing Glu13. The mIL-5nullMet E13Q variant was 
generated by PCR mutagenesis using the cDNA of mIL-5nullMet as template (3.7.1). 
mIL-5nullMetE13Q cDNA was used to transform Rosetta E.coli cells as described for 
mIL-5nullMet variant protein. This protein was expressed, and refolded under the 
exactly same conditions utilized for mIL-5nullMet. Surprisingly mIL-5nullMetE13Q 
precipitated during the concentration step almost completely.  
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Figure 4-22. Purification of mIL-5nullMet E13Q. Chromatogram of gelfiltration chromatography 
using Superdex 75 (left). The flow rate was controlled a 0.25 ml/min. SDS-PAGE analysis 
shows: momomers (lanes 1 and 2) and dimer (lanes 3-5) from the peak I and peak II, 
respectively. Proteins were separated by non-reducing SDS-PAGE and stained with silver 
staining. The protein dimer is indicated by D and the protein monomer by m. 
 
The remaining soluble mIL-5nullMet E13Q protein was applied to Superdex 
200 column (preparative grade, 16/60), in order to eliminate monomeric protein and 
high molecular weight aggregates. Usually after this chromatography, the IL-5 dimer 
was eluted as a pure fraction as observed in the case of wt-hIL-5 and mIL-5nullMet. 
However, in this case, the mIL-5nullMet E13Q dimer did not appear highly pure. It was 
concluded that the impurities could not be eliminated by anion exchange or RP-
HPLC. The mIL-5nullMetE13Q dimer was then purified using analytical superdex 75 
column. 200 μl of concentrated mIL-5nullMetE13Q were applied to FPLC analytical 
superdex 75 column (3.13.4.2). The chromatogram profile showed that the 
monomeric protein was eluted in the first peak (see chromatographic peak I on 
Figure 4-22) and the mIL-5nullMet E13Q dimer was eluted in the second peak (see 
chromatographic peak II on Figure 4-22). SDS-PAGE analysis confirmed that the 
mIL-5nullMet E13Q dimer was obtained as a pure fraction. This unexpected elution 
profile using the analytical Superdex 75 is possibly due to an total unfolding state of 
mIL-5 monomers. The concentration of the protein was estimated by coomassie blue 
staining of the gel against known/defined concentrations of hIL-5, since the UV-
spectrum did not show a regular UV-spectrum of a protein. The mIL-5nullMet E13Q 
yield was 50 μg for each 100 mg of refolded protein (50 μg/L of cell culture).  
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In order to compare if mIL-5 E13Q mimics the known antagonistic effect of 
hIL-5 E13Q (Graber et al., 1995; McKinnon et al., 1997; Tavernier et al., 1995b),  
The hIL5 E13Q antagonist variant was generated by cycle PCR using the cDNA of 
wt-hIL-5 as a template. Human IL-5 E13Q cDNA was cloned into the pET-3d vector 
using Nco I and BamH I restriction sites (see Fig 4-1) and the resulting vector was 
used to transform E.coli cells. Expression, renaturation and purification were carried 
out under the same conditions used for hIL-5 (3.13.2 and 3.13.3). The yield of the 
IL-5 E13Q mutant was 2-4 mg/L of cell culture. 
 
4.2.2 Biological activity assay 
 
The biological activity of recombinant mIL-5nullMet, mIL-5nullMet E13Q, wild type 
hIL-5 and hIL-5 E13Q was examined using cell proliferation assays (3.14.6). The 
human erythroleukemia cell line (TF-1) was established from the bone marrow of a 
patient with erythroleukemia. This disease is characterized by erythroblastic and 
leukoblastic tissue proliferation (Kitamura et al., 1989). TF-1 cells grow in the 
presence of different cytokines including IL-5 (Kitamura et al., 1989). 
The TF-1 cells were shown to proliferate when incubated in the presence of 
hIL-5 or mIL-5nullMet (Fig 4-23). The TF-1 cell proliferation was monitored by 
measuring DNA synthesis by [3H] thymidine incorporation (Fig 4-23). Our results 
confirm previous findings which have shown that mIL-5 is active in human cells 
(Cornelis et al., 1995; Kitamura et al., 1989; Kodama et al., 1991; McKenzie et al., 
1991a). The concentration of hIL-5 or mIL-5nullMet required for the half-maximal 
proliferative response (EC50) was <17 and <200 pM, respectively. The EC50 of both 
cytokines were close to those values reported in the literature. Additionally, the EC50 
value shown for mIL-5nullMet was similar to the EC50 value (<180 pM) of 
commercially available mIL-5 expressed in insect cells (R&D systems). The 
proliferation of TF-1 cells with mIL-5nullMet also demonstrates for the first time that 
the glycosylation moiety of mIL-5 is not required for biological activity as it was 
similarly shown for hIL-5. 
 
RESULTS 
____________________________________________________________________ 
90 
 
 
Figure 4-23. Proliferation of the TF-1 cells by IL-5. The ability of hIL-5 or mIL-5nullMet 
causes proliferation of TF-1 cells in a dose-dependent manner. EC50 values were calculated 
by Origin program. Data are shown from three independent experiments. 
 
The TF-1 cells were also used to evaluate the antagonistic ability of hIL-5 
E13Q from E. coli in proliferation assays. The TF-1 cells did not proliferate in the 
presence of this protein, although high protein concentrations were used. When the 
TF-1 cells were cultured in the presence of a fixed concentration of wt-hIL-5 (2 nM) 
and serial dilutions of hIL-5 E13Q, hIL-5, the molecule E13Q was capable to confer 
a complete antagonist effect with a half maximal inhibition concentration IC50 of 0.7 
nM (Figure 4-24). Our IC50 (0.7 nM) was relatively similar to the IC50 previously 
reported by Tavernier and colleagues (0.3 nM) (Tavernier et al., 1995b). The 
inhibition properties of the hIL-5 E13Q are based on its incapacity of activate the 
TF-1 cells through the IL-5 receptor, although hIL-5 E13Q presented the same 
interaction and the same affinity constant with hIL-5Rα as those of wt-hIL-5 
(Tavernier et al., 1995b). 
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Figure 4-24. Analysis of human IL-5 E13Q on TF-1 cells. The graphic shows the half 
maximal inhibition concentration (IC50). TF-1 proliferation was measured by [3H] thymidine 
incorporation for serial dilutions of mutant E13Q. Data are shown from three independent 
experiments. 
 
The fusion protein of KSI/mIL-5nullMet E13Q was well expressed in the 
bacterial system and the mIL-5nullMet E13Q antagonist could be purified after CNBr 
cleavage. But the mIL-5nullMet E13Q dimer was very difficult to purify after 
renaturation and the yield obtained was very low. The low amounts did not allow a 
further analysis of the possible antagonistic properties in TF-1. Therefore, in this 
case, the corresponding biological assay could not be performed. 
 
4.2.3 Crystallization of mIL-5nullMet variant 
 
Crystallization trials were performed using a fine screen of the crystallization 
conditions published for hIL-5 (Graber et al., 1993; Hassell et al., 1993; Milburn et 
al., 1993). In addition, conditions of commercial crystal screen 1 and 2 (Hampton) 
were used. The mIL-5nullMet protein was found to precipitate in most of the individual 
setups of either two screening kits (Crystal screen 1 and 2).  
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Figure 4-25. Crystals from mIL-5nullMet (left) or hIL-5 (right). Both proteins crystallized in the 
same setup (100 mM Tris-HCl pH 8.5, 210 mM sodium acetate, 24% PEG 4000). Crystals 
exhibit different morphology. The diffraction limits were 2.5 Å and 2.7 Å for mIL-5nullMet (left) 
and hIL-5 (right), respectively. 
 
Hence, mIL-5nullMet was crystallized under the same crystallizations 
conditions reported for the crystallization of hIL-5 (Graber et al., 1993; Hassell et al., 
1993; Milburn et al., 1993). The setup for mIL-5nullMet was 100 mM Tris-HCl, pH 
8.5, different concentrations of PEG 4000 (22-26 %), and sodium acetate (0.2-0.23 
mM) at room temperature. The crystallization set up was performed by the hanging 
drop vapor diffusion method. Each hanging drop contained 1μl of protein (5-8 mg 
ml-1) and 1μl of reservoir solution. Crystals grew from almost all setups after 5 days, 
but an elevated PEG 4000 concentration resulted in larger and more three 
dimensional crystals. For the X-ray analysis, crystals were grown from 100 mM 
Tris-HCl, pH 8.5, 26 % PEG 4000, and 0.21 mM sodium acetate with protein 
concentration of 6.0 mg ml-1. The morphology shown for the mIL-5nullMet crystal was 
different to that of hIL-5 crystallized in the same buffer (Fig 4-25).  
 
4.2.4 Structure of mIL-5nullMet variant 
 
A flash-frozen crystal was mounted onto a nylon loop and a full dataset was acquired 
on Rigaku Micro Max 007 equipped with VariMax HighRes optics. A native dataset 
of 360° images was collected at 100 K from a single crystal grown from 0.1 M Tris 
pH 8.5, 26% (v/v) PEG 4000, 0.21 M sodium acetate. The crystal to detector 
distance was set to 130 mm and each frame had exposure times of 180 sec for 1° 
RESULTS 
____________________________________________________________________ 
93 
oscillation. The dataset was processed using the software package Crystal Clear. The 
crystals belong to the monoclinic space group P21 with unit cell parameters a = 39.19 
Å, b = 47.08 Å, c = 55.05 Å, α = 90°, γ = 90°, and β = 96.41°. Calculation of the 
Matthews coefficient suggested either the presence of an IL-5 monomer in the 
asymmetric unit requiring the two-fold screw axis to overlap with the two-fold 
symmetric of the IL-5 dimer, or the presence of the complete IL-5 dimer in the 
asymmetric unit.  
The latter would result in rather tight packing with a relatively low solvent 
content in the crystal. Self-rotation function using the software GLRF suggested the 
presence of a two-fold non-crystallographic symmetry indicative for the IL-5 dimer 
present in the asymmetric unit. Molecular replacement using the software Phaser and 
the PDB file of hIL-5 (PDB 1HUL) as an input model were employed to solve the 
structure of mIL-5nullMet. The initial analysis confirms the mIL-5nullMet structure as a 
symmetrical homodimer. A full dimer was found in the asymmetric unit resulting in 
a low solvent content of 37% in the crystal. This low solvent content reveals that the 
molecules of mIL-5nullMet are densely packed. The data processing and refinement 
statistics for mIL-5nullMet are summarized in table 4-8. 
The overall dimension of the mIL-5nullMet structure is about 57Å x 21Å x 19 
Å (Fig 4-26). The monomer subunit is composed of four α-helices and two β-sheets 
(β). Analysis of the crystal structure shows that mIL-5 forms the expected left-
handed four helical bundle. As it holds true for hIL-5, the mIL-5 exists as an 
intertwinned dimer with three helices A, B, and C provided by one chain and helix D 
coming from the second chain (Figure 4-26). The N- and C-terminal are disordered 
in the structure and are probably flexible. The arrangement and location of the 
secondary structure elements of mIL-5 are similar to hIL-5, all α-helices exhibit 
similar length (helix A: Val8-Ser25; helix B: His39-Glu56; helix C: Thr62-Gly85; 
helix D: Thr91-Leu107). 
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Figure 4-26. Structure of the mIL-5nullMet. The monomers are shown in blue and magenta. 
Each monomer consists of four helices A-D and A’-D’. The β1-strand connects the helices A 
and B or A’ and B’, and β2-strand connects the helices C and D or C’ and D’ (green). The N-
terminus (N) is found in the start of helix A or A’, and C-terminus (CO) is in the end of helix D 
or D’. 
 
The two β-sheets are formed by residues Arg32 to Pro34 (β1) and Glu89 to 
Arg91 (β2). The β-sheet 1 is tightly packed against the hydrophobic core of the four 
helices bundle, with the C-terminal of the Arg32 residue involved in hydrophobic 
interaction with residues of helix B, i.e., Gly51, Ile54 and Leu55. The β-sheet 2 is 
located at the solvent-accessible surface. The exposed residues Glu89 to Arg92 were 
found to be important for binding to IL-5Rα. Interestingly, the residues in the β-
sheet 2 are highly conserved in mIL-5 and hIL-5. This is in contrast, to the residues 
in β-sheet 1 which are not conserved.  
Since the full mIL-5 dimer is located in the asymmetric unit, dimer 
symmetric or its absence can yield valuable insights into the flexibility of the mIL-5 
molecule. By superimposing the two-monomer subunits it can be seen that the 
backbone of the two monomeric subunits is basically identical (r.m.s. deviation is 
0.5Å for 208 Cα atoms), only the C-termini (helix D) and the N-termini (helix A) 
deviate significantly. 
Of the 74 water molecules observed in the mIL-5 structure only three 
molecules occupy identical positions in both monomers. These water molecules are 
located in a hydrophobic environment between helices B and C and form a 
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hydrogen-bond network connecting the carbonyl oxygen of Phe49 and Phe69. They 
are shielded from the access of bulk solvent by the residues Lys56 and Lys76.  
 
Table 4-8. Data processing and refinement statistics for mIL-5nullMet 
 
A. Data processing   
Space group P21 
Cell constant a = 39.19 Å, b = 47.08 Å, c = 55.05 Å 
α = 90.0°, β = 96.41°, γ = 90.0° 
 Low                                 High 
Resolution (Å) 50.0-2.55                     2.62-2.55 
No unique reflections 5940                                 435 
Completeness (%) 94.63                                91.77 
B. Refinement statistics  
Rfree (%) 25.7                                   22.4 
Rcrys (%) 21.0                                   22.1 
Solvent content (%, v/v) 37.0 
PROCHECK analysis  
Residues in most-favored regions (%) 88.9 
Residues in additional allowed region 
(%) 
21.0 
Residues in generously allowed region 
(%) 
0.0 
Residues in disallowed region (%) 0.0 
 
In summary, the structure of mIL-5nullMet is well defined, with exceptions of 
the N-terminal residues Glu2 to Ser6, and the C-terminal residues Trp108 to Glu113 
indicating that the N and C-termini are not ordered and likely flexible. The final 
model of mIL-5nullMet has a good overall stereochemistry with 169 residues (88.9 %) 
in most the favorable region of the Ramachandran plot (PROCHEK) and no residues 
in the disallowed regions (Table 4-8). 
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5 DISCUSSION 
 
5.1 Production of recombinant mouse IL-5 in E. coli 
 
Airway hyperresponsivenes is a hallmark of asthma pathogenesis, which occurs as a 
consequence of tissue damage due to the accumulation of large numbers of 
eosinophils within the airways (Enokihara et al., 1990; Magnan and Vervloet, 1998). 
Different cytokines and chemokines are crucially involved in this process. IL-5 
influences the development of eosinophils at the bone marrow level and increases the 
number of eosinophils within the inflammation area (Kay, 2005; Wills-Karp and 
Karp, 2004). Different strategies to ablate eosinophil populations have shown that 
these cells constitute an integral part of experimental allergic asthma development 
(Humbles et al., 2004; Lee et al., 2004). Animal models that mimic allergen-airway 
remodeling has proven to be a valuable tool to study this disease condition. 
The murine model exhibits the same pulmonary pathogenesis as observed in 
human asthma. Mice display allergen induced eosinophilia (Hogan et al., 2003) and 
eosonophil accumulation leads to airway and bronchial hyperresponsiveness (Cho et 
al., 2004). Although other animal models are also available for the study of the 
pathophysiology of asthma, the extensive use of mice in immunological research 
provides a clear advantage for the analysis of the molecular mechanisms underlying 
this disease. In addition, the availability of a wide range of different transgenic and 
knockout mice, together with the availability of athymic nude mice, provides 
excellent in vivo systems to study the molecular mechanisms of tissue inflammation. 
However, there is no report on the expression of murine IL-5 in E. coli. Prokaryotic 
expression system looks more promising for the analysis of factors involved in 
asthma than eukaryotic expression system, due to its considerably cheaper 
production costs. 
Our objective was to find a suitable protocol for the cloning, expression, 
fermentation and purification of mouse IL-5 which could serve as basis for large-
scale production processes. At the same time, this protocol could also be used for the 
production of antagonistic molecules. The obtained mouse IL-5 could then be used 
in mouse trials and structural studies. 
The initial approach consisted in the cloning of the mouse IL-5 cDNA into 
the commercial expression vectors pET-3d and pET-28b. Although the mouse IL-5 
was cloned with NH2-terminal tags of different length or without tags, respectively, 
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expression of a recombinant protein failed. In addition, different chimeric 
murine/human IL-5 constructs were tested. The cDNA encoding for the first 10 and 
20 residues of mouse IL-5 was replaced by those of human IL-5, but the expression 
of these IL-5 chimeras in bacteria did also fail. Different factors that influence 
protein expression in E.coli, such as codon usage, secondary structure of the mRNA 
and stability of the mRNA are well known and may represent a limiting factor in 
recombinant protein expression (Jana and Deb, 2005; Kane, 1995; Schlax and 
Worhunsky, 2003). 
The fusion of cytokines with E. coli proteins, such as thioredoxin, has 
become a suitable tool for protein expression. In our approach, thioredoxin was used 
as a fusion partner, because it can be overexpressed in bacteria without the formation 
of inclusion bodies (LaVallie et al., 1993). The mouse IL-5 was highly expressed in 
fusion with thioredoxin using the pET-32a vector. But the fusion protein 
accumulated in inclusion bodies, probably due to the dimeric nature of mouse IL-5. 
These inclusion bodies were solubilized using GuHCL (guanidinium hydrochloride), 
β-ME and EDTA, thereby preventing a proteolytic cleavage. Thus, a different 
strategy was required for the expression of the fusion protein of mouse IL-5 together 
with a chemical cleavage that could be performed under denaturing conditions. 
Different reagents as 3-bromo-3-methyl-2 (2-nitrophenylmercapto)-3H-
indole (BNPS-Skatole), 2-Nitro-5 thiocyanobenzoic acid (NTCB) and cyanogen 
bromide (CNBr) have been used for chemical cleavage of proteins under denaturing 
conditions. The reaction is carried out in acetic acid (70-80%), alkaline conditions 
(Tris, pH 8.5-90) or formic acid (70-80%), respectively. They are often accompanied 
by side reactions such as oxydation of tyrosine and histidine residues (BNPS-
Skatole), cyanylation of the thiols groups (NTCB) and modification of methionine in 
homoserine (CNBr). The reagent most frequently used is CNBr, which cleaves 
specifically after Met residue. In contrast, BNPS-Skatole and NTCB cut at the C-
terminal of Trp and Cys with much less specificity.  
Although the mouse IL-5 contains six Met residues, these Met residues of the 
mouse IL-5 do not participate in receptor binding. In addition, they are not conserved 
in different species (see figure 4-19). It was further shown, that the biological 
activity of mouse IL-5 was dependent on its homodimer configuration, linked 
together by disulphide bridges (Tavernier et al., 1989). Interestingly, the Trp111 is 
highly conserved in distinct species (4.4 see figure 4-19) and the hIL-5 W111D (in 
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mouse Trp 109) mutation reduces the strength of the receptor binding by a factor of 
500-fold (Graber et al., 1995). Therefore, the CNBr cleavage was the option to digest 
the fusion protein. 
Of the six Met residues in mouse IL-5, only five Met residues of mouse IL-5 
were substituted by the respective amino acids derived from the human counterpart 
(M5T, M29L, M65R, M105L and M111I, according to mIL-5 numbering). The first 
Met residue in mouse IL-5 was maintained for CNBr digestion. The resulting mouse 
IL-5 Met deficient mutant (plasmid pET-32a-Thioredoxin/mouse IL-5nullMet) was 
highly expressed in E.coli. However, after CNBr cleavage different peptides from E. 
coli thioredoxin were generated. After allowing protein refolding, the mouse IL-
5nullMet dimer was formed as shown by SDS-PAGE, but the peptides generated after 
CNBr digestion prevented further purification. Thus, the mouse IL-5 dimer purity 
was very low.  
In a following step, We took advantage of the pET-31b vector which harbors 
an unique AlwN I cloning site, thus allowing the unidirectional insertion with 
bacterial ketosteroid isomerase (KSI). The KSI does not have internal methionine 
and, as consequence, does not produce additional peptides after CNBr cleavage. The 
expressed fusion protein was found within inclusion bodies. Chemical cleavage with 
cyanogens bromide (CNBr) was used to release the mouse IL-5 monomer (see 
materials and methods 3.13.2). The mouse IL-5 dimer was obtained using the same 
refolding and purification conditions as for the human IL-5. Using different 
analytical methods (SDS-PAGE under non-reducing conditions as well as analytical 
RH-HPLC) the purity of mIL-5 could be estimated to be ≥ 96 % 
The first step was to evaluate the biological activity of mouse IL-5 in cell 
proliferation assays. The mouse IL-5nullMet was able to induce proliferation of TF-1 
cells in vitro. A comparison of the half maximal response (EC50) value of the mouse 
IL-5nullMet (200 pM) and mouse IL-5 (180 pM) from sf9 cells (R&D systems) reveals 
that the mouse IL-5nullMet was biologically active and glycosylation of this protein 
was not necessary for activity.  
 
5.2 Structural studies of the mouse IL-5 
 
So far, only the structure of the human IL-5 (hIL-5) has been determined by X-ray 
crystallography. Depicting the X-ray structure of the mouse IL-5 system may 
provide an important clue towards our understanding of the mechanisms governing 
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the species-specific interactions of IL-5. After mouse IL-5 purification, the protein 
was crystallized under the same conditions described for human IL-5. Crystal 
structure analysis shows that mouse IL-5nullMet exhibits the same topology compared 
to the human IL-5 (Milburn et al., 1993). 
 
Table 5-1. Alignment of α-helix sequences of human IL-5 and mouse  
IL-5nullMet 
 
Secondary structure Sequence Alignment Similarity 
(%) 
 
α-helix A 
  
64 
 
 
α-helix B 
 
 
 
 
62 
 
α-helix C 
 
 
 
 
80 
 
α-helix D 
 
 
 
 
80 
 
Upper sequence (human IL-5) 
Lower sequence (mouse IL-5nullMet) 
Conserved amino acids are in blue boxes. Gaps are designated with hyphen (-) 
 
A detailed comparison of the structures of mouse IL-5nullMet with its human 
homologue IL-5 (PDB 1HUL) reveals some structural differences. The length of α-
helices differ slightly, e.g., the α helices A, B, and D are formed by 17, 18, and 15 
residues in mouse IL-5nullMet in contrast to 20, 16, and 17 residues in human IL-5, 
Nevertheless, the protein sequence appears highly conserved (Table 5-1). Helix C is 
formed by 25 residues in both cytokines (Table 5-1). 
Superimposition of both IL-5 structures allows determining the exact 
positional differences of the N- and C-termini. The N-terminus of the helix A of 
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mouse IL-5 was moved 3.79 Å with respect to human IL-5 only in one monomer 
(Pro6); for the second monomer the Pro6 was absent at the N-terminus (Figure 5-1). 
In the case of the C-terminus of mouse IL-5 (Glu110), it differs 5.48 and 5.86 Å in 
comparison to human IL-5 (Figure 5-1).  
 
3.79 
5.48 
5.86 
Pro 6 only in hIL-5
Pro 6
Pro 6
Glu 110
Glu 110
Glu 110
Glu 110
 
 
Figure 5-1. Alignment of mouse IL-5nullMet structure with human IL-5 structure. Line 
representation illustrates the superimposition of both secondary structures from mouse IL-
5nullMet (blue) and hIL-5 (green) backbones. The N-terminal residue (Pro6 in green) was 
moved by 3.79 Å in mouse IL-5nullMet in one monomer, but is not present in the second 
monomer. The C-terminal residue (Glu110 in green) appeared 5.48 or 5.86 Å away from its 
counterpart on hIL-5 (Glu110 in blue). The residue before of Glu110 (Thr109) is shown in 
magenta. 
 
These and other small differences between the structures of mouse IL-5 and 
human IL-5 may explain the species-specificity observed for mouse IL-5 receptor 
activation. Superimposition of the mouse IL-5 and human IL-5 structures shows 
additionally, that the helix A of mouse IL-5 is shortened by one turn. Furthermore, 
the N-terminus of mouse IL-5 seems much less ordered despite the fact that traceable 
electron density can be observed from residue Thr7 in one monomer and from Pro5 
in the other monomer. 
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These results suggest that the helix A of mouse IL-5 may be more flexible 
than the human IL-5 counterpart at the N-terminus due to the amino acid difference 
located further up in the helix A; Leu10 in human IL-5 is replaced by the smaller Val 
in mouse IL-5. The Leu10 residue in hIL-5 is, however, in close contact with Leu74 
in helix C possibly forming a stable hydrophobic interaction. On the other hand, in 
mouse IL-5, the side chain of Val10 is supposed to be too short for this hydrophobic 
interaction; therefore, it can be hypothesized that a stabilization of the N-terminus 
cannot be achieved to this extent leading to a more flexible N-terminus in mouse IL-
5. 
Also the C-terminal helix D is shortened in mouse IL-5 by one turn if 
compared to hIL-5, and the C-terminal residues of the mouse IL-5 adopt a less 
regular secondary structure. The probable cause for the increased flexibility in the C-
terminal end of mouse IL-5 could reside in the side chain conformation of residue 
Trp111. In one monomer the side chain of the Trp111 is more solvent exposed 
compared to hIL-5, due to the change in backbone conformation in the preceding 
residues Thr109 to Glu110. The Cα-atom of Glu109 in mouse IL-5 occupies the 
same position as the Cα-atom of Trp111 in hIL-5, leading to a significant shift of the 
Cα-atom of the Trp111 of mouse IL-5. In the second monomer of the mouse IL-5 
dimer, the electron density cannot be traced beyond the backbone atoms of Glu109, 
suggesting that the flexibility in the C-terminus is, indeed, higher in mouse IL-5. In 
line with this hypothesis, temperature factors of the residues in the C-terminal turns 
of both helices D of mouse IL-5 are higher as compared to the residues in the core 
helical part. Since the C-terminal residue Glu110 has been shown to be crucial for 
human IL-5Rα binding and activation (Cornelis et al., 1995; Graber et al., 1995; 
Morton et al., 1995; Tavernier et al., 1995a), such differences in the backbone 
conformation might contribute to species specificity. Currently, there is no evidence 
that the residue Trp111 is involved in any direct interaction with the receptor IL-
5Rα, but it is believed to be mediate anchoring of the C-terminal end of helix D in 
human IL-5. 
The N-terminus of the helix B of mouse IL-5 appears extended by one turn 
with respect to human IL-5. The probable cause for this might be the fact that Thr45 
in hIL-5 is replaced by Ile45 in mouse IL-5. The polar side chain of Thr45 is 
important for the access to the solvent via its hydroxyl end, thereby requiring a less 
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tight packing of the core. In contrast, the Ile45 in mouse IL-5 allows for tight 
packing, thereby stabilizing the N-terminal end of the helix B in mouse IL-5. Helices 
C and the short β-strands formed by overhand connections loops are identical in 
mouse IL-5 and hIL-5. 
Our results show that the production of mIL-5nullMet is feasible. Studies are 
underway, in order to produce antagonistic molecules of mIL-5 that could be 
evaluated in mice asthma model. 
 
5.3 Human IL-5Rα/IL-5 complex structure 
 
After differentiation, precursor T cells develop into - at least - two effectors T cell 
subsets, called Th1 and Th2. Each one is characterized by their particular cytokine 
secretion pattern. The Th1 subset mainly produces the cytokine interferon-γ, which is 
a key messenger for killing of intracellular pathogens. The Th2 cells secrete IL-4, 
IL-5, IL-10 and IL-13, all of which are required to fight extracellular infections, such 
as helminth parasites. It is well known that these Th2 cytokines also play a very 
important role in the pathophysiology of asthma. In particular, a strong correlation 
between disease severity and IL-5 production was found (Enokihara et al., 1990; 
Magnan and Vervloet, 1998). It is unclear why certain antigens (allergens) cause 
asthma. Once Th2 cells release higher amounts of IL-5, which induce terminal 
differentiation, activation and survival of eosinophil cells (Woodcock et al., 1997), 
airway remodeling is induced as a consequence of tissue damage (Kay, 2005; Wills-
Karp and Karp, 2004). The first step in eosinophil activation is the interaction of IL-
5 and the corresponding IL-5 receptor. The cellular IL-5 receptor is a heterodimer 
consisting of an IL-5 specific alpha subunit (IL-5Rα) mediating binding and a 
common beta subunit (βc), which is also shared by the IL-3 and GM-CSF receptors 
(Wells and de Vos, 1996). The IL-5Rα is the highly-specific binding subunit, 
whereas the association of the low-affinity βc subunit mediates signaling into the 
effector cell (Wells and de Vos, 1996). 
Because of the central role of eosinophils in the development of asthma, they 
represent a promising target for the design of new therapeutic strategies that may 
block their activation. Currently asthma therapy is based on the use of anti-
inflammatory steroids and sympathomimetic substances which mediate 
bronchodilatation. Although this represents a clear therapeutic benefit, novel causal 
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therapies targeted against key molecules of asthma pathogenesis may improve the 
current treatment options.  
New therapeutic approaches could e.g. target directly IL-5 either by 
administration of blocking antibodies or by IL-5 antagonist proteins, peptides or 
small molecules. Such strategies have already been developed. For example, the anti-
IL-5 antibody (Mepolizumab) has been shown to inhibit the eosinophil maturation 
and reduces the number of progenitor cells and the extent of tissue damage (Garrett 
et al., 2004). However, the anti-5 therapy did not deplete the eosinophils in the tissue 
(Oldhoff et al., 2006). In addition, peptides with antagonistic action on IL-5 have 
been tested as new therapies (England et al., 2000; Ishino et al., 2005; Ruchala et al., 
2004). The peptides evaluated so far, mediate binding via the same contact residues 
as IL-5 and, therefore, might block the interaction with the receptor alpha chain. 
However, the antagonistic properties of these peptides and their possible use as a 
therapeutic option for asthma in humans must still be evaluated.  
In 1996 Milburn and colleagues reported the X-ray crystallography structure 
of the human IL-5 expressed in E. coli (Milburn et al., 1993). Later on, the structure 
of the human IL-5 produced in an eukaryotic expression system, was also 
determined (Guisez et al., 1993; Johanson et al., 1995). Furthermore, the X-ray 
crystallography structure of the extracellular domain of the human IL-5Rβ was 
published (Carr et al., 2001). The IL-5Rα is required for ligand-specific binding as 
first step of the IL-5 receptor activation. The analysis of the three dimensional 
structure of the IL-5Rα/IL-5 complex by using the X-ray crystallography technique 
will help to understand the precise molecular basis of this interaction. This 
knowledge will lay the ground to identify or design novel antagonistic molecules for 
asthma treatment.  
The X-ray structural analysis of the human IL-5/IL-5Rα complex may 
become the most promising approach for rational drug design. On the other hand, 
antagonistic molecules, which may block the βc could disrupt the IL-3 and GM-CSF 
functions such as the activation of immature myelomonocytic cells and the induction 
of differentiation of granulocyte and macrophage cells, respectively.  
The first attempt to determine the human IL-5/IL-5Rα complex structure by 
X-ray crystallography was done by Johanson and colleagues in 1995 (Johanson et 
al., 1995). They used deglycosylated human IL-5 and glycosylated human IL-5Rα to 
prepare and cocrystallize the human IL-5/IL-5Rα complex. Only neddle crystals 
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were grown from this complex. But, the crystal structure of human IL-5/IL-5Rα 
complex could not be determined successfully.  
This work provides the first preliminary human IL-5Rα/IL-5 complex 
structure at a resolution of 2.5 Å. The human IL-5Rα/IL-5 complex structure 
demonstrates that the ligand-binding region of the human IL-5Rα is dispersed all 
over three Fn-III domains of the extracellular part of human IL-5Rα (Figure 5-2). 
The human IL-5Rα recognizes its ligand through the first NH2-terminal Fn-III 
domain and, additionally, by its cytokine recognition motif (CRM), which is formed 
by the second and third Fn-III domains (Figure 5-2).  
 
NH2-terminal
domain
CRM
IL-5
 
Figure 5-2. Structure of the human IL-5Rα/IL-5 binary complex. Ribbon diagram of the 
complex structure shows the IL-5Rα in blue and the IL-5 in green. The IL-5Rα area 
participating in the CRM formation is indicated with the bracket. 
 
The human IL-5Rα/IL-5 complex structure shows a different binding 
topology compared to other members of the class I cytokine receptor family. A 
common feature of the class I receptors is the presence of two similar extracellular 
tandem domains which adopt a Fn-III like conformation (Bazan, 1990). These 
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receptors recognize the ligand through its cytokine recognition motifs (CRM) that is 
formed by these two Fn-III like extracellular domains (Figure 5-3).  
 
IL-4Rα
IL-4
CRM
IL-5Rα
IL-5
CRM
 
 
Figure 5-3. Representative structures of the class I cytokine family complexes. The CRM is 
defined as the region in which the ligand binds the specific receptor (red dotted lines) The IL-
4Rα/IL-4 (magenta and red) complex shows that the CRM is formed by two Fn-III like 
domains (right). The three dimensional structure of hIL-5Rα/hIL-5 (blue and green) shows a 
new binding topology. Six cysteine residues are shown as yellow sticks. Two disulfide 
bridges are found in the second Fn-III domain between Cys114-Cys135 and Cys162-
Cys176, respectively. The third disulfide bridge (Devos et al., 1994) is found in the third Fn-
III domain between Cys249-Cys296. The WSXWS motif (red sticks) is also found in the third 
Fn-III domain. 
 
There are four conserved cysteine residues in the first Fn-III like domain and 
a conserved WSXWS (Trp-SerX-Trp-Ser, where X is any residue) sequence in the 
second Fn-III like domain (Figure 5-3). Known structures of the IL-4Rα/IL-4 and 
prolactin receptor/growth hormone (ProlR/GH) complexes have shown so far, that 
the two Fn-III like domains form an L shape. The ligand is bound to the elbow 
region, which is composed by several loops connecting the β-strands of each Fn-III 
type domain (de Vos et al., 1992; Hage et al., 1998; Hage et al., 1999; Somers et al., 
1994). Similarly, the second/third tandem Fn-III domains of human IL-5Rα form 
DISCUSSION 
____________________________________________________________________ 
106 
cytokine recognition motifs (CRM), characteristic for the class I receptor family 
(Wells and de Vos, 1996). Although the human IL-5 also interacts with the elbow 
region formed by the CRM (Figure 5-3, see red dotted area), this complex adopts a 
binding topology in which the CRM needs the first Fn-III domain of the human IL-
5Rα to bind the ligand (Figure 5-3). 
 
5.4 Cytokine recognition by human IL-5Rα 
 
In our work, we used in vitro interaction analysis of different human IL-5Rα variants 
to determine the residues involved in IL-5 recognition. Our functional data confirm 
the binding topology of the preliminary structure, in which all three Fn-III domains 
of the human IL-5Rα are involved in the direct interaction with IL-5. 
BIAcore analysis shows that the first Fn-III like domain of the human IL-5Rα 
plays a very crucial role in IL-5 binding (Figure 5-4). The human IL-5Rα variants 
lacking this domain were not able to bind to IL-5 (4.1.4 see Del1 in table 4-4 and 
figure 4-9). Additionally, BIAcore analysis data demonstrate that the IL-5 binding 
properties of the first Fn-III domain also mainly depend on the Asp55 and Tyr57 
residues (4.1.4 see table 4-4 and figure 4-9). The conservative replacement of D55E 
in human IL-5Rα had a small effect on the binding properties with a 4-fold 
decreasing affinity. This D55E variant was found to increase the koff (4.1.4 see table 
4-4 and figure 4-9). Thus, these results suggest that the large size of the Glu side 
chain could generate a steric hindrance that could possibly be responsible for the 
decrease in ligand affinity. The negatively charged Asp55 residue was mutated for 
the neutral analogue Asn (D55N). This mutation showed less affinity because it 
posses similar kon and an increased koff (unpublished data; (Ortmann, 2004)). 
However, the D55A mutation shows a dramatic decrease in the binding affinity, due 
to slow association rates and fast dissociation rates as shown by Ishino and 
Colleagues (Ishino et al., 2004). On the other hand, the receptor Y55F variant did not 
show any effect on receptor binding for IL-5 (4.1.4 see table 4-4). In contrast, the 
Y57A mutation resulted in a drastic reduction of ligand binding (KD = 1.3 μM) 
(unpublished data; (Ortmann, 2004)), possibly due to a different secondary structure 
of the receptor (4.1.2 see figure 4-7). These findings correlate with previous results 
that also showed no specific binding of the Y57A receptor variant (Cornelis et al., 
1995). The Tyr57 residue in IL-5Rα is highly conserved among all IL-5Rα 
sequences found in Swiss-Prot (www.expasy.org). These results suggest that the 
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aromatic side chain of Tyr57 plays an important role in maintaining the oligomeric 
structure of the receptor. 
 
Arg188
Arg297
Asp55
Asp56
Tyr57
Glu58
 
Figure 5-4. Schematic representation of the crucial hIL-5Rα residues involved in IL-5 
binding. The residues present in all three Fn-III like domains of hIL-5Rα, which are 
responsible for association with the ligand are shown in the red squares. In the first domain 
Asp55 (green), Asp 56 (yellow), Tyr57 (red) and Glu58 magenta are shown. In the second 
and third domain the Arg 188 and Arg 297, are respectively shown. 
 
In addition, Asp56 and Glu58 are crucial for the high affinity interaction of 
the receptor with IL-5 as shown by different groups (Cornelis et al., 1995; Ishino et 
al., 2004). These findings demonstrate the importance of the first Fn-III domain for 
human IL-5Rα ligand binding (Figure 5-4). 
The IL-5Rα contains a free cysteine (Cys66) residue at the first Fn-III 
domain. Our data demonstrated that this Cys66 is modified by β-mercaptoethanol (β-
ME) during receptor purification (4.1.2 see table 4-3). The mutation of the C66A 
avoids the interaction of β-ME with the free thiol group of the Cys residue, and the 
IL-5Rα C66A variant still binds IL-5 with similar KD as compared to the wild type 
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human IL-5Rα (4.1.4 see table 4-4 and figure 4-9). However, BIAcore analysis 
shows that the C66A mutation increases the kon (5.2 x10-5 (s-1M-1)) and decreases the 
koff (1.4 x103 (s-1)) leading to overall KD value of 3.0 nM. The KD determined in this 
work for the human IL-5Rα C66A is in complete agreement with previous results 
(Johanson et al., 1995; Morton et al., 1994). 
The ligand recognition mechanism was also dependent on the Arg188 residue 
present in the second Fn-III domain of the human IL-5Rα. The mutation R188K 
resulted in a significant reduction of the binding activity (4.1.4 see table 4-4). These 
results suggest that the structural elements of the guanidinium group of the Arg are 
the major factors involved in binding, rather than just the positive charge of Arg188 
(Figure 5-4). In addition, the R188A mutation was also shown to be crucial for the 
high affinity interaction with human IL-5 (Cornelis et al., 1995; Ishino et al., 2004). 
The position of Arg188 seems to be important in class I cytokine receptors. For 
example, in the growth hormone receptor there is a tryptophan residue (Trp104) 
instead of Arg (Arg188), as shown by CRM alignment of the two receptors 
(Cornelis, Plaetinck et al. 1995). This Try104 residue plays a key role in ligand 
binding (Sundstrom et al., 1996). 
Conservative mutation of F182A or I183A demonstrates that these residues 
are not required or involved in ligand binding (4.1.4 see table 4-4). I could be further 
shown that the deletion of the second and third Fn-III domains of the human IL-5Rα 
had a dramatic effect on the binding activity of the receptor (4.1.4 see Del2 in table 
4.4). Ishino and colleagues also demonstrated that the Arg297 residue in the third 
Fn-III domain of human IL-5Rα is important for ligand binding (Ishino et al., 2004).  
Our findings and those previously published (Cornelis et al., 1995; Ishino et 
al., 2004) demonstrated that, in contrast to other class I cytokine receptors, the CRM 
of human IL-5Rα is not sufficient for the full binding activity.  
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Figure 5-5. Comparison of the structures of class I complexes. The structures of the IL-5Rα/IL-5 
(left) and gp130/vIL-6 (right) complexes are shown in ribbon representation. The IL-5Rα 
(blue) interacts with IL-5 (green) by using all three Fn-III domains (D1, and CRM (D2 and 
D3)). The two gp130 receptor molecules (red and yellow) interact with one vIL-6 molecule 
(blue) by using an interface between D1 from one gp130 molecule (red) and D2 and D3 from 
the other molecule (yellow), and vice versa.  
 
The crystal structure of the complex formed by the human cytokine receptor 
gp130 and viral IL-6 (vIL-6) showed, that gp130 requires its N-terminal 
immunoglobulin (Ig)-like activation domain, in order to be functionally responsive 
to the cytokine (Chow et al., 2001). However, significant differences occur between 
these two cytokine class I receptor complexes (Figure 5-5): (i) The gp130/vIL-6 
adopts a tetrameric arrangement consisting of two vIL-6 molecules and two gp130 
receptors (Chow et al., 2001). In contrast, only one human IL-5 molecule binds to 
one human IL-5Rα (Figure 5-5). (ii) In the binding interface, each vIL-6 molecule 
bridges two different gp130 receptors, and each gp130 receptor binds two vIL-6 
(Chow et al., 2001). (iii) The gp130/vIL-6 complex is tethered through the 
interaction of one face of vIL-6 with gp130 (D2D3) and through a second vIL-6 
epitope interacting with the N-terminal Ig-like domain of a different gp130 (D1) 
(Chow et al., 2001). In contrast, the human IL-5Rα/IL-5 complex is formed through 
the interaction of the human IL-5 with the first Fn-III domain and CRM of the 
receptor (Figure 5-5). These data show that the IL-5Rα/IL-5 complex adopts a 
totally novel binding topology. 
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5.5 Stoichiometrical interaction of human IL-5Rα and human IL-5 
 
Previous analysis using site-directed mutagenesis showed the importance of charged 
residues of human IL-5 for human hIL-5Rα binding (Graber et al., 1995; Tavernier 
et al., 1995b).  
 
180
I
II
 
 
Figure 5-6. Regions involved in the interaction between hIL-5Rα and hIL-5. Residues 
responsible for the interaction between hIL-5Rα and hIL-5 are present in region I and II (red 
dotted squares). Region I shows the Asp55 (orange spheres), Asp56 (light blue spheres), 
Tyr 57 (orange spheres) and Glu58 (light blue spheres) of the IL-5Rα (blue) and the β-sheet 
consisting of Glu89, Arg90, Arg91 and Arg 92 (red) of the IL-5 (green). Region II shows the 
Arg188 (magenta spheres) and Arg 297 (blue spheres) of the IL-5Rα and Glu110 (red and 
yellow spheres) from both IL-5 monomers.   
 
Our results for the preliminary human IL-5Rα/IL-5 structure are consistent 
with these former human IL-5 mutagenesis data (Figure 5-6). The human IL-
5Rα/IL-5 complex structure suggests that the interaction between ligand and 
receptor could involve the negative patch in the first Fn-III domain of human IL-5Rα 
(Asp55-Glu58) and the positively charged patch in IL-5 (Arg90 and Arg91 (β-sheet 
2)) (see region I of the figure 5-6). Moreover, the positive patch of the CRM in the 
human IL-5Rα (Arg188 and Arg297) (Figure 5-6) could interact with the negative 
charged Glu110 of the human IL-5 (Graber et al., 1995; Tavernier et al., 1995b) (see 
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region II of the figure 5-6). Since the human IL-5 has a dimeric structure (Milburn et 
al., 1993) binding of two human IL-5Rα molecules appeared possible. The 
preliminary structure of the human IL-5Rα/IL-5 complex clearly demonstrates that 
only one IL-5Rα molecule binds one human IL-5 dimer molecule (molar 
stoichiometry of binding of 1:1) (Figure 5-7) (Devos et al., 1993; Johanson et al., 
1995), consistent with functional data from our studies and other groups.  
33
24
Cellular membrane
 
Figure 5-7. Stoichiometry of the IL-5Rα and IL-5 complex. The structure of IL-5Rα and IL-5 
complex shows a 1:1 stoichiometry. Both IL-5Rα (Asp55, Asp56, Tyr57 and Glu58) and IL-5 
(Glu89, Arg90, Arg91 and Arg92) epitope residues are represented by magenta and red 
arrows, respectively. The Glu110 of IL-5 that interacts with IL-5Rα is shown in red spheres. 
The Glu110 of the second monomer of IL-5 is depicted in yellow spheres. The red circle 
shows the second binding site in IL-5 (green). The black dotted lines show the free and 
occupied area for the IL-5Rα on the IL-5 dimer. 
 
Our data show that the steric hindrance of the first bound receptor prevents 
the binding of a second IL-5Rα molecule to the IL-5Rα/IL-5 complex (Figure 5-7). 
The first receptor binds in close proximity to the central symmetric axis of the IL-5 
dimer in which the Glu110 is found (Figure 5-7). This 1:1 stoichiometry shown for 
our complex structure was anticipated by Devos and Johanson groups (Devos et al., 
1993; Johanson et al., 1995).  
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How would then a biologically active receptor be formed? In order to address 
this central question, the group of Chaiken et al. showed in an elegant approach 
using asymmetric mutagenesis for IL-5 (Li et al., 1996), that the human IL-5Rα 
binds to the single shared α chain site on IL-5. Most importantly, they demonstrated 
that the human IL-5Rα/IL-5 only recruits one βc (Fig 5-8).  
Consequently, they proposed a step by step- model, in which the βc is 
recruited to bind IL-5 once IL-5Rα is bound. The favored βc site is the “cis” site, 
namely the site involving the predominating Glu13 of the IL-5 (Li et al., 1996). In 
this model, the low affinity complex is formed by hIL-5Rα/hIL-5 in a 1:1 ratio. 
Subsequently, this complex forms a trimeric complex by recruiting one IL-5Rβ (Fig 
5-8). A similar assumption has also been made in the molecular models proposed by 
Johanson and colleagues in 1995 (Johanson et al., 1995).  
 
Cellular membrane
1 2
 
Figure 5-8. Model of the biologically active hIL-5 receptor complex. The structure of the low 
affinity and active IL-5Rα/IL-5 (left) and modeled βc (right) receptor complexes are shown. 
Two CRM of βc are defined as the region in which the active IL-5Rα/IL-5 binds the βc 
(numbers 1 and 2). 
 
The IL-5Rα/IL-5 complex is different from other class-2 cytokine/receptor 
complexes, such as interleukin-10 and interferon-γ. Interleukin-10 and interferon-γ 
are symmetric homodimers with a similar topology (Walter and Nagabhushan, 
1995). The crystal structure of the IL-10R1 and IL-10 shows that one IL-10 
homodimer binds two IL-10R1 molecules (Figure 5-9) (Josephson et al., 2001). 
Equally, an interferon-γ dimer binds two high affinity interferon-γ receptor 
molecules (Walter et al., 1995). Our data, in contrast, provide evidence for a new 
topology interaction by the IL-5Rα/IL-5 complex. 
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Figure 5-9. Differences between class I and class II cytokine complexes. In the class I 
cytokine complex shown one IL-5 dimer (green) binds only one molecule of the IL-5Rα 
(blue). The class II cytokine complex shows one IL-10 dimer (magenta) interacting with two 
molecules of the IL-10R1 (red). 
 
Taken together these results, this thesis provides for the first time insights 
into the IL-5Rα/hIL-5 complex structure. It further confirms that the stoichiometrical 
interaction between IL-5Rα and IL-5 follows a 1:1 ratio at the structural level. 
Finally, this thesis adds important knowledge to the central role the three Fn-III like 
domains play in ligand binding. 
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6 ABSTRACT 
 
Interleukin-5 (IL-5) is a member of the hematopoietic class I cytokines and is 
specifically involved in eosinophil activation. IL-5 plays an important role in disease 
conditions such as allergic asthma and other hypereosinophilias, which are 
characterized by highly increased levels of eosinophils in peripheral blood and 
tissues. The IL-5 receptor is a heterodimer consisting of a binding alpha subunit (IL-
5Rα) and a common beta subunit (IL-5Rβ). This IL-5Rβ is shared with the IL-3 and 
GM-CSF receptors. The IL-5Rα is required for ligand-specific binding, whereas the 
association of the IL-5Rβ subunit triggers intracellular signal transduction. Previous 
studies have described the crystallographic structure of human IL-5 (hIL-5), as well 
as that of the common IL-5Rβ chain (IL-5Rβc)  
However, no experimental structural data are yet available for the interaction 
of the high-affinity IL-5 receptor IL-5Rα with its ligand IL-5. Therefore, this thesis 
had the principle objective to gain new insights into the basis of this important 
agonist-receptor interaction. In particular, data on the recombinant expression, 
purification and preparation of the binary complex of hIL-5 bound to the receptor 
ectodomain of hIL-5Rα are shown, as well as the subsequent crystal structure 
analysis of the binary ligand-receptor (hIL-5Rα/hIL-5) complex.  
Both proteins were expressed in an Escherichia coli expression system, 
purified to homogeneity, and crystallized. However, since the initial analysis of these 
crystals did not show any X-ray diffraction, each step of the preparation and 
crystallization procedure had to be stepwise optimized. Several improvements 
proved to be crucial for obtaining crystals suitable for structure analysis. A free 
cysteine residue in the N-terminal domain of the hIL-5Rα ectodomain protein was 
mutated to alanine to remove protein heterogeneity. In addition, hIL-5 affinity 
chromatography of the receptor protein proved to be absolutely crucial for crystal 
quality. Additive screening using the initial crystallization condition finally yielded 
crystals of the binary complex, which diffracted to 2.5Å resolution and were suitable 
for structure analysis. The preliminary structure data demonstrate a new receptor 
architecture for the IL-5Rα ligand-binding domain, which has no similarities to other 
cytokine class I receptor structures known so far. The complex structure 
demonstrates that the ligand-binding region of human IL-5Rα is dispersed over all 
three extracellular domains, and adopts a binding topology in which the cytokine 
recognition motif (CRM) needs the first Fn-III domain of the human IL-5Rα to bind 
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the ligand.  
In a second project, a prokaryotic expression system for murine IL-5 (mIL-5) 
was established to allow the production of mIL-5 and mIL-5 antagonist that should 
facilitate functional studies in mice. Since the expression of mIL-5 in E. coli had 
never been successful so far, a fusion protein system was generated expressing high 
yields of mIL-5. Chemical cleavage with cyanogen bromide (CNBr) was used to 
release mIL-5 monomers, which were subsequently purified and refolded. This 
technique yielded an active murine IL-5 dimer as confirmed by TF-1 cell 
proliferation assays. The protein was crystallized and the structure of mIL-5 could be 
determined at 2.5Å resolution. The molecular structure revealed a symmetrical left-
handed four helices bundle dimer similar to human IL-5. Analysis of the structure-
/function relationship allowed us to design specific mIL-5 antagonist molecules, 
which are still under examination. Taken together, these findings provide further 
insights in the IL-5 and IL-5R interaction which may help to further understand and 
depict this and other cytokine-receptor interactions of similar architecture, e.g. the 
IL-13 ligand-receptor system. Ultimately, this may represent another piece of puzzle 
in the attempts to rationally design and engineer novel IL-5-related pharmacological 
therapeutics. 
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7 ZUSAMMENFASSUNG 
 
Interleukin-5 (IL-5) ist ein Mitglied der Gruppe der hematopoetischen Zytokine der 
Klasse I und spielt eine Schlüsselrolle bei der Aktivierung von eosinophilen 
Granulozyten. IL-5 hat damit ein wichtige pathophysiologische Funktion bei der 
Entstehung von Krankheiten wie allergischem Asthma und anderen 
Hypereosinophilien, die alle durch eine stark erhöhte Zahl von Eosinophilen in 
peripherem Blut und Geweben charakerisiert sind. Der IL-5 Rezeptor ist ein 
Heterodimer, der aus einer alpha-Untereinheit (IL-5Rα) und einer mit den IL-3 und 
GM-CSF Rezeptoren gemeinsamen beta-Untereinheit (IL-5Rβ) besteht. Der IL-5Rα 
ist für die spezifische Liganden-Bindung notwendig, während der mit der IL-5Rβ 
Untereinheit assozierte Komplex die intrazelluläre Signaltransduktion einleitet.  
In früheren Studien konnte bereits die Kristallstruktur des menschlichen IL-5 
(hIL-5) und der gemeinsamen IL-5Rβ-Kette (IL-5Rβc) aufgeklärt werden. Allerdings 
liegen bisher noch keine experimentellen Strukturdaten für die Interaktionen des 
hochaffinen IL-5 Rezeptor IL-5Rα mit seinem Ligand IL-5 vor. Deshalb war es die 
Hauptzielsetzung dieser Arbeit, neue Einblicke in die molekulare Basis der 
Interaktion von IL-5 Rezeptor und Agonisten zu gewinnen. Im Einzelnen beschreibe 
ich in dieser Arbeit die rekombinante Expression, Aufreinigung und Herstellung des 
binären Komplexes von der hIL-5 Bindung an die extrazellulären Domäne des 
Rezeptors hIL-5Rα sowie die anschließende kristallographische Strukturanalyse 
dieses binären Ligand-Rezeptor-Komplexes (hIL-Rα/hIL-5). Beide Proteine wurden 
in einem Escherichia coli-Expressionssystem rekombinant hergestellt, bis zur 
Homogenität gereinigt und anschließend kristallisiert. Die Analysen dieser ersten 
Kristalle zeigten nicht die gewünschte Beugung der Röntgenstrahlung, weshalb in 
allen anschließenden Schritten eine schrittweise Optimierung der Produktions- und 
Kristallisationsbedingungen durchgeführt wurde. Als Ergebnis dieser 
Optimierungsstrategie konnten schließlich Kristalle erhalten werden, die für eine 
Strukturanalyse geeignet waren. Ein ungepaartes Cystein in der N-terminalen 
Domäne des extrazellulären hIL-5Rα-Protein wurde durch Alanin ersetzt, um so die 
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Protein-Heterogenität durch Cystein-Oxidationsprodukte zu verringern. Die 
affinitätschromatographische Aufreinigung des Rezeptorproteins war ebenfalls 
entscheidend, um eine hohe Kristallqualität zu erreichen. Die Verwendung 
verschiedener Additivsubstanzen zusätzlich zu der initialen 
Kristallisationsbedingungen führte letztlich zur Bildung für die Strukturanalyse 
geeigneter Einzelkristallen des binären Komplexes (hIL-5Rα/hIL-5). Ihre Messung 
ergab Beugungsdaten mit einer maximalen Auflösung von 2.5Å. Eine erste 
Strukturanalyse zeigt klar, dass die Liganden-bindende Domäne des IL-5Rα 
Rezeptors eine bisher unbekannte, neuartige Rezeptor-Architektur aufweist, die 
keinerlei Ähnlichkeit zu bisher bekannten Zytokinrezeptor-strukturen der Klasse I 
hat. Die Struktur des Komplexes zeigt zudem, dass das Liganden-bindende Epitop 
von IL-5Rα über alle drei extrazelluläre Domänen verteilt ist und eine Topologie 
aufweist, in der zusätzlich zu dem Zytokin-Erkennungsmotiv (CRM) die erste Fn-III 
Domäne von hIL-5Rα benötigt wird, um den Liganden hochaffin binden zu können. 
In einem zweiten Projekt wurde ein prokaryotisches Expressionssystem für 
murines Interleukin-5 (mIL-5) entwickelt, welches die Produktion von mIL-5 und 
eines mIL-5 Antagonisten für funktionelle Studien in einem Mausmodell 
ermöglichen sollte. Da eine rekombinante Produktion von mIL-5 in E.coli bisher 
nicht erfolgreich war, wurde ein Fusionsproteinsystem entwickelt, welches die 
Produktion großer Mengen von mIL-5 Protein erlaubt. Es wurde eine chemische 
Spaltung mit Cyanbromid (CNBr) durchgeführt, um das Monomer aus dem 
Fusionsprotein freizusetzen. Das so erhaltene mIL-5 Monomer wurde gereinigt und 
renaturiert. Nach Rückfaltung zeigt das dimere Protein in TF-1 Zellen eine mit den 
Literaturwerten vergleichbare biologische Aktivität. Das so erhaltene mIL-5 Protein 
wurde kristallisiert und mittels Röntgenbeugung analysiert. Auf diese Weisen 
konnten Beugungsdaten von mIL-5 Kristallen mit einer maximalen Auflösung von 
2.5Å erhalten werden. Die Struktur weist ähnlich wie das humane IL-5 ein 
symmetrisches Vier-Helix Bündel auf. Die Struktur-/Funktionsanalyse ermöglichte 
daraufhin, definierte mIL-5-Antagonisten zu entwickeln, die sich derzeit noch in der 
Untersuchung befinden. Zusammengefasst tragen die hier präsentierten Ergebnisse 
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dazu bei, die molekularen Grundlagen der spezifischen IL-5 und IL-5R Bindung 
sowie Interaktionen ähnlichen Liganden-Rezeptor-Typen zu verstehen. Letztendlich 
besteht die Hoffnung, dass diese und ähnliche Arbeiten ein weiteres wichtiges 
Puzzlestück darstellen bei dem Versuch, neue und innovative pharmakologische 
Therapieansätze zu entwickeln, die bei dem für die Pathophysiologie von Asthma 
wichtigen Schlüsselmolekül IL-5 angreifen.     
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9 APPENDIX 
 
ABBREVIATIONS 
 
The standard one-letter code is used for amino acids. i.e. Point mutations are labelled 
like C66A, in which cystein 66 is mutated to alanine. 
 
aa   amino acid 
ACN   Acetonitril 
AE   anion exchange chromatography 
AHR   Airway hyperresponsiveness 
AIC2B   Mouse beta chain 
Aid   Activation-induced cytidine deaminase 
Amp   Ampicillin 
APS   Amonium-persulphate 
ATP   Atopic path test 
βc   Beta common chain 
BCDF   B-cell differentiation factor 
BCGF   B-cell growth factor 
BCL1   B leukaemia cells line 
BIAcore  Biomolecular interaction analysis 
Blimp-1  B lymphocyte-induced maturation protein-1 
β-ME   β-Mercaptoethanol 
BNPS-Skatole  3-bromo-3-methyl-2 (2-notrophenylmercapto)-3H-indole 
bp   Base pair 
CD   Circular dicroism 
CIS   Cytokine-inducible SH2-containing proteins 
CHAPS  3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CHES   2-(N-Cyclohexylamino) ethane Sulfonic Acid 
cDNA   Complementary DNA 
CM5   Carboxymethyl dextran-5 
CNBr   Cyanogen bromide 
cpm   Counts per minute 
CRH   Cytokine receptor homology 
CRM   Cytokine recognition motif 
Da   Dalton 
DC   Dendritic cell 
deg   degrades 
DTT   Dithiothreitol 
EC50   Fifty maximal inducer concentration 
dH2O   Distilled water 
ECD   Extracellular binding domain 
ECM   Extra cellular matrix  
E. coli   Escherichia coli 
ECP   Eosinophils cationic protein 
EDF   Eosinophil differentiation factor 
EDN   Eosinophil-derived neurotoxin 
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EDTA   Ethylenediaminetetraacetic acid 
EG   Ethylene glycol 
EP0   Eosinophil peroxidase 
ERK   Extracellular receptor-activated kinase 
ESI   Electro-spray mass spectrometry 
EtBr   Etidium bromide 
Fn-III-like  Fibronectin type III-like domain 
GH   Growth hormone 
GHR   Growth hormone receptor 
GM-CSF  Granulocyte macrophage colony-stimulating factor 
GM-CSFR  Granulocyte macrophage colony-stimulating factor receptor 
Grb2   Growth factor receptor-bound adaptor protein 
GSH   Reduced glutathione  
GSSH   Oxidized glutathione  
GuHCl   Guanidinium hydrochloride 
FPLC   Fast pressure liquid chromatography 
HEPES  N-2-Hydroxyethylpiperazin-N’-2-ethanosulpho acid 
HES   Hypereosinophilic syndrome 
hIL-5   Human interleukin-5 
hIL-5Rα  Human interleukin-5 receptor alpha 
IB   Inclusion bodies 
IC50   Half maximal inhibition concentration 
IgE   Immunoglobulin-E 
IL   Interleukin 
IPTG   Isopropyl-beta-D-thiogalactopyranoside 
IR   Immune response 
JAK   Janus kinase 
K   Kelvin degrees 
KD   Affinity constant 
kDa   Kilodaltons 
Koff   Dissociation constant 
Kon   Association constant 
KSI   Ketosteroid isomerase  
λ   Wavelength 
LB   Luria Bertani medium 
MAPK   Mitogen-activated protein kinase 
MBP   Major basic protein 
M-CSF  Macrophage colony-stimulating factor 
Mepolizumad  Antibody against hIL-5 
MES   2-Morpholinoethanesulfonic acid 
mg   miligram 
mIL-5   mouse IL-5 
ml   mililiter 
MOPS   3-(N-morpholino) propanesulfonic acid 
MPD   2-Methyl-2,4-pentanediol 
mRNA   messenger ribonucleic acid  
MW   Molecular weight 
MWCO  Molecular weight cut off 
m/z   mass/charge 
NaAc   Sodium acetate 
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NFκβ   Nuclear factor kappa beta 
nm   nanometers 
nM   nanomolar 
NTCB   2-Nitro-5 thiocyanobenzoic acid 
OD600   Optical density at 600 nm 
ON   Over night 
ORF   Open reading frame 
PAGE   Polycrylamide gel electrophoresis 
PCR   Polymerase chain reaction  
PDB   Protein data bank 
PEG   Polyethylen glycol 
pfu pol   Pyrococcus furious polymerase 
PI3K   Phosphatidyl inositol 3-kinase 
PIAs   Protein inhibitors STAT 
RP-HPLC  Reverse phase-HPLC 
ProlR   Prolactin receptor 
rms   root mean square 
rpm   revolutions per minute 
RT   Room temperature 
RU   Resonance units 
SDS   Sodium dodecyl sulphate 
SOCS   Suppressor of cytokine signalling 
SPR   Surface plasmon resonance 
STAT   Signal transducer and activator of transcription 
TB   Terrific medium 
TCA   Trichloroacetic acid 
TEMED  N,N,N',N'-Tetramethylethylenediamine 
TFA   Tri-fluoro acetic acid 
Tris   Tris (-hydroxylmethyl)-aminoethan 
TRF   T-cell replacing factor 
U   International units 
VCAM-1  Vascular cell adhesion molecule-1 
VLA-4   Vascular ligand adhesion-4 
v/v   volumen/volumen 
w/v   weight/volumen 
wt   Wild type 
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